{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.18078"}, {"@name": "filename", "#text": "24919_arquivo1193_1.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DE PERNAMBUCO \nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nDEPARTAMENTO DE CI\u00caNCIAS FARMAC\u00caUTICAS \nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS \n\nFARMAC\u00caUTICAS \n \n \n \n \n \n \n \n \n \n \n \n\nAVALIA\u00c7\u00c3O TOXICOL\u00d3GICA \nPR\u00c9-CL\u00cdNICA E ATIVIDADE \n\nLAXANTE DE Aloe ferox Miller \n \n \n \n \n \n \n \n \n\nVanessa Ribeiro Leite \n \n \n \n\nRECIFE \n2010 \n\n46 \n \n\n\n\nVanessa Ribeiro Leite \n \n \n \n \n \n \n \n \n\nAVALIA\u00c7\u00c3O TOXICOL\u00d3GICA \nPR\u00c9-CL\u00cdNICA E ATIVIDADE \n\nLAXANTE DE Aloe ferox Miller \n \n \n \n \n \n \n\nDisserta\u00e7\u00e3o submetida e aprovada pelo \nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias \nFarmac\u00eauticas do Centro de Ci\u00eancias da Sa\u00fade \nda Universidade Federal de Pernambuco, como \nrequisito parcial para obten\u00e7\u00e3o do grau de \nMestre em Ci\u00eancias Farmac\u00eauticas. \n \nOrientador: Prof. Dr. Almir Gon\u00e7alves \nWanderley \n\n \n \n \n \n \n \n \n \n \n \n  \n \n \n \n \n \n \n \n \n\nRECIFE \n2010 \n\n \n\n47 \n \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLeite, Vanessa Ribeiro \n\n \n\nAvalia\u00e7\u00e3o toxicol\u00f3gica pr\u00e9-cl\u00ednica e atividade laxante\nde Aloe ferox Miller / Vanessa Ribeiro Leite.  \u2013 Recife: O \nAutor, 2010.   \n\n  \n\n90 folhas: il., fig., tab. e graf. \n \nDisserta\u00e7\u00e3o (mestrado) \u2013 Universidade Federal de\n\nPernambuco. CCS. Ci\u00eancias Farmac\u00eauticas, 2010. \n  \n\n \n  \n Inclui bibliografia. \n \n\n \n\n 1. Aloe ferox Miller. 2. Atividade laxante.  3.\nToxicidade cr\u00f4nica.  4. Hematologia.  5. Bioqu\u00edmica. \nI. T\u00edtulo. \n\n  \n\n \n         \n\n  615.9  CDU (2.ed.) UFPE  \n          615.9 \n \n\nCDD (20.ed.) CCS2010-118  \n\n \n \n \n \n\n48 \n \n\n\n\n \nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \nDEPARTAMENTO DE CI\u00caNCIAS FARMAC\u00caUTICAS \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS FARMAC\u00caUTICAS \n \n \n \n\nReitor \n \n\nAmaro Henrique Pessoa Lins \n \n\nVice-Reitor \n \n\nGilson Edmar Gon\u00e7alves e Silva \n \n\nPr\u00f3-Reitor para Assuntos de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o \n \n\nAn\u00edsio Brasileiro de Freitas Dourado \n \n\nDiretor do Centro de Ci\u00eancias da Sa\u00fade \n \n\nJos\u00e9 Thadeu Pinheiro \n \n\nVice-Diretor do Centro de Ci\u00eancias da Sa\u00fade \n \n\nM\u00e1rcio Ant\u00f4nio de Andrade Coelho Gueiros \n \n\nChefe do Departamento de Ci\u00eancias Farmac\u00eauticas \n \n\nDalci Jos\u00e9 Brondani \n \n\nVice-Chefe do Departamento de Ci\u00eancias Farmac\u00eauticas \n \n\nAnt\u00f4nio Rodolfo de Faria \n \n\nCoordenador do Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Farmac\u00eauticas \n \n\nPedro Jos\u00e9 Rolim Neto \n \n\nVice-Coordenador do Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Farmac\u00eauticas \n \n\nBeate Saegesser Santos \n \n \n \n \n \n \n \n\n49 \n \n\n\n\n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nDedico aos meus pais, Josemar e V\u00e2nia; \u00e0s \nminhas irm\u00e3s, Alexandra e Tatiana; ao meu \nnoivo, Edilson; e aos meus sogros, Pl\u00ednio e \nMaria, que sempre me apoiaram e confiaram \nque alcan\u00e7aria meus objetivos. \n\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n50 \n \n\n\n\n \nAGRADECIMENTOS \n\n \n \n\nA Deus, por me conceder a vida e me dar coragem e sa\u00fade para superar todas as \ndificuldades que ela possa oferecer. \n \nAos meus pais, Josemar Ribeiro Leite e Maria do Carmo V\u00e2nia do Nascimento Leite, \npor sempre estarem do meu lado, me dando incentivo, educa\u00e7\u00e3o e pela confian\u00e7a que \ndepositam em mim. \n \nA minhas irm\u00e3s, Alexandra Ribeiro Leite e Iracema Tatiana Ribeiro Leite, pela \npaci\u00eancia nos meus dias de estresse e por me ajudarem com seus conhecimentos, na \nconstru\u00e7\u00e3o deste trabalho. \n \nA minha querida sobrinha, Maria Clara Leite Ferreira, por me dar tanta alegria, me \najudando assim a continuar nos momentos de maior desespero. \n \nAo meu amado noivo, Edilson Celestino dos Santos, pelo carinho, compreens\u00e3o e \nincentivo na constru\u00e7\u00e3o deste trabalho e em tudo que fa\u00e7o. \n \nAos amigos que constru\u00ed no laborat\u00f3rio, H\u00e9lida Maria de Lima maranh\u00e3o, Carlos \nFernando Brasileiro de Vasconcelos, Giovanna Christinne Rocha de Medeiros, \nRafaella Farias N\u00f3brega e Jamilka Leopoldina da Silva, pela grande amizade e ajuda \nconstante no desenvolvimento do meu trabalho. \n \nAo Prof. Dr. Almir Gon\u00e7alves Wanderley pela oportunidade, orienta\u00e7\u00e3o, apoio e \naprendizado que me foi proporcionado. \n \nA Profa. Dra. Simone Sette Lopes Lafayette e \u00e0 Profa. MSc. Maria do Carmo Correa \nAra\u00fajo Fraga, pela orienta\u00e7\u00e3o na realiza\u00e7\u00e3o deste trabalho, confian\u00e7a e simpatia. \n \nAos colegas de laborat\u00f3rio: Cristiano Ribeiro de Lima, Eduardo da Silva Gon\u00e7alves, \nGermana Freire Rocha Caldas, Iggor Macedo do Amaral Costa, Juciene Bezerra \nRodrigues da Silva, Luana Janine Lopes da Costa e M\u00e1rio Correia de Lima Neto, pela \namizade e colabora\u00e7\u00e3o. \n \nA Rejane de Sousa Silva pela grande amizade e assist\u00eancia t\u00e9cnica exemplar; e a \nFredson Jos\u00e9 Soares (Seu Fredson) pela grande disposi\u00e7\u00e3o em ajudar e alegria \nconstante que contagia a todos que o cercam. \n \nAos professores e funcion\u00e1rios do Departamento de Fisiologia e Farmacologia/CCB-\nUFPE pela oportunidade de conv\u00edvio e disponibilidade de seus laborat\u00f3rios. \n \nA Coordena\u00e7\u00e3o, professores, funcion\u00e1rios e colegas do curso de P\u00f3s-Gradua\u00e7\u00e3o em \nCi\u00eancias Farmac\u00eauticas/CCS-UFPE, pelo aprendizado fornecido, conviv\u00eancia e troca de \nexperi\u00eancias. \n \nAo laborat\u00f3rio Odaly Soares, pelo fornecimento do material para pesquisa. \n \n\n51 \n \n\n\n\n \nSUM\u00c1RIO \n\n \nLISTA DE FIGURAS \nLISTA DE TABELAS \nRESUMO \nABSTRACT \n1. INTRODU\u00c7\u00c3O...........................................................................................................11 \n2. REVIS\u00c3O DE LITERATURA....................................................................................15 \n    2.1. Produtos Naturais..................................................................................................16 \n    2.2. Atividade Laxante.................................................................................................17 \n\n    2.3.Import\u00e2ncia de Estudos Toxicol\u00f3gicos de Plantas Medicinais..............................19 \n\n    2.4. An\u00e1lise Toxicol\u00f3gica Pr\u00e9-Cl\u00ednica.........................................................................20 \n\n          2.4.1. Toxicidade aguda.........................................................................................21 \n\n          2.4.2. Toxicidade Cr\u00f4nica......................................................................................22 \n\n2.5. Aloe ferox Miller..................................................................................................23 \n\n2.5.1. Bot\u00e2nica........................................................................................................23 \n\n2.5.2. Fitoqu\u00edmica.................................................................................................. 24 \n\n2.5.3. Farmacologia................................................................................................26 \n\n2.5.3.1. Atividade Antiinflamat\u00f3ria..............................................................26 \n\n2.5.3.2. Atividade Cicatrizante e Imuno-moduladora..................................27 \n\n2.5.3.3. Fun\u00e7\u00e3o Gastrintestinal.....................................................................28 \n\n2.5.3.4. Atividade Antic\u00e2ncer.......................................................................29 \n\n2.5.3.5. Atividade Antimicrobiana e Antif\u00fangica.........................................30 \n\n2.5.4. Toxicologia...................................................................................................30 \n\n3. OBJETIVOS................................................................................................................31 \n4. ARTIGO I: Evaluation of the acute toxicity and laxative activity of Aloe ferox Miller \n\n(Asphodelaceae) resin\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..32 \n\n5. ARTIGO II: Chronic oral toxicity of Aloe ferox Miller (Asphodelaceae) in rats\u2026...46 \n\n6. CONCLUS\u00c3O.............................................................................................................78 \n\n7. REFER\u00caNCIAS .........................................................................................................80 \n\n \n\n \n\n \n\n \n \n\n \n\n52 \n \n\n\n\n \nLISTA DE FIGURAS \n\n \n                REVIS\u00c3O DA LITERATURA \n \n\n         Figura 1   Aloe ferox Miller ...............................................................................................................24 \n         Figura 2  Alo\u00edna .................................................................................................................................26 \n\n \n \n\n                ARTIGO I \n \n\nFigura 1   Figure 1: Effect of the administration of Aloe ferox extract resin (Af 50, 100 and 200           \n\n                g.kg-1) by oral route on gastrointestinal motility. The data represent the mean \u00b1 SEM (n     \n\n               = 8/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202640 \n\n         Figura 2   Figure 2: UV absorption spectrum of hydroxyanthracene derivates expressed as aloin \n\n           \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026\u2026..41       \n  \n  \n   ARTIGO II \n \n\nFigura 1  Figure 1: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5  g.kg-1 \n\nby oral route on body weigth gain of female Wistar rats for 13 weeks. The        data \n\nrepresent the mean \u00b1 SEM (n = 8-13/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026..61               \n\n         Figura 2   Figure 2: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-     \n\n                                   1)  by oral route on body weigth gain of male Wistar rats for 13 weeks. The data \n\n represent the mean \u00b1 SEM (n = 12-13/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202661 \n\n         Figura 3   Figure 3: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-      \n\n 1)  by oral route on water consumption of female Wistar rats for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 8-13/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...62 \n\n         Figura 4   Figure 4: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-  \n\n 1) by oral route on water consumption of male Wistar rats for 13 weeks. The  data \n\nrepresent the mean \u00b1 SEM (n = 12-13/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026....62 \n\n         Figura 5   Figure 5: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg- \n\n                      1) by oral route on food consumption of female Wistar rats for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n =8- 13/group)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026.63 \n\n         Figura 6   Figure 6: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n                          1) by oral route on food consumption of male Wistar rats for 13 weeks. The  data \n\nrepresent the mean \u00b1 SEM (n = 12-13/group).................................................................63 \n\n \n\n \n\n \n\n \n\n53 \n \n\n\n\nLISTA DE TABELAS \n\n \n            ARTIGO II \n \nTabela 1        Table 1: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in female Wistar rats treated for 4 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.64 \n\nTabela 2       Table 2: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in female Wistar rats treated for 8 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026.65 \n\nTabela 3        Table 3: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in female Wistar rats treated for 13 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026..66 \n\nTabela 4        Table 4: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in male Wistar rats treated for 4 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026...67 \n\nTabela 5        Table 5: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in male Wistar rats treated for 8 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.....\u2026\u2026\u2026....68 \n\nTabela 6        Table 6: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nhematological parameters in male Wistar rats treated for 13 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026\u2026\u202669 \n\nTabela 7       Table 7: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nbiochemical parameters in female Wistar rats treated for 4 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.70 \n\nTabela 8       Table 8: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nbiochemical parameters in female Wistar rats treated for 8 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202671 \n\nTabela 9       Table 9: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nbiochemical parameters in female Wistar rats treated for 13 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026..72 \n\nTabela 10       Table 10: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nbiochemical parameters in male Wistar rats treated for 4 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026...73 \n\nTabela 11       Table 11: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on \n\nbiochemical parameters in male Wistar rats treated for 8 weeks\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026.74 \n\nTabela 12       Table 12: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route \n\nbiochemical parameters in male Wistar rats treated for 13 weeks\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026....75 \n\nTabela 13       Table 13: Effect of dry extract of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by \n\noral route on absolute live (g) and relative body weight ratio (g/100g of animal) in female Wistar \n\nrats treated for 13 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026..76 \n\nTabela 14       Table 14: Effect of dry extract of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by \n\noral route on absolute live (g) and relative body weight ratio (g/100g of animal) in male Wistar rats \n\ntreated for 13 weeks\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u202677 \n\n \n\n \n\n \n \n\n \n \n\n54 \n \n\n\n\nRESUMO \n \n\nAloe ferox, Asphodelaceae, \u00e9 uma planta que se desenvolve em terras com chuvas mais \nou menos moderadas e secas e solos menos f\u00e9rteis; possui ampla distribui\u00e7\u00e3o em toda a \n\u00c1frica do Sul, tendo maior concentra\u00e7\u00e3o nas Prov\u00edncias do Cabo Leste e Oeste. No \nBrasil, esta planta \u00e9 encontrada no interior de S\u00e3o Paulo, Santa Catarina e na regi\u00e3o \nnordeste; sendo esta \u00faltima a que possui melhores condi\u00e7\u00f5es de cultivo. Aloe ferox \u00e9 \npopularmente utilizada como laxante, por\u00e9m existe uma car\u00eancia de estudos referentes \u00e0 \nefic\u00e1cia de seu uso como laxante bem como de informa\u00e7\u00f5es toxicol\u00f3gicas detalhadas \nsobre a esp\u00e9cie. Neste contexto, o trabalho teve como objetivo avaliar o efeito da resina \nde Aloe ferox Miller sobre o tr\u00e2nsito intestinal em ratos e investigar a seguran\u00e7a de seu \nuso. Para isso foram realizados o teste de motilidade intestinal em camundongos, nas \ndoses de 0.05, 0.1 e 0.2 g/kg, teste de toxicidade aguda em ratos e avaliou-se a \ninflu\u00eancia da administra\u00e7\u00e3o cr\u00f4nica (13 semanas) por via oral do extrato da resina de \nAloe ferox, nas doses de 0.1, 0.5 e 1.5 g/kg, sobre os par\u00e2metros bioqu\u00edmicos, \nhematol\u00f3gicos e morfol\u00f3gicos em ratos. Os resultados mostraram que na toxicidade \naguda, Aloe ferox n\u00e3o produziu morte dos animais em doses de at\u00e9 5 g/kg. Para a \natividade laxante, observou-se que ap\u00f3s 30 minutos da administra\u00e7\u00e3o Aloe ferox \naumentou a motilidade intestinal em camundongos em mais de 90% em todas as doses \nadministradas. No entanto, a administra\u00e7\u00e3o cr\u00f4nica promoveu altera\u00e7\u00f5es em v\u00e1rios \npar\u00e2metros bioqu\u00edmicos, hematol\u00f3gicos e morfol\u00f3gicos. No que se diz respeito aos \npar\u00e2metros hematol\u00f3gicos, Aloe ferox, na dose de 1.5 g/kg induziu uma redu\u00e7\u00e3o nos \nvalores de eritr\u00f3citos, hemat\u00f3crito e hemoglobina nos primeiros trinta dias de \ntratamento e aumento dos valores desses par\u00e2metros no \u00faltimo m\u00eas de tratamento para \nambos os sexos e promoveu o aumento do RDW em f\u00eameas tratadas com a mesma dose \n(1.5 g/kg). Com rela\u00e7\u00e3o aos par\u00e2metros bioqu\u00edmicos, os animais tratados com Aloe \nferox na dose de 1.5 g/kg sofreram uma redu\u00e7\u00e3o nos n\u00edveis de creatinina e aumento de \nbilirrubina total e indireta em ambos os sexos. Nas f\u00eameas verificou-se uma redu\u00e7\u00e3o nos \nn\u00edveis de HDL e triglicer\u00eddeos e aumento de bilirrubina direta. Os machos apresentaram \naumento de fosfatase alcalina e ALT. A an\u00e1lise morfol\u00f3gica de v\u00edsceras, enc\u00e9falo e \n\u00f3rg\u00e3os reprodutivos bem como a massa absoluta e relativa destes \u00f3rg\u00e3os apresentou \naltera\u00e7\u00f5es nos animais que sobreviveram ao tratamento com Aloe ferox na dose de 1.5 \ng/kg. As principais altera\u00e7\u00f5es observadas foram massa absoluta e relativa diminu\u00edda do \nba\u00e7o em f\u00eameas e do intestino nos machos. Os resultados encontrados nos levam a \nconcluir que Aloe ferox \u00e9 eficaz no tratamento da constipa\u00e7\u00e3o intestinal, por\u00e9m induz \naltera\u00e7\u00f5es significativas em v\u00e1rios par\u00e2metros bioqu\u00edmicos, hematol\u00f3gicos e \nmorfol\u00f3gicos em ratos Wistar de ambos os sexos, indicando que a administra\u00e7\u00e3o desta \nplanta pode exercer efeito t\u00f3xico ao ser humano.  \n \nPalavras-chave: Aloe ferox Miller, atividade laxante, toxicidade aguda, toxicidade \ncr\u00f4nica, hematologia, bioqu\u00edmica. \n\n \n \n\n  \n\n \n \n \n \n \n\n55 \n \n\n\n\nABSTRACT \n \n\nAloe ferox, Asphodelaceae, is a plant that grows in land with rainfall more or less \nmoderate, dry and less fertile soil is widely spread throughout South Africa, being more \nconcentrated in the provinces of Eastern and Western Cape. In Brazil, this plant is found \nin S\u00e3o Paulo interior, Santa Catarina and in the northeast, the latter being the one with \nthe best growing conditions. Aloe ferox is popularly used as a laxative, but there is a \nlack of studies concerning the effectiveness of its use as laxative as well as detailed \ntoxicological information on the species. In this context, the aimed to evaluate the effect \nof Aloe ferox Miller resin on intestinal transit in rats and to investigate the safety of its \nuse. For that were tested with intestinal motility in mice at doses of 0.05, 0.1 and 0.2 \ng/kg, acute toxicity test in rats and evaluated the influence of chronic administration \norally resin extract of Aloe ferox at doses of 0.1, 0.5 and 1.5 g/kg  on the biochemical, \nhematological and morphological studies in rats. The results showed that the acute \ntoxicity, Aloe ferox not produced death of the animals at doses up to 5 g/kg . For \nlaxative activity, it was observed that after 30 minutes of administration Aloe ferox \nincreased intestinal motility in mice by more than 90% in all doses administered. \nHowever, chronic administration promoted changes in several biochemical, \nhematological and morphological. With regard to hematological parameters, Aloe ferox, \na dose of 1.5 g/kg  induced a reduction in the values of erythrocytes, hematocrit and \nhemoglobin in the first thirty days of treatment and increase the values of these \nparameters in the last month of treatment for both gender and promoted RDW increase \nin females treated with the same dose (1.5 g./kg). Regarding the biochemical \nparameters, the animals treated with Aloe ferox in a dose of 1.5 g/kg  had a reduction in \ncreatinine levels and increased total and indirect bilirrubin in both sexes. In females, \nthere was a reduction in HDL and triglycerides and increased direct bilirrubin. Males \nshowed increased alkaline phosphatase and ALT. Morphological analysis of viscera, \nbrain and reproductive organs as well as the absolute and relative weight of these organs \nshowed changes in the animals that survived the treatment with Aloe ferox in a dose of \n1.5 g/kg . The main changes were absolute and relative weight of spleen decreased in \nfemales and intestine in males. The results lead us to conclude that Aloe ferox is \neffective in the constipation treatment, but induces significant changes in several \nbiochemical, hematological and morphological studies in rats of both sexes, indicating \nthat the administration of this plant can have toxic effects when human. \n \nKeywords: Aloe ferox Miller, laxative activity, acute toxicity, chronic toxicity, \nhematology, biochemistry. \n \n\n \n \n\n \n \n \n \n \n \n \n \n \n\n56 \n \n\n\n\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n\n1. INTRODU\u00c7\u00c3O \n \n \n \n \n \n\n57 \n \n\n\n\n \n1. INTRODU\u00c7\u00c3O \n \n\nO uso dos produtos naturais iniciou-se h\u00e1 milhares de anos por popula\u00e7\u00f5es de v\u00e1rios \n\npa\u00edses com o intuito de tratar diversas doen\u00e7as (SOUZA et al., 2008). Os primeiros escritos, \n\nem linguagem cuneiforme, v\u00eam da Mesopot\u00e2mia e datam de cerca de 2600 a.C. (NEWMAN; \n\nCRAGG; SNADER, 2000). O rei da Babil\u00f4nia Mardu Kapalidine II mandou construir um \n\njardim, onde cultivou 64 esp\u00e9cies de plantas medicinais, muitas das quais ainda s\u00e3o utilizadas \n\nna medicina popular (CARVALHO, 1999). A hist\u00f3ria do desenvolvimento das civiliza\u00e7\u00f5es \n\nOriental e Ocidental \u00e9 rica em exemplos da utiliza\u00e7\u00e3o de recursos naturais na medicina, no \n\ncontrole de pragas e em mecanismos de defesa, destacando-se a civiliza\u00e7\u00e3o Eg\u00edpcia, Greco-\n\nRomana e Chinesa (VIEGAS JR, BOLZANI e BARREIRO, 2006). \n\nNo Brasil, o uso de plantas medicinais tem sua hist\u00f3ria ligada \u00e0 cultura ind\u00edgena, \n\nportuguesa e africana (ALBUQUERQUE, 1997; VASCONCELOS et al., 2000). A cren\u00e7a \n\nem sortil\u00e9gios, bem como as pr\u00e1ticas m\u00e1gicas j\u00e1 se havia disseminado no Brasil pela \n\ninflu\u00eancia dos ind\u00edgenas e portugueses, quando alguns negros (feiticeiros e curadores) foram \n\ntrazidos como escravos. Estes, por meio de pr\u00e1ticas divinat\u00f3rias, transes m\u00edsticos e rituais \n\nespec\u00edficos, invocavam as for\u00e7as superiores para propiciar conselhos e interven\u00e7\u00f5es para \n\nproblemas de sa\u00fade (SANTOS FILHO, 1991). O s\u00e9culo XVIII, em particular, abriu as portas \n\npara o conhecimento cient\u00edfico da medicina e, embora a arte de cura tenha sido refinada, as \n\nplantas continuaram a ocupar uma posi\u00e7\u00e3o de destaque, o que permaneceu como paradigma \n\nat\u00e9 o s\u00e9culo XX. Desta forma, at\u00e9 a d\u00e9cada de 1930, cerca de 90% dos medicamentos oficiais \n\neram de origem vegetal (CORR\u00caA et al., 2003). Surgiu assim, a primeira edi\u00e7\u00e3o da \n\nFarmacop\u00e9ia dos Estados Unidos do Brasil, abordando mais de 200 plantas medicinais \n\n(BRAND\u00c3O et al., 2008). \n\nO Brasil \u00e9 um pa\u00eds rico em diversidade, cujo territ\u00f3rio possui cinco principais biomas \n\nsendo designados como floresta amaz\u00f4nica, cerrado, mata atl\u00e2ntica e caatinga. Portanto, \u00e9 \n\numa rica fonte de produtos terap\u00eauticos. No entanto, este potencial para a descoberta \u00e9 \n\npobremente explorado ou regulamentado, contrastando com o que ocorre em pa\u00edses com \n\nAlemanha, Estados Unidos e Canad\u00e1 (CALIXTO, 2000; RATES, 2001; VEIGA-J\u00daNIOR, \n\n2008). \n\nEm meados do s\u00e9culo passado, mais especificamente na d\u00e9cada de 1960, ocorreu nos \n\npa\u00edses desenvolvidos iniciando pela Alemanha, Fran\u00e7a e Reino Unido, e posteriormente \n\ndifundindo-se para outros pa\u00edses da Europa e Am\u00e9rica do Norte, um interesse maior pela \n\n58 \n \n\n\n\nfitoterapia e, ao inv\u00e9s de utilizar a infus\u00e3o, cozimento ou tintura dos f\u00e1rmacos vegetais \n\npassam a usar formas farmac\u00eauticas mais elaboradas, como os comprimidos, c\u00e1psulas e \n\ngel\u00e9ias (CUNHA et al., 2003). Este interesse surgiu principalmente devido \u00e0s popula\u00e7\u00f5es \n\nacreditarem que os fitoter\u00e1picos s\u00e3o isentos ou possuem poucos efeitos colaterais, e que s\u00e3o \n\naparentemente eficazes nos casos onde a medicina tradicional n\u00e3o alcan\u00e7ou resultados \n\nesperados, o que nem sempre \u00e9 confirmado pelas pesquisas cient\u00edficas que avaliam a efic\u00e1cia \n\ne a seguran\u00e7a assim como a garantia de qualidade de produ\u00e7\u00e3o (CALIXTO, 2000; \n\nCARVALHO et al.,2008). \n\nA OMS define fitoter\u00e1pico como \u201cqualquer produto medicinal acabado e rotulado que \n\ncontenha como ingredientes ativos partes a\u00e9reas ou subterr\u00e2neas de plantas ou outro material \n\nderivado de plantas, ou combina\u00e7\u00f5es destes, quer em estado natural, quer como preparados \n\nde plantas\u201d (WORLD HEALTH ORGANIZATION- WHO, 1991). Neste contexto, os \n\nfitoter\u00e1picos v\u00e3o desde plantas medicinais frescas rec\u00e9m-colhidas pela popula\u00e7\u00e3o at\u00e9 \n\nprepara\u00e7\u00f5es farmac\u00eauticas padronizadas usadas pela sofisticada ind\u00fastria farmac\u00eautica. A \n\nOMS desempenhou um papel importante na identifica\u00e7\u00e3o e produ\u00e7\u00e3o de fitoter\u00e1picos seguros \n\ne eficazes para uso na aten\u00e7\u00e3o prim\u00e1ria \u00e0 sa\u00fade, e apoiou com firmeza o emprego de \n\nmedicamentos \u00e0 base de plantas medicinais para promover a sa\u00fade das comunidades \n\ncarentes, principalmente nos pa\u00edses em desenvolvimento como Brasil, M\u00e9xico ou \u00cdndia.  \n\nA fitoterapia atualmente existe principalmente no mercado informal, o que representa \n\num grande perigo \u00e0 sa\u00fade da popula\u00e7\u00e3o devido \u00e0 grande comercializa\u00e7\u00e3o de drogas vegetais \n\nsem o controle fitossanit\u00e1rio e de identifica\u00e7\u00e3o e pureza. \u00c9 necess\u00e1rio que haja um maior e \n\nmelhor controle desse ramo farmac\u00eautico, uma vez que os fitoter\u00e1picos representam uma \n\nalternativa vi\u00e1vel e econ\u00f4mica para as popula\u00e7\u00f5es carentes (BENDAZZOLI, 2000). \n\nNos c\u00edrculos alopatas, \u00e9 comum afirmar que o uso de plantas medicinais desencadeia \n\nefeitos t\u00f3xicos, em especial hepatotoxicidade; enquanto que na popula\u00e7\u00e3o em geral prevalece \n\na vis\u00e3o oposta de que as plantas medicinais s\u00e3o seguras. Do ponto de vista cient\u00edfico, \n\npreconiza-se que qualquer subst\u00e2ncia ingerida em excesso \u00e9 potencialmente prejudicial. \n\nNenhum material vegetal \u00e9 exce\u00e7\u00e3o a esse princ\u00edpio geral (ELDIN; DUNFORD, 2001).  \n\nO processo legal de regulamenta\u00e7\u00e3o e legisla\u00e7\u00e3o de plantas medicinais difere de pa\u00eds a \n\npa\u00eds (CALIXTO, 2000). No Brasil, o controle para o uso de plantas para finalidades \n\nterap\u00eauticas s\u00f3 foi regulamentado com a publica\u00e7\u00e3o da Portaria n\u00ba 06 da Secretaria de \n\nVigil\u00e2ncia Sanit\u00e1ria (SVS) de 31 /05/95 (BRASIL, 1995). Essa norma foi elaborada a partir \n\nde diversas sugest\u00f5es da sociedade civil brasileira que apontavam a necessidade de serem \n\norganizadas as atividades de registro dessa classe de medicamentos, de forma a melhorar o \n\n59 \n \n\n\n\ngrau t\u00e9cnico dos produtos fitoter\u00e1picos comercializados no pa\u00eds. A Portaria 06/95 \n\ndesencadeou um processo de adequa\u00e7\u00e3o desse mercado, procurando transitar de uma fase \n\nconfusa e liberal para um novo contexto, \u00e9tico e rigidamente constru\u00eddo. Tal processo, \n\niniciado com a publica\u00e7\u00e3o da portaria em 1995, envolve dois per\u00edodos de cinco anos para a \n\nrealiza\u00e7\u00e3o dos estudos toxicol\u00f3gicos e da efic\u00e1cia terap\u00eautica (BRASIL, 1995). \n\nEm vista da necessidade de normatiza\u00e7\u00e3o de estudos toxicol\u00f3gicos e da efic\u00e1cia de \n\nprodutos fitoter\u00e1picos, a Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA), atrav\u00e9s da \n\nPortaria n\u00ba 116/96 de 08/08/96, elaborou roteiro t\u00e9cnico de estudos toxicol\u00f3gicos pr\u00e9-cl\u00ednicos \n\ne cl\u00ednicos, complementada por preceitos gerais para estudos de efic\u00e1cia terap\u00eautica (BRASIL, \n\n1996). \n\nA publica\u00e7\u00e3o da Resolu\u00e7\u00e3o RDC n\u00ba 17, de 24/02/2000, instituiu e normatizou o \n\nregistro de fitoter\u00e1picos junto \u00e0 ANVISA. Para revalida\u00e7\u00e3o do registro de produtos \n\nfitoter\u00e1picos j\u00e1 comercializados, esta portaria estabeleceu prazo m\u00e1ximo de cinco anos para \n\nestudos de efic\u00e1cia cl\u00ednica bem como os protocolos experimentais para os estudos \n\ntoxicol\u00f3gicos dos fitoter\u00e1picos brasileiros (BRASIL, 2000). \n\nH\u00e1 ainda uma grande lacuna entre atividades biol\u00f3gicas descritas e uso popular, assim \n\ncomo uma car\u00eancia de estudos quanto aos efeitos adversos, contra-indica\u00e7\u00e3o, toxicidade e \n\nvalida\u00e7\u00e3o da efic\u00e1cia e seguran\u00e7a do fitoter\u00e1pico nativo (PUPO, GALLO E VIEIRA, 2007). \n\nNeste contexto, faz-se necess\u00e1ria a avalia\u00e7\u00e3o do potencial terap\u00eautico e de seguran\u00e7a das \n\nplantas medicinais, bem como de seus princ\u00edpios ativos isolados, a fim de promover o \n\ndesenvolvimento de formula\u00e7\u00f5es eficazes e seguras. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n60 \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2. REVIS\u00c3O DA LITERATURA \n \n \n \n \n \n \n\n61 \n \n\n\n\n \n \n\n \n \n \n \n2. REVIS\u00c3O DA LITERATURA \n \n \n2.1. PRODUTOS NATURAIS \n \n\nAp\u00f3s uma s\u00e9rie de transforma\u00e7\u00f5es tecnol\u00f3gicas que faz da planta medicinal uma \n\ndroga vegetal, esta cont\u00e9m certo n\u00famero de subst\u00e2ncias que, em geral, age sobre o \n\norganismo humano (GOTTLIEB; BORIN, 1997). Em todas as esp\u00e9cies cont\u00eam \n\nprinc\u00edpios ativos e subst\u00e2ncias inertes (GARCIA, 1995). \n\nOs princ\u00edpios ativos n\u00e3o se distribuem de maneira uniforme no vegetal, podendo \n\nconcentrar-se nas flores, folhas e ra\u00edzes, sementes, frutos ou casca. Os vegetais n\u00e3o \n\napresentam uma concentra\u00e7\u00e3o uniforme de seus princ\u00edpios ativos durante o seu ciclo de \n\nvida, podendo tamb\u00e9m variar com o habitat, a colheita e a prepara\u00e7\u00e3o (MATOS, 2000). \n\nOs mais importantes princ\u00edpios ativos de origem vegetal incluem os glicos\u00eddeos \n\nantraquin\u00f4nicos, saponinas, cianogen\u00e9ticos, cardioativos, cumar\u00ednicos, flavon\u00f3ides, \n\nalcal\u00f3ides, taninos, \u00f3leos essenciais e subst\u00e2ncias arom\u00e1ticas (GARCIA, 1995). \n\nOs glicos\u00eddeos desempenham um importante papel na vida da planta, uma vez \n\nque participam dos processos regulat\u00f3rios, protetores e sanit\u00e1rios do vegetal. Os \n\nglicos\u00eddeos s\u00e3o subst\u00e2ncias que, por hidr\u00f3lise, originam dois ou mais a\u00e7\u00facares (por\u00e7\u00e3o \n\nglicona) e um n\u00facleo fundamental, denominado aglicona. Esta por\u00e7\u00e3o \u00e9 a determinante \n\nda a\u00e7\u00e3o farmacol\u00f3gica que o grupamento os\u00eddico modula, sendo respons\u00e1vel pela \n\nclassifica\u00e7\u00e3o dos glicos\u00eddeos em antraquin\u00f4nicos, sapon\u00ednicos, cianog\u00eanicos, \n\ncardioativos e cumar\u00ednicos (ROBBERS et al.,1997). \n\nA absor\u00e7\u00e3o dos glicos\u00eddeos cardioativos pelo organismo \u00e9 cumulativa, de \n\nmaneira que \u00e9 mais freq\u00fcente sua intoxica\u00e7\u00e3o por uso cr\u00f4nico, embora haja a \n\npossibilidade de intoxica\u00e7\u00e3o aguda. Os fen\u00f4menos que ocorrem em conseq\u00fc\u00eancia dessa \n\nadministra\u00e7\u00e3o abrangem sensa\u00e7\u00e3o de mal-estar, n\u00e1usea, v\u00f4mito, suores frios, \n\nconvuls\u00f5es, desmaio e morte por parada card\u00edaca. A principal esp\u00e9cie medicinal do \n\ngrupo \u00e9 a Deladeira (Digitalis purp\u00farea L.), usada terapeuticamente na insufici\u00eancia \n\n62 \n \n\n\n\ncard\u00edaca. Seu princ\u00edpio ativo, a digitoxina, encontra-se entre as subst\u00e2ncias consideradas \n\naltamente t\u00f3xicas (MATOS, 2000). \n\nAs plantas que produzem antraquinonas s\u00e3o bastante utilizadas por sua a\u00e7\u00e3o \n\nlaxante. Entre os derivados da antraquinona incluem-se a antrona, a oxantrona, o \n\nantranol e o diantranol. Nesse grupo, os vegetais mais comumente utilizados na \n\nind\u00fastria farmac\u00eautica s\u00e3o a c\u00e1scara sagrada (Rhaminus purshiana) a sene (Senna \n\nAlexandria) e o ruibarbo (Rheum palmatum) (MATOS, 2000). \n\nOs flavon\u00f3ides est\u00e3o entre os compostos naturais mais disseminados em plantas, \n\nsendo as principais categorias estruturais gerais as flavonas, flavononas, flavon\u00f3is, \n\nantocianidinas e isoflavonas. De acordo com Podolsky (1994) diversas atividades \n\nfarmaol\u00f3gicas s\u00e3o atribu\u00eddas aos flavon\u00f3ides, dentre elas redu\u00e7\u00e3o da fragilidade capilar, \n\na\u00e7\u00f5es anti-inflamat\u00f3rias, antial\u00e9rgica, antiviral, antitumoral, antimicrobianas e \n\nantioxidantes. Eldin et al. (2006), destacam a sua fun\u00e7\u00e3o nas dislipidemias inibindo a \n\noxida\u00e7\u00e3o do LDL, conseq\u00fcentemente, diminuindo a aterogenicidade e o risco de doen\u00e7a \n\ncoron\u00e1ria. No entanto, alguns flavon\u00f3ides possuem atividade pr\u00f3-oxidante diminuindo a \n\ncapacidade respirat\u00f3ria de mitoc\u00f4ndrias isoladas, pela sua auto-oxida\u00e7\u00e3o, gerando \n\nesp\u00e9cies reativas de oxig\u00eanio (SANTOS et al,,1998). \n\nAs cumarinas s\u00e3o lactonas derivados do \u00e1cido o-hidroxicin\u00e2mico, amplamente \n\ndistribu\u00eddas no reino vegetal. Estes compostos possuem efeitos antipir\u00e9ticos e \n\npropriedades broncodilatadoras e antiasm\u00e1ticas (LEAL et al., 2000). De acordo com \n\nKurster e Rocha (2000) a cumarina e seus metab\u00f3litos re\u00fanem amplo espectro de a\u00e7\u00f5es \n\nfarmacol\u00f3gicas, destacando a 4-hidr\u00f3xi-cumarina, da qual deriva importantes f\u00e1rmacos \n\nanticoagulantes com a varfarina; a escopoletina, por sua atividade antiespasm\u00f3dica; a \n\numbeliferona, com atividades inibidoras de carcinog\u00eanese, antiespasm\u00f3dicas e \n\nantiarr\u00edtimica e a esculetina, que possui atividade antitumoral e antif\u00fangica. No homem, \n\na 7-hidr\u00f3xi-cumarina \u00e9 o principal metab\u00f3lito da cumarina e apresenta atividade \n\ncitost\u00e1tica em adenocarcinomas (LOPES- GONZ\u00c1LES et al., 2000).  \n\n \n\n2.2. ATIVIDADE LAXANTE \n\n \n\nA constipa\u00e7\u00e3o intestinal (CI) pode ser definida como elimina\u00e7\u00e3o de fezes \n\nressecadas, endurecidas, com freq\u00fc\u00eancia menor do que tr\u00eas evacua\u00e7\u00f5es semanais, ou, \n\ncomo crit\u00e9rio geral, pode-se defini-la como qualquer dificuldade em realizar defeca\u00e7\u00e3o, \n\n63 \n \n\n\n\nexigindo esfor\u00e7o maior do que o habitual (AMBROGINI, 2003; CHONG, 2001; \n\nKRIGGER, 2006).  \n\n A freq\u00fc\u00eancia de constipa\u00e7\u00e3o varia entre 2 e 28% dos indiv\u00edduos (LOCKE et al., \n\n2000). A diminui\u00e7\u00e3o na velocidade no tr\u00e2nsito col\u00f4nico (in\u00e9rcia col\u00f4nica) e a \n\ndificuldade em eliminar as fezes (altera\u00e7\u00f5es funcionais de assoalho p\u00e9lvico, reto ou \n\n\u00e2nus) s\u00e3o dois mecanismos fisiopatol\u00f3gicos utilizados para explicar a constipa\u00e7\u00e3o \n\n(LENNARD-JONES, 2002). As causas mais comuns de constipa\u00e7\u00e3o s\u00e3o de \n\ncaracter\u00edstica idiop\u00e1tica ou secund\u00e1ria (FUCHS et al., 2004). As causas idiop\u00e1ticas se \n\ndividem em individuais e ambientais. As individuais compreendem a alimenta\u00e7\u00e3o \n\ndeficiente ou err\u00f4nea, hidrata\u00e7\u00e3o insuficiente, h\u00e1bito intestinal inadequado, postura \n\nincorreta ao defecar, neglig\u00eancia ao reflexo evacuat\u00f3rio e sedentarismo. As ambientais \n\ncompreendem a hospitaliza\u00e7\u00e3o, viagens, condi\u00e7\u00f5es desfavor\u00e1veis \u00e0 defeca\u00e7\u00e3o no local \n\nde trabalho. As causas secund\u00e1rias de constipa\u00e7\u00e3o incluem influ\u00eancias medicamentosas, \n\nneurol\u00f3gicas, end\u00f3crinas e metab\u00f3licas, psiqui\u00e1tricas e proctol\u00f3gicas (FUCHS et al., \n\n2004).  \n\nEmbora a abordagem inicial na constipa\u00e7\u00e3o seja a identifica\u00e7\u00e3o da causa e, \n\nbaseado nela o estabelecimento do tratamento adequado, cujo manejo sintom\u00e1tico \n\nprioriza medidas n\u00e3o farmacol\u00f3gicas, freq\u00fcentemente o uso laxantes se imp\u00f5e \n\n(LENNARD-JONES, 2002). No entanto, sabe-se que o uso em longo prazo \u00e9 ineficaz e \n\npode levar a efeitos colaterais prejudiciais, como o aumento da constipa\u00e7\u00e3o, o risco de \n\nimpacta\u00e7\u00e3o fecal e o c\u00e2ncer de c\u00f3lon e reto (BOHMER et al., 2001; EMLY; \n\nROCHESTER, 2006). Quando o tratamento medicamentoso \u00e9 institu\u00eddo, deve ser \n\nmantido at\u00e9 que se alcancem os objetivos propostos, em um per\u00edodo de seis a 24 meses; \n\na partir desse intervalo, a retirada da medica\u00e7\u00e3o deve ser gradual (MELO et al., 2003; \n\nTOBIAS et al., 2008). \n\nAs medica\u00e7\u00f5es laxantes podem ser divididas de acordo com o seu mecanismo de \n\na\u00e7\u00e3o, conforme descritas a seguir (PREECE, 2002): \n\nOs laxantes utilizados para aumentar o volume do bolo fecal s\u00e3o o \u00e1gar-agar, a \n\nmetilcelulose, carboximetilcelulose, o plantago e o farelo de trigo. O acr\u00e9scimo de \n\nfibras contidas em medicamentos industrializados busca reproduzir o que aconteceria \n\nfisiologicamente com uma ingest\u00e3o correta de fibras. S\u00e3o produtos cuja utiliza\u00e7\u00e3o \n\nprolongada n\u00e3o oferece riscos colaterais importantes, mas podem, em uma fase inicial, \n\ntornar mais exuberantes alguns sintomas desconfort\u00e1veis, como distens\u00e3o e dor \n\nabdominais, meteorismo intestinal e flatul\u00eancia (PREECE, 2002).  \n\n64 \n \n\n\n\nLaxantes osm\u00f3ticos s\u00e3o subst\u00e2ncias pouco absorv\u00edveis ou inabsorv\u00edveis pelo \n\nintestino delgado que, gra\u00e7as a sua osmolaridade, s\u00e3o retentores de \u00e1gua na luz \n\nintestinal e largamente usados. Entre eles, temos os sais de s\u00f3dio e magn\u00e9sio, e os \n\na\u00e7\u00facares inabsorv\u00edveis, como produtos contendo lactulose ou sorbitol, in\u00f3cuos, restando \n\ncomo inconveni\u00eancia a produ\u00e7\u00e3o de gases e distens\u00e3o abdominal (PREECE, 2002). \n\nOs laxativos cat\u00e1rticos, irritantes ou estimulantes comp\u00f5em um grupo de \n\nsubst\u00e2ncias, derivados antraquin\u00f4nicos cuja a\u00e7\u00e3o se faz sobre o plexo mioent\u00e9rico, \n\naumentando a motilidade col\u00f4nica, assim como a secre\u00e7\u00e3o de \u00e1gua pelo \u00edleo e pelo \n\nc\u00f3lon. Senos\u00eddeos cascara sagrada, sene, \u00f3leo de r\u00edcino, fenolftale\u00edna, dioctil-\n\nsulfossuccinatos, bisacodyl, utilizados em preparados, isoladamente ou em associa\u00e7\u00e3o, \n\ns\u00e3o alguns exemplos. Possuem efeito imediato, por\u00e9m sua prescri\u00e7\u00e3o generalizada n\u00e3o \u00e9 \n\naconselh\u00e1vel, nem sua manuten\u00e7\u00e3o por per\u00edodos prolongados. A experi\u00eancia de \n\nespecialistas com esse modelo de laxativos reconhece que as doses inicialmente \n\neficazes, tendem a ser aumentadas com o tempo de uso (pela altera\u00e7\u00e3o das termina\u00e7\u00f5es \n\nnervosas intestinais), al\u00e9m de sintomas dolorosos abdominais, que potencialmente \n\npodem provocar (PREECE, 2002). \n\n\u00d3leos minerais t\u00eam a\u00e7\u00e3o lubrificante tanto da parede intestinal quanto do bolo \n\nfecal, facilitando sua passagem pela luz col\u00f4nica, s\u00e3o conhecidos como laxantes \n\nemolientes. No entanto, o \u00f3leo mineral pode diminuir a absor\u00e7\u00e3o de c\u00e1lcio e vitaminas \n\nlipossol\u00faveis (ESCOTT-STUMP, 2007). Al\u00e9m disso, n\u00e3o s\u00e3o recomendados \u00f3leos \n\nminerais e laxantes estimulantes para crian\u00e7as (NASPGHAN, 2006), devido ao uso do \n\n\u00f3leo poder induzir a disfagia que pode levar \u00e0 aspira\u00e7\u00e3o pulmonar, causando pneumonia \n\naspirativa (GALAL et al, 2007; MELO et al, 2003). \n\nO uso rotineiro de suposit\u00f3rios ou preparados para aplica\u00e7\u00e3o t\u00f3pica pode ser \n\nempregado nas constipa\u00e7\u00f5es com origem na disfun\u00e7\u00e3o retal. Ainda que um \n\nprocedimento desconfort\u00e1vel em tratamentos cont\u00ednuos chegue a ser, em alguns casos, a \n\nmelhor proposta terap\u00eautica (AMBROGINI, 2003), uma vez que os suposit\u00f3rios de \n\nglicerina n\u00e3o apresentam efeitos colaterais significativos (NASPGHAN, 2006; \n\nSANTOS, 2003). \n\n \n\n2.3. IMPORT\u00c2NCIA DE ESTUDOS TOXICOL\u00d3GICOS DE PLANTAS \nMEDICINAIS \n\n \n\n65 \n \n\n\n\nO emprego de plantas capazes de produzir efeitos no corpo humano \u00e9 t\u00e3o antigo \n\nquanto \u00e0 pr\u00f3pria humanidade (CUNHA et al. 2003). O homem paleol\u00edtico j\u00e1 as utilizava \n\nno tratamento de doen\u00e7as, o que \u00e9 comprovado n\u00e3o apenas por estudos das tradi\u00e7\u00f5es dos \n\npovos, mas tamb\u00e9m por investiga\u00e7\u00f5es antropol\u00f3gicas, paleontol\u00f3gicas e arqueol\u00f3gicas \n\n(CASTRO 1981; LOPES et al, 2009). Apesar dos avan\u00e7os cient\u00edficos mais recentes, o \n\nuso de plantas medicinais como recurso terap\u00eautico ainda encontra-se fundamentado \n\nprincipalmente na cultura popular, havendo necessidade de informa\u00e7\u00f5es quanto \u00e0 \n\nefic\u00e1cia e seguran\u00e7a (SCHENKEL et al, 2000). \n\n A toxicidade de uma subst\u00e2ncia a ser testada para fins farmacol\u00f3gicos e \n\nterap\u00eauticos deve ser o primeiro passo que um farmacologista ou toxicologista precisa \n\ndeterminar, de maneira que, durante os experimentos, n\u00e3o venha a ter surpresas \n\ndesagrad\u00e1veis com os efeitos nocivos aos animais de experimento ou at\u00e9 mesmo a \n\nmorte deles. Uma subst\u00e2ncia altamente t\u00f3xica promover\u00e1 um efeito danoso ao \n\norganismo vivo e/ou ao ambiente, ainda quando empregado em m\u00ednimas quantidades, \n\nenquanto que as subst\u00e2ncias de baixa toxicidade precisam de altas doses para promover \n\num efeito t\u00f3xico (VEN\u00c2NCIO, 2006). \n\n O medicamento fitoter\u00e1pico \u00e9 um corpo estranho ao organismo e, como todo \n\nxenobi\u00f3tico, os produtos de sua biotransforma\u00e7\u00e3o s\u00e3o potencialmente t\u00f3xicos e assim \n\ndevem ser encarados at\u00e9 que se prove o contr\u00e1rio (LAPA et al., 2000). Na Alemanha, \n\ndesde 1978 cerca de quatro mil medicamentos fitoter\u00e1picos v\u00eam sendo submetidos a um \n\nrigoroso programa de farmacovigil\u00e2ncia e avalia\u00e7\u00e3o toxicol\u00f3gica, e muitos deles foram \n\nretidos do mercado devido aos seus efeitos delet\u00e9rios ao ser humano (KELLER, 1996). \n\n No Brasil, as pesquisas realizadas para a avalia\u00e7\u00e3o do uso seguro de plantas \n\nmedicinais e fitoter\u00e1picos ainda s\u00e3o incipientes, assim como o controle da \n\ncomercializa\u00e7\u00e3o pelos \u00f3rg\u00e3os oficiais em feiras livres, mercados p\u00fablicos ou lojas de \n\nprodutos naturais (VEIGA-J\u00daNIOR, PINTO e MACIEL, 2005). \n\n  \n\n \n\n2.4. AN\u00c1LISE TOXICOL\u00d3GICA PR\u00c9-CL\u00cdNICA \n\n \n\nToxicologia \u00e9 a ci\u00eancia que tem como objeto de estudo o efeito adverso de \n\nsubst\u00e2ncias qu\u00edmicas e f\u00edsicas sobre organismos vivos, sendo tamb\u00e9m referida como a \n\nci\u00eancia dos venenos. Tem como principal finalidade de estabelecer a dose segura da \n\n66 \n \n\n\n\nsubst\u00e2ncia qu\u00edmica em quest\u00e3o que pode interagir com o organismo vivo de modo a \n\nprevenir o aparecimento de efeitos colaterais (LEITE e AMORIM, 2006).  \n\nDevido a raz\u00f5es \u00e9ticas, morais e legais, a obten\u00e7\u00e3o de dados toxicol\u00f3gicos em \n\nseres humanos \u00e9 bastante limitada, sendo a maioria dos dados obtidos atrav\u00e9s de testes \n\ntoxicol\u00f3gicos pr\u00e9-cl\u00ednicos que utilizam animais de laborat\u00f3rio em condi\u00e7\u00f5es \n\npadronizadas (BOELSTERLI, 2003). Desta maneira, a toxicologia continua dependendo \n\nfortemente do uso de testes em animais para a previs\u00e3o do risco de toxicidade dos \n\ncompostos qu\u00edmicos em seres humanos (HOUCK e KAVLOCK, 2008). \n\nGrande parte dos dados obtidos a partir de testes toxicol\u00f3gicos pr\u00e9-cl\u00ednicos pode \n\nter valor de aplica\u00e7\u00e3o na esp\u00e9cie humana. Desde que sejam realizados sob condi\u00e7\u00f5es \n\nadequadas e que seja feita a escolha apropriada da esp\u00e9cie e linhagem animal, via de \n\nadministra\u00e7\u00e3o e regime de dosagem (MORTON, 1998). \n\nNo Brasil, a ANVISA, atrav\u00e9s da Resolu\u00e7\u00e3o n\u00ba 90 de 16 de Mar\u00e7o de 2004, \n\ninstituiu que os m\u00e9todos realizados para os estudos toxicol\u00f3gicos pr\u00e9-cl\u00ednicos de plantas \n\nmedicinais devem incluir estudos de toxicidade aguda e de doses repetidas (subcr\u00f4nica e \n\ncr\u00f4nica). Nestes estudos deve constar a avalia\u00e7\u00e3o dos par\u00e2metros bioqu\u00edmicos e \n\nhematol\u00f3gicos, evolu\u00e7\u00e3o da massa corp\u00f3rea, bem como a histologia dos \u00f3rg\u00e3os \n\n(BRASIL, 2004). Al\u00e9m dos ensaios de toxicidade aguda e de doses repetidas a \n\nResolu\u00e7\u00e3o n\u00ba 90 de 2004 tamb\u00e9m sugere a inclus\u00e3o de estudos especiais de \n\ngenotoxicidade e carcinogenicidade. \n\n \n\n2.4. 1. Toxicidade aguda \n\n \n\n Toxicidade aguda \u00e9 definida como conjunto de efeitos adversos que ocorrem \n\ndentro de um per\u00edodo curto, ap\u00f3s a administra\u00e7\u00e3o de uma dose \u00fanica, ou doses m\u00faltiplas \n\nadministradas dentro de um per\u00edodo de 24 horas, tendo como objetivo determinar a \n\nsintomatologia em curto prazo ap\u00f3s a administra\u00e7\u00e3o de um composto, bem como o \n\nbin\u00f4mio dose-efeito letal, que \u00e9 estimado por um par\u00e2metro denominado dose letal \n\n50%, mais conhecida como DL50 (BARROS; DAVINO, 2003). O per\u00edodo de estudo \n\nabrange de 7 a 14 dias, seguidos por an\u00e1lises cl\u00ednicas e patol\u00f3gicas (UKELIS et al., \n\n2008). \n\n O teste de DL50 foi introduzido inicialmente por J.W. TREVAN em 1927, \n\natendendo a finalidade de estimar o risco t\u00f3xico de subst\u00e2ncias tais como digitalis e \n\ninsulina para uso humano. Ele sugeriu que se considerasse como dose letal aquela que \n\n67 \n \n\n\n\nmatasse 50% dos animais injetados. Isto porque os valores em torno da DL50 variam \n\nmenos que aqueles ao redor da DL1 ou da DL99.  \n\n Este valor \u00e9 um par\u00e2metro estat\u00edstico onde o c\u00e1lculo da dose letal m\u00e9dia seria \n\nobtido atrav\u00e9s de um gr\u00e1fico, no qual se encontram nas ordenadas a percentagem de \n\nanimais mortos e nas abscissas as doses empregadas, obtendo-se uma curva dose-\n\nresposta, representada, teoricamente, por uma curva Gaussiana (BARROS; DAVINO, \n\n2003; BOTHAM,2004; SCHLEDE et al., 2005). A partir da d\u00e9cada de 1970, o teste de \n\nDL50 tornou-se pr\u00e9-requisito para v\u00e1rias ag\u00eancias reguladoras, como a Food and Drug \n\nadministration (FDA), respons\u00e1veis pela aprova\u00e7\u00e3o de novos f\u00e1rmacos. Para que o teste \n\nde DL50 fosse realizado eram utilizados mais de 100 animais para cada esp\u00e9cie estudada \n\n(normalmente ratos e camundongos) e para cada subst\u00e2ncia testada (VALADARES, \n\n2006). \n\n Devido \u00e0 necessidade de um grande n\u00famero de animais para o estudo de DL50, \n\nem 2002 este teste foi eliminado (BOTHAM, 2004), sendo substitu\u00eddo por testes \n\nalternativos, tais como a Dose Fixa, Toxicidade Aguda de Classe e Teste \u201cUp and \n\nDown\u201d, os quais trouxeram melhora significativa para o bem-estar do animal \n\n(VALADARES, 2006). O princ\u00edpio do teste de dose fixa \u00e9 a identifica\u00e7\u00e3o da menor \n\ndose que promove rea\u00e7\u00e3o t\u00f3xica evidente, obtendo a faixa estimada da DL50 e sinais de \n\ntoxicidade aguda (OECD 420). O teste de toxicidade aguda de classe tamb\u00e9m utiliza o \n\nconceito de dose fixa, por\u00e9m, o objetivo final \u00e9 a taxa de mortalidade (OECD 423); \n\nenquanto o teste de \u201cUp and Down\u201d tem como finalidade estimar o valor da DL50, \n\ntestando seq\u00fcencialmente animais individuais, com a dose para cada animal sendo \n\najustada para cima ou para baixo, dependendo do resultado pr\u00e9vio do animal anterior \n\n(OECD 425). \n\n O teste de toxicidade aguda \u00e9 importante para todos os tipos de produto, \n\nindependente do tempo de uso proposto para a esp\u00e9cie humana, pois evidencia os \n\npotenciais riscos de intoxica\u00e7\u00f5es agudas, inadvertidas ou n\u00e3o, e a forma de preveni-las. \n\nAl\u00e9m disso, d\u00e3o suporte \u00e0 escolha das doses para os demais testes de toxicidade (LAPA \n\net al., 2000). \n\n \n\n2.4.2. Toxicidade Cr\u00f4nica \n\n \n\nO teste de toxicidade cr\u00f4nica tem como objetivo avaliar a\u00e7\u00f5es qualitativas e/ou \n\nquantitativamente diferentes produzidas pelo maior tempo de exposi\u00e7\u00e3o ao produto, \n\n68 \n \n\n\n\ncom m\u00faltiplas doses, permitindo tamb\u00e9m, medir a lat\u00eancia dos efeitos t\u00f3xicos e o \n\nac\u00famulo da droga no organismo. Uma vez comprovada a rela\u00e7\u00e3o entre doses e efeitos \n\nt\u00f3xicos \u00e9 poss\u00edvel determinar a maior dose que n\u00e3o produz efeito t\u00f3xico detect\u00e1vel. Este \n\n\u00e9 um par\u00e2metro importante na avalia\u00e7\u00e3o da margem de seguran\u00e7a do f\u00e1rmaco no qual se \n\nbaseia o c\u00e1lculo da dose inicial a ser empregada nos testes cl\u00ednicos (KLAASSEN; \n\nWATKINS, 2001). \n\nA dura\u00e7\u00e3o dos testes de toxicidade tem rela\u00e7\u00e3o direta com a dose a ser \n\nadministrada em humanos. Se o teste \u00e9 feito em dose \u00fanica, ou parcelado em 24 horas, a \n\nadministra\u00e7\u00e3o experimental intermitente dever\u00e1 ser de no m\u00ednimo 14 dias; se o \n\ntratamento humano \u00e9 previsto para 7 ou 30 dias (ou mais), os animais dever ser tratados \n\nininterruptamente por um m\u00ednimo de 30 a 90 dias, respectivamente. De acordo com essa \n\ndura\u00e7\u00e3o, os testes de doses repetidas s\u00e3o subdivididos em testes subagudos, ou de doses \n\nrepetidas \u2013 menos de 30 dias de tratamento; testes subcr\u00f4nicos \u2013 m\u00ednimo de 30 dias ou \n\ntestes cr\u00f4nicos \u2013 m\u00ednimo de 90 dias (LAPA et al., 2000). \n\nLarini (1997) classifica a toxicidade cr\u00f4nica em toxicidade em curto prazo, \n\nm\u00e9dio e em longo prazo. Na toxicidade em curto prazo \u00e9 administrada dose di\u00e1ria por \n\num per\u00edodo de 28 dias, sendo recomendadas pelo menos tr\u00eas doses experimentais. A \n\nmaior dose n\u00e3o deve produzir mais do que 10% de mortalidade, ap\u00f3s uma dose inicial. \n\nA toxicidade em m\u00e9dio prazo representa a capacidade das subst\u00e2ncias em produzir \n\nefeitos adversos, como resultado da administra\u00e7\u00e3o de doses repetidas, em animais de \n\nlaborat\u00f3rio, durante um per\u00edodo de tempo n\u00e3o superior a 10% de vida m\u00e9dia do animal \n\nutilizado. A toxicidade em longo prazo \u00e9 obtida a partir da administra\u00e7\u00e3o di\u00e1ria do \n\nagente t\u00f3xico em animais de laborat\u00f3rio durante 12 meses. A via oral de administra\u00e7\u00e3o \n\n\u00e9 a preferida e, neste caso a subst\u00e2ncia deve ser incorporada \u00e0 dieta do animal. \n\nDurante o estudo de toxicidade cr\u00f4nica \u00e9 necess\u00e1rio que haja observa\u00e7\u00e3o di\u00e1ria \n\ndo animal quanto a altera\u00e7\u00f5es de massa corporal, cor e textura dos p\u00ealos, consumo de \n\n\u00e1gua e ra\u00e7\u00e3o, temperatura corporal, par\u00e2metros respirat\u00f3rios e cardiovasculares e quanto \n\na mudan\u00e7as no comportamento e presen\u00e7a de altera\u00e7\u00f5es motoras. Ao final do ensaio, os \n\nanimais devem ter o sangue coletado para as dosagens bioqu\u00edmicas e hematol\u00f3gicas e, \n\nap\u00f3s eutan\u00e1sia, exames morfol\u00f3gicos macro e microsc\u00f3picos dos principais \u00f3rg\u00e3os \n\n(BARNES e DOURSON, 1988). \n\n \n\n2.5. Aloe ferox Miller \n\n \n\n69 \n \n\n\n\n2.5.1. Bot\u00e2nica \n\n \n\nA esp\u00e9cie Aloe ferox pertence \u00e0 fam\u00edlia Asphodelaceae (anteriormente conhecida \n\ncomo Liliaceae) e g\u00eanero Aloe, que compreende cerca de 420 esp\u00e9cies, muitas delas \n\nutilizadas em v\u00e1rios pa\u00edses, inclusive no Brasil, para fins medicinais e cosm\u00e9ticos \n\n(BACH; LOPES, 2007).  \n\nAloe ferox Miller (Figura 1) tamb\u00e9m conhecida como Aloe amargo, Aloe \n\nvermelho, Cape Aloe, Zulu, Xhosa e Sotho- Umhlab \u00e9 uma planta que se desenvolve em \n\nterras com chuvas mais ou menos moderadas e secas e solos menos f\u00e9rteis; possui \n\nampla distribui\u00e7\u00e3o em toda a \u00c1frica do Sul, tendo maior concentra\u00e7\u00e3o nas Prov\u00edncias do \n\nCabo Leste e Oeste (WYK e WYK, 2002; SHACKLETON; GAMBIZA, 2007). No \n\nBrasil, os maiores produtores da planta encontram-se no interior de S\u00e3o Paulo \n\n(particularmente no munic\u00edpio de Jarinu), Santa Catarina e na regi\u00e3o Nordeste. Sendo \n\nesta \u00faltima a que possui as melhores condi\u00e7\u00f5es de plantio (MAGALH\u00c3ES, 2005). \n\nAloe ferox \u00e9 comum em encostas rochosas, freq\u00fcentemente em grande \n\nquantidade, onde ele cria uma exibi\u00e7\u00e3o deslumbrante no inverno. Cresce tanto em \n\ncampo aberto quanto em \u00e1reas espessas. As plantas tamb\u00e9m podem diferir quanto \u00e0 \n\ncomposi\u00e7\u00e3o de metab\u00f3litos secund\u00e1rios de regi\u00e3o para regi\u00e3o, devido \u00e0s condi\u00e7\u00f5es \n\nlocais (GLEN e HARDY, 2000). \n\nAloe ferox Miller \u00e9 uma plantas robusta, com caule \u00fanico, medindo 2 \u2013 5 m em \n\nesp\u00e9cimes mais velhos, com folhas dispostas em rosetas. As folhas secas permanecem \n\nna parte inferior do tronco, formando uma esp\u00e9cie de \u201csaia\u201d ao redor do tronco. Possui \n\nfolhas largas, carnudas, de colora\u00e7\u00e3o que vai de verde acinzentado a vermelho, e \n\napresentando espinhos marrons ao longo da borda; os espinhos tamb\u00e9m podem estar \n\npresentes nas superf\u00edcies inferiores e superiores das folhas. Plantas jovens tendem a ser \n\nbastante espinhosas (VAN WYK, 2003). \n\nAs flores de Aloe ferox apresentam colora\u00e7\u00e3o que variam de amarelo-alaranjado \n\nao vermelho brilhante. Possuem seis a doze ramos e suas p\u00e9talas internas apresentam \n\ncor branca em suas pontas. A flora\u00e7\u00e3o ocorre entre maio e agosto, podendo, em pa\u00edses \n\nmais frios, retardar at\u00e9 setembro. Plantas jovens atingem a maturidade (com flor e \n\nsemente) dentro de quatro a seis anos, e sob condi\u00e7\u00f5es favor\u00e1veis podem chegar a mais \n\nde 50 anos (GLEN e HARDY, 2000). \n\n70 \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 1: Aloe ferox Miller \n\n2.5.2. Fitoqu\u00edmica \n\n \n\nAloe ferox \u00e9 uma planta bastante estudada do ponto de vista de seus constituintes \n\nqu\u00edmicos, entre as mais de 130 subst\u00e2ncias identificadas destacam-se: alcal\u00f3ides, \n\nantraquinonas, antronas, derivados benz\u00eanicos, cromonas, cumarinas, piranos, pironas, \n\nflavon\u00f3ides, ester\u00f3ides, sacar\u00eddeos, enzimas, amino\u00e1cidos, minerais inorg\u00e2nicos, entre \n\noutros (MELO et al., 2009). \n\n Segundo Jia et al.(2008), foi detectada a presen\u00e7a de alo\u00edna, aloe-emodina, \n\npolissacar\u00eddeos, manose e acemanan, um glicosaminoglicano, no suco das folhas de \n\nAloe ferox. A fra\u00e7\u00e3o polissacar\u00eddea no suco das folhas da planta possui massa molecular \n\nentre 150 e 1000 KDa, sendo o maior componente do suco de Aloe ferox; o maior \n\nres\u00edduo de a\u00e7\u00facar encontrado na fra\u00e7\u00e3o polissacar\u00eddea \u00e9 composto por manose. \n\n Loots et al. (2007), analisaram os extratos liofilizado e etan\u00f3lico a 95% do gel \n\ndas folhas de Aloe ferox por meio de cromatografia gasosa acoplada \u00e0 espectro de \n\nmassa(CG-SM). De todos os componentes detectados, os grupos de compostos melhor \n\ndescritos por seus benef\u00edcios \u00e0 sa\u00fade foram os \u00e1cidos fen\u00f3licos, polifen\u00f3is, ester\u00f3is, \n\n\u00e1cidos graxos e ind\u00f3is. Al\u00e9m destes, v\u00e1rios alcanos, pirimidinas, alcal\u00f3ides, \u00e1cidos \n\norg\u00e2nicos, alde\u00eddos, \u00e1cidos dicarbox\u00edlicos, cetonas e alco\u00f3is tamb\u00e9m foram \n\nidentificados. \n\n71 \n \n\n\n\n Dos polifen\u00f3is e \u00e1cidos fen\u00f3licos identificados por Loots e colaboradores \n\n(2007), aqueles encontrados em maior concentra\u00e7\u00e3o foram \u00e1cido benz\u00f3ico, \u00e1cido p-\n\ntolu\u00edco, \u00e1cido p-cumar\u00edco, \u00e1cido p-salic\u00edlico, \u00e1cido hidroxifenilac\u00e9tico, \u00e1cido ferr\u00falico, \n\naloe-emodina, crisofanol e \u00e1cido van\u00edlico. Fitoester\u00f3is tamb\u00e9m foram identificados por \n\ncromatografia gasosa; destes, o ?-sitosterol ocorre em maiores concentra\u00e7\u00f5es no extrato \n\nliofilizado, contribuindo em 93% dos fitoester\u00f3is totais encontrados. O extrato etan\u00f3lico \n\nfoi menos efetivo na extra\u00e7\u00e3o destes componentes, tendo sido identificado apenas o \n\ncolestanol. A presen\u00e7a de \u00e1cidos graxos poliinsaturados de cadeia longa (PUFAs) \n\ntamb\u00e9m \u00e9 descrita no gel das folhas de Aloe ferox, sendo os mais importantes os \u00e1cidos \n\nlinol\u00e9ico e linol\u00eanico (LOOTS et al., 2007). \n\n O exsudato das folhas de Aloe ferox cont\u00e9m 15 a 40% de antronas C-glicosiladas \n\n(derivados antraquin\u00f4nicos) como alo\u00edna e hidroxialo\u00edna. Al\u00e9m destes componentes, o \n\nexsudato tamb\u00e9m cont\u00e9m aloenina derivada da pirona e livre e 2-acetonil-7-hidr\u00f3xi-5-\n\nmetilcromonas, tais como aloesona, furoaloesona, aloeresina A, aloeresina B (Aloesina) \n\ne Aloeresina C. Aloe ferox tamb\u00e9m cont\u00e9m feroxidina livre e glicosilada e ferarolida \n\n(SCHMELZER et al. , 2008). \n\n Magwa et al. (2006) identificou mais de vinte compostos vol\u00e1teis no \u00f3leo \n\nessencial extra\u00eddo das folhas de Aloe ferox Miller. Dentre eles, 1,3,6-octatrieno \n\n(23,87%), 3-ciclohexeno-1-acetalde\u00eddo, ?-4-dimetil (9,51%), 2,4-decadien-1-ol (E,E) \n\n(7,45%) e 2-heptanol (7,31%) foram os componentes encontrados em maior abund\u00e2ncia \n\nnos compostos vol\u00e1teis. Os seguintes componentes qu\u00edmicos ocorreram em menor \n\nquantidade: ?- terpineno, (4,84%), ?- terpinoleno (4,0%), canfeno (3,27%), (-)-\n\nbornilacetato (2,43%), tridecano (1,95%) e ?-humuleno (1,74%).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                               Figura 2: Alo\u00edna \n\n2.5.3. Farmacologia \n\n \n\n72 \n \n\n\n\nNumerosas esp\u00e9cies de Aloe s\u00e3o conhecidas por suas propriedades medicinais, \n\nno entanto, apenas Aloe ferox, Aloe perryi e Aloe vera demonstraram import\u00e2ncia \n\ncomercial (GRINDLAY, 1986). \n\nO gel de Aloe ferox tem sido descrito por sua atividade antiinflamat\u00f3ria, \n\ncicatrizante, antitumoral, antiviral, antimicrobiana, anti-diab\u00e9tica, imunoestimulante e \n\nde redu\u00e7\u00e3o do (TIZARD, 1989; WANG, 1998; REYNOLDS, 1999; PECERE, 2000; \n\nSTRICKLAND, 2001; BAUTISTA, 2004). O constituinte ativo do exsudato do Aloe \n\nferox \u00e9 a antrona, que concede atividade estimulante laxante \u00e0 planta (BLUMENTHAL, \n\n1998). Estudos demonstraram que aloe-emodina, um constituinte identificado no suco \n\ndas folhas de Aloe ferox, apresenta atividade antiviral, antioxidante, efetiva na \n\npreven\u00e7\u00e3o de c\u00e2ncer de f\u00edgado e inibidora do crescimento de c\u00e9lulas tumorais \n\nneuroectodermais (YEN, 2000; PECERE, 2000; KUO, 2002). \n\n \n\n2.5.3.1. Atividade Antiinflamat\u00f3ria \n\n \n\nA inflama\u00e7\u00e3o \u00e9 uma resposta imune n\u00e3o-espec\u00edfica do corpo a qualquer tipo de \n\nles\u00e3o, sendo caracterizada pela presen\u00e7a de rubor (eritema), calor (aumento da \n\ntemperatura local), tumor (edema) e dor, levando muitas vezes, \u00e0 perda da fun\u00e7\u00e3o do \n\n\u00f3rg\u00e3o ou tecido inflamado (LAPA et al., 2003). De acordo com Clayton (1993) as fases \n\nda inflama\u00e7\u00e3o s\u00e3o: vasodilata\u00e7\u00e3o que reduz a press\u00e3o sangu\u00ednea e aumenta o fluxo \n\nsang\u00fc\u00edneo, seguido de incha\u00e7o devido \u00e0 quantidade excessiva de fluido tecidual; e dor. \n\nVazquez (1996) demonstrou que o gel de Aloe ferox exerce a\u00e7\u00e3o \n\nantiinflamat\u00f3ria, ao inibir a produ\u00e7\u00e3o de prostaglandina E2 a partir do \u00e1cido \n\naraquid\u00f4nico; enquanto que Yagi (1982) que a glicoprote\u00edna do gel de Aloe ferox cliva \n\nas liga\u00e7\u00f5es da mol\u00e9cula de bradicinina, reduzindo a dor e a inflama\u00e7\u00e3o. Em estudo mais \n\nrecente Bautista (2004), associou o efeito da bradicinina com a inibi\u00e7\u00e3o da s\u00edntese de \n\nprostaglandinas. \n\nA inflama\u00e7\u00e3o tamb\u00e9m est\u00e1 envolvida em doen\u00e7as como a artrite. A artrite \n\nreumat\u00f3ide, especificamente, assemelhasse \u00e0 artrite adjuvante em ratos. Estudos \n\ndemonstraram que a inje\u00e7\u00e3o de Aloe ferox nas patas dos ratos diminuiu a inflama\u00e7\u00e3o em \n\n50% e promoveu a libera\u00e7\u00e3o de fator de crescimento de fibroblastos e, conseq\u00fcente, \n\nreparo tecidual (DAVIS, 1992). Tamb\u00e9m foi encontrado que Aloe ferox possui atividade \n\nanalg\u00e9sica, devido \u00e0 presen\u00e7a de salicilatos em sua composi\u00e7\u00e3o, promovendo efeitos \n\nsemelhantes ao da aspirina (SHELTON, 1991). \n\n73 \n \n\n\n\n \n\n2.5.3.2. Atividade Cicatrizante e Imuno-moduladora \n\n \n\nA cicatriza\u00e7\u00e3o de feridas \u00e9 um complexo e din\u00e2mico processo que geralmente \n\nenvolve fases distintas marcando os est\u00e1gios de cura, e requer v\u00e1rios tipos de c\u00e9lulas \n\npara completar uma diversidade de atividades celulares (CHITHIRA, 1998; McNEES, \n\n2006). \n\nEstudos realizados com o suco da folha inteira de Aloe ferox indicam que esta \n\nplanta acelera a progress\u00e3o e fechamento de feridas. O aumento na taxa de cicatriza\u00e7\u00e3o \n\nde feridas \u00e9 caracterizado por uma redu\u00e7\u00e3o no per\u00edodo de tempo para epiteliza\u00e7\u00e3o total \n\nou parcial (JIA et al., 2008). \n\nPolissacar\u00eddeos s\u00e3o conhecidos por ter propriedade efetiva no reparo de feridas \n\nde pele. Fra\u00e7\u00f5es polissacar\u00eddeas identificadas em Aloe ferox foram capazes de promover \n\numa cascata de atividades biol\u00f3gicas, incluindo o aumento da fun\u00e7\u00e3o reticuloendotelial, \n\nmodula\u00e7\u00e3o de respostas imunes, promo\u00e7\u00e3o da atividade antiviral e estimula\u00e7\u00e3o da \n\nhematopoiese. Cada uma dessas atividades biol\u00f3gicas tem o seu pr\u00f3prio benef\u00edcio para a \n\ncura (REYNOLDS e DWECK, 1999; LEUNG et al., 2004; TALMADGE \n\net al., 2004).  \n\nA maior fra\u00e7\u00e3o polissacar\u00eddea de Aloe ferox \u00e9 a manose. Este a\u00e7\u00facar se liga aos \n\nreceptores na superf\u00edcie dos fibroblastos, estimulando-os e ativando a acelera\u00e7\u00e3o de seu \n\ncrescimento e replica\u00e7\u00e3o celular (EAST e ISACKE, 2002). Acemannan, um pol\u00edmero \n\n1,4-?-acetilado da manose, \u00e9 conhecido por induzir a produ\u00e7\u00e3o de diversas citocinas \n\ninflamat\u00f3rias, algumas das quais se acredita ter a\u00e7\u00e3o na cicatriza\u00e7\u00e3o de feridas \n\n(BARBUL, 1990). Al\u00e9m do mais, esse pol\u00edmero foi utilizado em pacientes HIV-1 \n\npositivo, demonstrando um aumento significativo no n\u00famero de mon\u00f3citos e \n\nmacr\u00f3fagos circulantes, uma vez que este composto pode exercer atividade antiviral e \n\nantitumoral in vivo, atrav\u00e9s da ativa\u00e7\u00e3o de macr\u00f3fagos, s\u00edntese de \u00f3xido nitroso (NO) e \n\naumento de linf\u00f3citos T citot\u00f3xicos (LEE et al., 2001; CHOI e CHUNG, 2003). Em um \n\nestudo piloto de tratamento de pessoas infectadas pelo HIV, Acemannan aumentou o \n\nn\u00famero de gl\u00f3bulos brancos, melhorando os sintomas (McDANIELS, 1990). \n\nA exposi\u00e7\u00e3o cr\u00f4nica \u00e0 radia\u00e7\u00e3o ultravioleta (UV) provoca queimaduras, \n\nenvelhecimento prematuro da pele e muta\u00e7\u00f5es gen\u00e9ticas levando ao c\u00e2ncer de pele. A \n\nexposi\u00e7\u00e3o a raios UV promove supress\u00e3o da resposta imunol\u00f3gica sist\u00eamica. Strickland \n\n74 \n \n\n\n\n(2001) demonstrou que o gel de Aloe ferox impediu a supress\u00e3o da resposta imune \n\nmediada por c\u00e9lulas T e a produ\u00e7\u00e3o de IL-10.  \n\n \n\n2.5.3.3. Fun\u00e7\u00e3o Gastrintestinal \n\n \n\nO suco de Aloe \u00e9 indicado como t\u00f4nico para o intestino, promovendo redu\u00e7\u00e3o no \n\npH intestinal, redu\u00e7\u00e3o do tempo de tr\u00e2nsito intestinal, benef\u00edcios \u00e0 flora bacteriana \n\nintestinal com redu\u00e7\u00e3o da fermenta\u00e7\u00e3o, redu\u00e7\u00e3o da putrefa\u00e7\u00e3o intestinal e digest\u00e3o e \n\nabsor\u00e7\u00e3o de prote\u00ednas (BLAND, 1985). \n\nYamamoto (1973) demonstrou que um componente de Aloe ferox suprime o \n\ncrescimento da \u00falcera e de L-histidina descaboxilase em ratos. Al\u00e9m disso, estudos a \n\nrespeito da atividade gastroprotetora de Aloe demonstram que este g\u00eanero promove \n\ninibi\u00e7\u00e3o da secre\u00e7\u00e3o de \u00e1cido g\u00e1strico, sendo \u00fatil para o tratamento da \u00falcera p\u00e9ptica \n\n(YUSUF, 2004).  \n\nQuando o suco de Aloe ferox \u00e9 administrado oralmente em animais, mananas, um \n\npolissacar\u00eddeo derivado da manose, promove diminui\u00e7\u00e3o do colesterol por inibi\u00e7\u00e3o de \n\nsua absor\u00e7\u00e3o (TIZARD, 1989). Em um estudo realizado em macacos, o suco de Aloe \n\nferox diminuiu o colesterol total em 61% com um aumento proporcional nos n\u00edveis de \n\nHDL (DIXIT, 1983). Al\u00e9m do mais, o suco de Aloe tem sido usado com efic\u00e1cia para \n\ndiminui\u00e7\u00e3o dos n\u00edveis de a\u00e7\u00facar no sangue bem como dos n\u00edveis de triglicer\u00eddeos. Foi \n\ndemonstrado que o exsudato amargo e o gel de Aloe diminuem os n\u00edveis de glicose no \n\nsangue em ratos; da mesma forma verificou-se que ambos os compostos t\u00eam efeito \n\nhepatoprotetor (CAN, 2004). \n\nO efeito cat\u00e1rtico e laxante do exsudato amargo de Aloe \u00e9 bem conhecido. \n\nInicialmente o efeito \u00e9 causado por sua influ\u00eancia sobre a motilidade do c\u00f3lon, \n\nresultando na acelera\u00e7\u00e3o do fluxo intestinal e redu\u00e7\u00e3o na absor\u00e7\u00e3o de liquido, o que leva \n\na um aumento nos n\u00edveis de \u00e1gua nas fezes (BLUMENTHAL, 1998). Em adi\u00e7\u00e3o ao \n\nefeito cat\u00e1rtico, a antraquinona estimula o fluxo do suco g\u00e1strico, melhorando a \n\ndigest\u00e3o; assim, Soeda (1964) constatou que fra\u00e7\u00f5es de Aloe ferox apresentam efeito \n\nprofil\u00e1tico. \n\n \n\n2.5.3.4. Atividade Antic\u00e2ncer \n\n \n\n75 \n \n\n\n\nSegundo Soeda (1969), Aloe ferox apresentou-se efetiva contra o c\u00e2ncer, de \n\nmaneira que todas as partes da planta inibiram o crescimento tumoral. Aloe-emodina \n\ndemonstrou a\u00e7\u00e3o inibit\u00f3ria da mutag\u00eanese, bem como as glicoprote\u00ednas (lecitinas) e \n\npolissacar\u00eddeos contidos no gel. \n\nKuo (2002) demonstrou que aloe-emodina induz a apoptose e age com efic\u00e1cia \n\ncontra o cancro de f\u00edgado em humanos. Da mesma forma, Pecere (2000) constatou que a \n\naloe-emodina n\u00e3o inibe a prolifera\u00e7\u00e3o de fibroblastos enquanto inibe seletivamente as \n\nc\u00e9lulas tumorais neuroectodermais em humanos. Strickland (2001) demonstrou que os \n\npolissacar\u00eddeos contidos em Aloe ferox s\u00e3o eficazes na preven\u00e7\u00e3o de c\u00e2ncer de pele n\u00e3o-\n\nmelanoma ao evitar a imunosupress\u00e3o de c\u00e9lulas T. \n\n \n\n2.5.3.5. Atividade Antimicrobiana e Antif\u00fangica \n\n \n\nEstudos com o extrato metan\u00f3lico de Aloe ferox demonstraram que esta planta \n\nexibe atividade contra as cepas de Neisseria gonorrhea em concetra\u00e7\u00f5es de 0,5 mg/ml. \n\nContudo a alo\u00edna (um componente puro isolado de Aloe ferox) inibiu o crescimento \n\nbacteriano em concentra\u00e7\u00f5es abaixo de 0,1 mg/ml (KAMBIZI et al. ,2008). No entanto, \n\nestudos sobre a citotoxicidade da alo\u00edna demonstraram que este composto n\u00e3o exibe \n\nnenhum efeito t\u00f3xico na cultura celular (KAMBIZI et al., 2007).  \n\nO uso t\u00f3pico de prepara\u00e7\u00f5es a partir do suco da folha inteira de Aloe ferox inibiu \n\no crescimento das cepas de Escherichia coli, Staphylococcus aureus, Klebsiella \n\npneumoniae e Pseudomonas aeruginosa (JIA et al., 2008). A an\u00e1lise antif\u00fangica de \n\nAloe ferox demonstrou que a alo\u00edna foi ativa contra as cepas de Candida albicans em \n\nconcentra\u00e7\u00f5es de 5 mg/ml. O extrato de aquoso da planta n\u00e3o exibiu nenhuma atividade \n\ncontra Candica albicans enquanto que o extrato metan\u00f3lico apresentou atividade em \n\nconcentra\u00e7\u00f5es de 20 mg/ml (KAMBIZI et al., 2008). Al\u00e9m disso, Soeda (1966) \n\nverificou que o suco de Aloe ferox apresenta atividade antif\u00fangica contra as cepas de \n\nTrichophyton spp. \n\n \n\n2.5.4. Toxicologia \n\n \n\nEm um estudo realizado pelo Instituto Franc\u00eas de Pesquisas e Ensaios \n\nBiol\u00f3gicos, o extrato das folhas de Aloe ferox Miller foi aplicado sobre a pele raspada \n\nde coelhos. Seus resultados demonstraram que um ligeiro eritema foi desenvolvido no \n\n76 \n \n\n\n\ntecido danificado em um dos seis animais estudados; tal sintoma diminuiu ap\u00f3s tr\u00eas \n\ndias. No mesmo estudo, foi relatado que ao instilar o extrato das folhas de Aloe ferox em \n\ncoelhos, houve pequenas altera\u00e7\u00f5es no olho; tais mudan\u00e7as tornaram-se vis\u00edveis uma \n\nhora ap\u00f3s a instila\u00e7\u00e3o e desapareceram depois de um dia (RYAN et al., 2007). \n\nKodym e Bujak (2002) encontraram que a alo\u00edna desenvolveu dermatite de \n\ncontato na pele de paciente al\u00e9rgico que recebeu aplica\u00e7\u00e3o t\u00f3pica de Aloe ferox. O uso \n\ncr\u00f4nico de antraquinonas por via oral pode levar \u00e0 perda de pot\u00e1ssio, desidrata\u00e7\u00e3o e \n\ndepend\u00eancia intestinal de laxantes (NUSKO, 2000). \n\nO exsudato de Aloe ferox pode reduzir a absor\u00e7\u00e3o de drogas devido \u00e0 diminui\u00e7\u00e3o \n\ndo tempo de tr\u00e2nsito intestinal, pode aumentar a perda de pot\u00e1ssio em pacientes que \n\nfazem uso de corticoster\u00f3ides ou diur\u00e9ticos tiaz\u00eddicos, e pode potencializar a a\u00e7\u00e3o dos \n\ndigit\u00e1licos e outros glicos\u00eddeos card\u00edacos, devido aos baixos n\u00edveis de pot\u00e1ssio \n\n(NUSKO, 2000). \n\nApesar de Aloe ferox ter seu uso amplamente disseminado para diversos fins, s\u00e3o \n\nescassos os dados existentes na literatura a respeito de sua seguran\u00e7a. Testes \n\ntoxicol\u00f3gicos pr\u00e9-cl\u00ednicos e cl\u00ednicos s\u00e3o de fundamental import\u00e2ncia para a avalia\u00e7\u00e3o da \n\nseguran\u00e7a de qualquer potencial medicamento, principalmente os de origem vegetal, \n\nque s\u00e3o rotineiramente tidos pela popula\u00e7\u00e3o como subst\u00e2ncias seguras e isentas de \n\nefeitos colaterais. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n77 \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n3. OBJETIVOS \n \n\n \n \n\n78 \n \n\n\n\n3. OBJETIVOS \n \n\n3.1. Geral \n\n \n\nGERAL \n\n \n\nAvaliar o efeito da resina de Aloe ferox Miller sobre o tr\u00e2nsito intestinal em ratos e \n\ninvestigar a seguran\u00e7a de seu uso. \n\n \n\n ESPEC\u00cdFICOS \n \n\n1. Estimar a DL50 do extrato da resina de Aloe ferox Miller. \n\n \n\n2. Demonstrar a atividade laxante da resina de Aloe ferox em camundongos (Mus \n\nmusculus). \n\n \n\n3. Identificar e quantificar a alo\u00edna presente na resina de Aloe ferox \n\n \n\n4. Analisar o efeito da administra\u00e7\u00e3o oral e cr\u00f4nica da resina de Aloe ferox Miller, \n\nsobre os par\u00e2metros hematol\u00f3gicos e bioqu\u00edmicos de ratos Wistar. \n\n \n\n5. Avaliar o efeito do tratamento cr\u00f4nico por via oral da resina de Aloe ferox Miller, \n\nsobre a morfologia macrosc\u00f3pica dos tecidos. \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n79 \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4. ARTIGO I \n \n\n \n\n \n\n \n \n \n \n \n\n80 \n \n\n\n\n1Evaluation of the acute toxicity and laxative activity of Aloe ferox Miller \n\n(Asphodelaceae) resin. \n \n \n\nLEITE, V.R.1; MARANH\u00c3O, H.M.L.1; VASCONCELOS, C.F.B.1; LIMA, C.R.1; \n\nMEDEIROS, G.C.R.1; WANDERLEY, A.G.1,2 * \n\n \n\n \n1 Department of Pharmaceutical Sciences, Federal University of \n\nPernambuco, Recife, 50740-521, Brazil. \n2 Department of Physiology and Pharmacology, Federal University of \n\nPernambuco, Recife, 50760-901, Brazil. \n\n \n\n \n\n* Corresponding author. Almir Gon\u00e7alves Wanderley, Departamento de Fisiologia e \n\nFarmacologia, CCB, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, \n\ns/n, CEP: 50670-901- Cidade Universit\u00e1ria, Recife, PE, Brasil \u2013 Tel: 55-81-2126-8530, \n\nfax: 55-81-2126-8976. Email address: almirgw@globo.com \n\n                                                 \n \n\n81 \n \n\n\n\nResumo \n \nAvalia\u00e7\u00e3o da toxicidade aguda e atividade laxante do extrato de \n\nAloe ferox Miller. \n \nAloe ferox Miller (Asphodelaceae), tamb\u00e9m conhecida como Cape aloe, \n\ntem sido utilizada por suas atividades antiinflamat\u00f3ria, imunoestimulante, \n\nantibacteriana e antif\u00fangica, cicatrizante de feridas e queimaduras, antitumoral \n\ne laxante. A resina da planta foi avaliada quanto \u00e0 sua toxicidade aguda e \n\natividade laxante. A alo\u00edna presente na resina foi identificada e os derivados \n\nhidroxiantrac\u00eanicos expressos como alo\u00edna foram quantificados usando \n\ncromatografia em camada delgada e espectrofotometria UV, respectivamente. \n\nOs resultados mostram que o extrato da resina de Aloe ferox, administrado nas \n\ndoses de 0.05, 0.1 e 0.2 g/kg aumentou a motilidade gastrintestinal ap\u00f3s 30 \n\nminutos em 93,5%, 91,8% e 93,8%, respectivamente. A dose \u00fanica de 5 g/kg \n\nde peso por via oral da resina de Aloe ferox n\u00e3o produziu mortalidade ou \n\naltera\u00e7\u00f5es no comportamento geral. Desta forma conclui-se que o extrato de \n\nAloe ferox possui atividade laxante e \u00e9 at\u00f3xica quando a administra\u00e7\u00e3o oral \n\naguda em ratos foi realizada.  \n\n \n\nPalavras-chave: Aloe ferox Miller, Asphodelaceae, motilidade gastrointestinal, \n\ntoxicidade aguda. \n\n82 \n \n\n\n\nAbstract \n \n\nAloe ferox Miller (Asphodelaceae), also named Cape aloe, has been \n\nused to have anti-inflammatory, immunostimulant, anti-bacterial and anti-fungal, \n\nwound and burn healing, antitumor, and laxative activities. The resin of this \n\nplant was evaluated for its laxative activity and for the acute toxicity. The Aloe \n\nferox extract at a dose of 0.05, 0.1 and 0.2 g/kg increased the gastrointestinal \n\nmotility at 30 min interval by 93.5%, 91.8% and 93.8% respectively. The single \n\noral dose of the Cape aloe resin extract at 5 g/kg did not resin extract was \n\neffective in gastrointestinal motility test, showing its laxative action and found to \n\nbe nontoxic when oral acute in rats was performed. \n\n \n\nKeywords: Aloe ferox Miller, Asphodelaceae, gastrointestinal motility, \n\nacute toxicity. \n\n83 \n \n\n\n\n1.Introduction \n \n\nAloe ferox Miller (Asphodelaceae) commercially known as Cape aloe is a \n\nplant native to South Africa and Lesotho (Sibuyi, 2007). Cape aloe was a local \n\ntraditional medicine adopted by colonists at the Cape of Good Hope and fist \n\nexported to Europe in the eighteenth century. It is known as a natural product \n\nprepared from the dried leaf exudates (Pole-Evans, 1919; Hodge, 1953; Grace, \n\n2008). Aloes is considered to have anti-inflammatory, immunostimulant, anti-\n\nbacterial and anti-fungal, wound and burn healing, antitumor, and laxative \n\nactivities and used in the treatment of skin cancer, eczema, psoriasis, arthritis, \n\ndigestive problems and diabetes. These treatments are based on anecdotal \n\nevidence or research findings done almost exclusively on Aloe vera (Loots, \n\n2007).  \n\nMiscellaneous bioactive constituents have been identified from the \n\nleaves and roots of Aloe ferox. These components belong to different classes \n\nsuch as polysaccharides, alkaloids, anthraquinones, saccarides, enzymes, \n\namino acids, inorganic mineral etc. (Vogler and Ernst, 1999; Eshun and He, \n\n2004). However, the main components of Aloe are aloin, aloe-emodin and \n\naloeresin.  \n\nAloin, a C-glycoside derivative of anthraquinone, may release the quinine \n\nwhen ingested, and the release the quinone (aloe-emodin), in turn, may \n\naccelerate the rate of ethanol metabolism in vivo (Chung, 1996). Aloeresin, a \n\nchromone type ingredient, show to be a superior potent anti-oxidant with the \n\nOxygen Radical Absorbance Capacity of 33 and 299 higher than green tea and \n\ngrape seed extracts, respectively. It is also well documented that aloeresin \npromotes not only anti-aging by restoring the immune function in UV-damaged \ncells but also light sensitivity and naturally darker skin pigmentation without \nharmful chemicals or side effects (Jones et al., 2002). \n\nThe whole-leaf juice of Aloe ferox inhibited the bacterial growth for \n\nEscherichia coli, Staphylococcus aureus, Klebsiella pneumoniae and \n\nPseudomonas aeruginosa after incubation for 24 h as well as antifungal action \n\nagainst Cryptococcus neoformans. The growth inhibition zone displayed for \n\nCryptococcus neoformans was 1.2\u00b10.05cm for Aloe ferox Miller (Jia, 2008).   \n\n84 \n \n\n\n\nKambizi et al. found that three compounds, Aloe-emodin, aloin A and \n\nchrysophanol isolated from Aloe ferox Miller were active against various \n\nbacterial strains. In their results, Aloin A showed the lowest minimum inhibitory \n\nconcentration (MIC) against Staphylococcus aureus (MIC = 62.5 mg/ml); Aloe-\n\nemodin was most effective against Escherichia coli (MIC = 62.5 mg/ml); while \n\nchrysophanol was more active against Staphylococcus epidermidis (MIC = \n\n31.25 mg/ml) (Kambizi et al., 2004). \n\nTaking account the comercialization and use of Aloe ferox resin in the \n\ntreatment of intestinal constipation and that no study has been published in the \n\nscientific literature about its toxicological profile, the aim of the present study \n\nwas evaluate the effect of Aloe ferox on intestinal transit in mice, as well as the \n\nsafety of this use through a study of acute toxicity. \n\n \n2. Materials and Method \n2.1. Preparation of the extract \n\nAloe ferox resin used in the current study was a commercial preparation \n\nproduced and supplied by Odaly Soares Laboratory (Cear\u00e1 \u2013 Brazil). In our \n\nlaboratory, this material was grinded down in automatic processor. Due to low \n\nsolubility in water, the resin was dissolved in a glycerin solution to 40% (v/v).  \n\n  \n\n2.2. Quantification of hydroxyanthracene derivates by UV-Vis \n\nspectrophotometry \n\n The extractive solution was obtained by heating 0.4 g of powdered \n\nsample with methanol, water, ferric chloride and hydrochloric acid solutions. \n\nAfter cooling, ether was added and an UV absorption spectrum was obtained, in \n\nalkaline medium, at the wavelength range from 200 to 600 nm (50 UV-Vis \n\nSpectrophotometer), taking the specific absorbance of aloe-emodin, obtained \n\nby oxidation of aloin, to be 512 nm. The methanol was used as the \n\ncompensation liquid. The percentage of hydroxyanthracene derivates \n\nexpressed as aloin was calculated from the expression (European \n\nPharmacopoeia, 1997): \n\nA x 19.6/ m \n\nA = absorbance at 512 nm \n\nm = mass of the substance examined in grams \n\n85 \n \n\n\n\n \n\n 2.3. Identification of aloin by thin layer chromatography \n\nTo 0.25 g of the powdered sample added 20 mL of methanol and 10 \u00b5L \n\nof this solution were applied silica gel plates (Merck-Alemanha art. 105554). \n\nAfter drying, the plate was eluated with water-methanol-ethyl acetate (13:17:100 \n\nv/v). Allowed the plate to dry in air, sprayed with 100 g/L solution of potassium \n\nhydroxide in methanol, the retention factor (Rf) was obtained and the plate was \n\nexamined in ultraviolet light at 365 nm. It was used an aloin solution as \n\nreference standard (Gutterman; Chauser-Volfson, 2000). \n\n \n\n2.4. Animals \n\nAdult female and male Wistar rats (Rattus norvegicus var. albinus), aged \n\n2-3 months and weighing 180-200 and 240-260 g respectively) and male Swiss \n\nalbino mice (Mus musculus), 6-8 weeks of age, weighing between 25-35g were \n\nobtained respectively from Department of Physiology and Pharmacology and of \n\nthe Laboratory of Aggeu Magalh\u00e3es at the Federal University of Pernambuco \n\n(UFPE). The animals were maintained in standard environmental conditions (22 \n\n\u00b1 2\u00baC; 12:12 h dark/light cycle). Water and chow (Labina\u00ae, Purina, Brazil) were \n\navailable ad libitum. The experimental protocol was approved by the Animal \n\nExperimentation Ethics Committee of UFPE (Process no. 007340/2009-20), in \n\naccordance with the National Institute of Health Guide for the Care and Use of \n\nLaboratory Animals. \n\n \n\n2.5. Biological activity \n\n2.5.1. Acute toxicity \n\nHealthy albino rats of either sex (n=4/group/sex) fasted overnight, but \n\nallowed acess to water ad libitum received by gavage a single dose of Aloe \n\nferox resin (5000 mg/kg of body weight). The control received vehicle (glycerin \n\nsolution) under the same experimental conditions. The signs and symptoms \n\ninduced by Aloe ferox resin were observed at 0, 0.5, 1, 2, 3 and 4 hours after \n\nand then once a day for the next 14 days. At the end of the period the number \n\nof survivors was recorded and the acute toxicological effect was estimated by \n\nthe method described by Souza Brito (1995). \n\n \n\n86 \n \n\n\n\n2.5.2. Gastrointestinal motility test \n\nMice with fasting for 16 hours were divided in seven groups (n=8/group) \n\nrandomly formed. The first group of animals, serving as control, received \n\nvehicle (glycerin solution). The second group serving as standard, received \n\nphysostigmine 1\u00b5g/kg. The rest of groups received the resin extract of Aloe \n\nferox (Af) at doses of 0.05, 0.1 and 0.2 g/kg. Treatments were administered \n\norally by gavage once. Activated charcoal (10%) was given orally (0.1 ml/10g) \n\nto all experimental, control and standard group of mice after 60 min of \n\nadministration of the drug. After 30 min of administration of activated charcoal, \n\nthe mice were sacrificed. The small intestine was removed and its length was \nmeasured from the pyloric sphincter to the ileocaecal junction. The distance \ntraversed by activated charcoal was recorded as a percentage of the total \nlength of the small intestine (percent gastrointestinal transit). The intestinal \ntransit of the resin of Aloe ferox was evaluated in mice using the method of \n\nStickney and Northup (1959).  \n\n \n\n2.6. Statistical analysis \n\nStatistical analyses were performed with the aid of the software \n\nGraphPad Prism 5\u00ae. The results were expressed as mean value \u00b1 standard \n\nerror of mean (SEM). The differences between control and treated groups were \n\ncompared using one-way ANOVA followed, when necessary, by Tukey \n\nComparison Test. A probability level of less than 5% (p &lt;0.05) was considered \n\nsignificant. \n\n \n3. Results \n\n \n\n3.1. Aloin identification and quantification  \n\n The chromatogram obtained with the solution test showed in the central \n\npart a zone of yellow fluorescence (aloin \u2013 Rf 0.35) similar in position to the \n\nzone corresponding to aloin in the chromatogram obtained with the reference \n\nsolution. The percentage content of hydroxyanthracene derivates expressed as \n\naloin was 33.5% and its UV absorption spectrum is showed in Figure 1.  \n\n \n \n\n87 \n \n\n\n\n \n   Figure 1: UV absorption spectrum of hydroxyanthracene derivates expressed \nas aloin \n\n \n\n \n \n\n3.2. Acute toxicity \n\nNo death was recorded in the 14 days of observation period in the male \n\nand female animals given 5 g/kg of the Aloe ferox resin extract orally. The \n\nanimals did not show any changes in the general appearance during the \n\nobservation period. \n\n \n\n3.3. Gastrointestinal motility  \n\nThe results of gastrointestinal motility test are reported in figure 1. The \n\nAloe ferox resin extract at a dose of 0.05, 0.1 and 0.2 g/kg induced increased \n\nstatistically significant on the gastrointestinal motility at 30 min interval by \n\n93.5%, 91.8% and 93.8% respectively whereas the gastrointestinal motility of \n\ncontrol was 43.4%.   \n\n88 \n \n\n\n\n0\n\n25\n\n50\n\n75\n\n100\n\n125\n\n0 50 100 200 0.001 (mg/kg)\nPhysostigmineAloe ferox\n\n* * * *\n\nD\nis\n\nta\nnc\n\ne \n(%\n\n)\n\n \nFigure 2: Effect of the administration of Aloe ferox extract resin (Af 0.05, 0.1 \nand 0.2 g/kg) by oral route on gastrointestinal motility. The data represent the \n\nmean \u00b1 SEM (n = 8/group). \n\n \n\n4. Discussion \nIn the present study, an oral administration of Aloe ferox resin, had a \n\nlaxative effect on mice, the effect induced by 0.05, 0.1 and 0.2 g/kg, p.o. being \n\nevident 30 minutes after its administration, supporting its ethno medicinal use.  \n\nThe laxative effect of aloe species is due to the presence of anthranoid \n\nglycosides derivatives, mainly aloin. The laxative effect of aloe species is due to \n\nthe presence of anthranoid glycosides derivatives, mainly aloin. After oral \n\nadministration, the aloin is not absorbed in the upper intestine, it is hydrolyzed \n\nin the colon by Eubacterium sp. and then reduced to the active metabolite aloe-\n\nemodin anthrone. It stimulates colonic motility, augmenting propulsion and \n\naccelerating colonic transit, which reduces fluid absorption from the fecal mass \n\n(Bradley, 1992; Akao et al., 1996). It also increases paracellular permeability \n\nacross the colonic mucosa probably owing to an inhibition of Na+-K+-ATPase or \n\nto an inhibition of chloride channels, which results in an increase in the water \n\ncontent in the large intestine (Witte, 1993). Glycerin is low toxicity, the LD50 for \n\nrats is 12.6 g/kg (p.o.) and it is used as laxative (Portantiolo, 2007), \n\nnevertheless, it did not cause diarrhea in the animals treated only with glycerin \n\n40% (v/v) solution and nor affected the reproductive parameters of pregnant \n\nrats analyzed. \n\n89 \n \n\n\n\nIn this study was performed an identification and quantification of aloin in \n\nthe resin of Aloe ferox, verifying that it contain aloin in sufficient quantity to exert \n\na laxative effect significant. \n\nThe acute toxicity study does not show any toxic symptoms, changes in \n\nbehavior or mortality at 5g/kg doses. According to Kennedy et al (1986), \n\nsubstances that present LD50 higher than 5 g/kg by oral route can be \n\nconsidered practically nontoxic. Therefore, it can be suggested that acute \n\ntoxicity of the Aloe ferox resin is practically null by oral route. \n\nIn summary the Aloe ferox resin extract was effective in gastrointestinal \n\nmotility test, showing its laxative action, as well as was confirmed the aloin \n\npresence and found to be nontoxic when oral acute in rats was performed. \n\nWhatever, the purgative activities of anthraquinoids (present in aloe species) \n\nare too powerful for them to be regularly used, and even periodic use of these \n\nlaxatives can induce pseudomelanosis coli, a risk factor for colorectal \n\nneoplasma(Hara, 2008). Furthermore, chronic toxicity, mutagenicity and others \n\ncarcinogenicity studies are necessary to further support the safe use of this \n\nplant. \n\nAcknowledgements \n\nThe authors thank Rejane de Souza Silva for excellent technical \n\nassistance and CAPES for financial support. \n\n \n\nReferences \n \n\n   AKAO, T., CHE, Q., KOBASHI, K. 1996. A purgative action of \n\nbarbaloin is induced by Eubacterium sp. strain BAR, a human intestinal \n\nanaerobe, capable of transforming barbaloin to aloe-emodin anthrone. \n\nBiol Pharm Bull 19,136-138. \nBRADLEY, P.R. 1992. British herbal compendium. British Herbal \n\nMedicine Association ,v.1, 199\u2013203. \nCHUNG J.H., CHEONG J.C., LEE J.Y., ROB H.K. Acceleration of \n\nthe Alcohol Oxidation Rate in Rats with Aloin, a Quinone Derivative of \n\nAloe. Biochemical Pharmacology, v.52, n.9, p.1461-1468, 1996. \n\n90 \n \n\n\n\nESHUN K., HE Q. Aloe Vera: a valuable ingredient for the food \n\npharmaceutical and cosmetic industries - a review. Critical Reviews in \nFood Science and Nutrition, v. 44, n. 2, 91- 96, 2004. \n\nEuropean Pharmacopoeia. Aloe capensis. Strasbourg: Conseil de \n\nI\u2019Europe, 362-363, 1997. \n\nGRACE O.M., SIMMONDSA M.S.J., SMITH G.F., VANWIKG A.E. \n\nTherapeutic uses of Aloe L. (Asphodelaceae) in southern Africa. Journal \nof Ethnopharmacology, v.119, n.3, p.604-614, 2008. \n\nGUTTERMAN, Y., CHAUSER-VOLFSON, E. A peripheral defense \n\nstrategy by varying barbaloin content in the succulent leaf parts of Aloe \n\narborescens Miller (Liliaceae). Bot. J. Lin. Soc. 28, 825-838, 2000. \nHARA H.,ISE Y., MORIMOTO N., SHIMAZAWA M., ICHIHASHI \n\nK., OHYAMA M., IINUMA M. Laxative Effect of Agarwood Leaves and Its \n\nMechanism. Bioscience, Biotechnology and Biochemistry, v.72, p. \n335-345, 2008. \n\nHODGE W.H. The drug aloes of commerce, with special reference \n\nto the Cape species. Economic Botany, v.7, p. 99-129, 1953. \nJIA Y., ZHAO A G., JIA J. Preliminary evaluation: The effects of \n\nAloe ferox Miller and Aloe arborescens Miller on wound healing. Journal \nof Ethnopharmacology, v.120, n.2, p.181\u2013189, 2008. \n\nJONES K., HUGHES J., HONG M., JIA Q., ORNDORF S. \n\nModulation of melanogenesis by aloesin: a competitive inhibitor of \n\ntyrosinase. Pigment Cell &amp; Melanoma Research, v.15, p. 335-340, \n2002. \n\nKAMBIZI L., SULTANA N., AFOLAYAN A.J. Bioactive compounds \n\nisolated from Aloe Ferox: a plant traditionally used for the treatment of \n\nsexually transmitted infections in the Eastern Cape, South Africa. \nPharmaceutical Biology, v.42, n. 8, p. 636\u2013639, 2004. \n\nKENNEDY G. L., FERENZ R. L., BURGESS B. A. Estimation of \n\nacute oral toxicity in rats by determination of the approximate lethal dose \n\nrather than the LD50. Journal of Applied Toxicology, v.6, n.3, p.145-\n148, 1986. \n\nLOOTS D.T., WESTHUIZEN F.H., BOTES, L. Aloe ferox leaf gel \n\nphotochemical content, antioxidant capacity, and possible health \n\n91 \n \n\n\n\nbenefits. Journal of Agricultural and Food Chemistry, v. 55, n.17, p. \n6891-6896, 2007. \n\nPOLE-EVANS I.B. Our Aloes: their history, distribution, and \n\ncultivation. Journal of the Botanical Society, v.5, p.11-116, 1919. \nPORTANTIOLO, C. S. 2007. FISPQ - Ficha de Informa\u00e7\u00f5es de \n\nSeguran\u00e7a de Produtos Qu\u00edmicos 34, 1-7. Quimidrol Com\u00e9rcio Ind\u00fastria \nImporta\u00e7\u00e3o LTDA. Dispon\u00edvel em &lt;\nwww.quimidrol.com.br/produtos/imgs/prd_99_espec.pdf > acessado em \n\n29 de Dezembro de 2009. \n\nSIBUY N.R.S, KATERERE D.R., BOBOYI T., MADIEHE A.M. \n\nDietary supplementation with Aloe ferox extracts reverses obesity in rats. \n\nSouth African Journal of Botany, v.73, n.2, p. 336, 2007. \nSTICKNEY, J.C., NORTHUP, D.W. Effect of gastric emptying \n\nupon propulsive motility of small intestine in rat. Proc. Soc. Exp. Biol. \nMed. 101:582, 1959. \n\nVOGLER B.K., ERNST, E. Aloe Vera: a systematic review of its \n\nclinical effectiveness. British Journal of General Practice, v.49, p. 823-\n828, 1999. \n\nWITTE, P. 1993. Metabolism and pharmacokinetics of \n\nanthranoids. Pharmacology, 47, 86-97. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n92 \n \n\nhttp://www.google.com.br/url?sa=t&amp;source=web&amp;ct=res&amp;cd=2&amp;url=http%3A%2F%2Fpubs.acs.org%2Fjournal%2Fjafcau&amp;ei=gi_OSt_pD5jk8Aayi-D8Aw&amp;rct=j&amp;q=J.+Agric.+Food+Chem.&amp;usg=AFQjCNH5PAfTp8G3y2WT0pD14ztU8PQzEg\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n5. ARTIGO II \n \n \n \n \n \n \n \n \n\n93 \n \n\n\n\nChronic oral toxicity of Aloe ferox Miller (Asphodelaceae) in rats. \n \n\n \n\nV. R. Leitea, H. M. L. Maranh\u00e3oa. C. F. B. Vasconcelosa,  G.C.R. Medeirosa, I. M. \n\nA. Costaa, A. G. Wanderleya,b, *\n\n \n\n \n\nDepartments of Pharmaceutical Science a and Physiology and Pharmacologyb, Federal \n\nUniversity of Pernambuco, Recife, 50760-901, Brazil. \n\n \n\n* Corresponding author. Almir Gon\u00e7alves Wanderley, Departamento de Fisiologia e \n\nFarmacologia, CCB, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, \n\ns/n, CEP: 50670-901- Cidade Universit\u00e1ria, Recife, PE, Brasil \u2013 Tel: 55-81-2126-8530, \n\nfax: 55-81-2126-8976. Email address: almirgw@globo.com \n\n94 \n \n\n\n\nAbstract \n\n \n\nAloe ferox Miller (Asphodelaceae) has been used to have anti-inflammatory, \n\nimmunostimulant, anti-bacterial and anti-fungal, wound and burn healing, antitumor, \n\nand laxative activities. The extract of the resin from Aloe ferox (Af) was evaluated for \n\nits chronic toxicity (13 weeks) on hematological, biochemical and morphologic \n\nparameters in male and female Wistar rats. Oral treatment with Af 0.1, 0.5 and 1.5 g.kg-\n\n1.day-1 (n = 12-13/group) failed, in both sexes, to changes body weight gain and food \n\nconsumption, however was observed an increase in the consumption of water among the \n\ntreated rats. The hematological examination showed that the animals treated with Af \n\ninduced alterations in the erythrocytes, hemoglobin, hematocrit, platelets, MCV and \n\nRDW values. The biochemical analysis showed a reduction in creatinine, triglycerides, \n\nHDL, ALT and increase in the levels of alkaline phosphatase, total and indirect \n\nbilirrubin and LDL parameters in relation of the control group. The macroscopic \n\nexamination of the viscera, encephalon and reproductive organs, as well as the absolute \n\nand relative weight of these organs presented changes in the treated groups. The main \n\nobserved alterations were decrease of the spleen in females and of the small intestine in \n\nthe males. In conclusion, the chronic oral administration of Aloe ferox resin extract \n\ninduce significant alterations in several biochemical, hematological and morphological \n\nparameters in rats of both sexes, indicating that Aloe ferox exercises toxic effects on the \n\norganism of Wistar rats. \n\n \n\nKeywords: Aloe ferox Miller; Asphodelaceae; Chronic toxicity. \n\n \n\n95 \n \n\n\n\nIntroduction \n\n \n\nAloe ferox is one of only a few plants depicted in San rock paintings (Reynolds, \n\n1950). The morphology of this species is characterized by persistent dry leaves on the \n\nlower portion of the single stem. The broad, fleshy leaves are dull green in summer or \n\nreddish-green in winter, with dark brown spines along the edges. They constitute a \n\nrather compact rosette arrangement around a stout stem (Palgrave, 1984) and aloe is \n\nwell-known and famous for its medicinal qualities (Magwa, 2006). In Brazil, the largest \n\nproducing of the plant are inside S\u00e3o Paulo (particularly in the municipal district of \n\nJarinu), Santa Catarina and in the Northeast area. Being this last one, the one that \n\npossesses the best planting conditions (Magalh\u00e3es, 2005).     \n\nThe bitter latex, tapped from the leaves by a traditional method and exported to \n\nEurope since 1761 (Marloth, 1915; Kruger and Beyers, 1977; Robertson, 1979; Forbes, \n\n1986; Wyk, 2008), is known commercially as \u201cCape aloes\u201d (Escop, 2003). This plant is \n\nmost widely used for its potent laxative and cathartic effects, attributed to \n\nanthraquinones and in particular aloe-emodin (Steenkampand and Stewart, 2007) in the \n\nleaf exudate. However, numerous other ethnomedicinal applications of the leaf exudate \n\nof Aloe ferox in southern Africa are known, such as relieving arthritis, anti-\n\ninflammatory and anti-diabetics effects and, commonly, the use of leaf sap as eye drops \n\nfor conjunctivitis and other eye ailments (Smith, 1888; Watt and Breyer-Brandwijk, \n\n1962; Crouch et al., 2006; Grace, 2008). The laxative effect is due to anthrone-C-\n\nglycosides, of which aloin (syn. barbaloin) is the main compound (Wyk et al., 1995). \n\nAloin occurs in tapped and dried leaf juice of Aloe ferox as a 1:1 mixture of aloin A and \n\naloin B, at levels of about 10\u201328% dry weight (Wyk et al., 1995).  \n\n The modern research has shown that the Aloe ferox contains a chromone type \n\nnatural ingredient, aloeresin, which is able to inhibit tyrosine at the cellular level \n\nwithout deterring cell viability. It is also shown to be a superior potent anti-oxidant with \n\nthe Oxygen Radical Absorbance Capacity of 33 and 299 higher than green tea and grape \n\nseed extracts, respectively. It is also well documented that aloeresin promotes not only \n\nanti-aging by restoring the immune function in UV-damaged cells but also light \n\nsensitivity and naturally darker skin pigmentation without harmful chemicals or side \n\neffects (Jones et al., 2002). \n\nCape aloe contains various carbohydrate constituents, such as polysaccharides \n\nand acemannan. Polysaccharides are known to have effective property in skin wound \n\n96 \n \n\n\n\nrepair. Polysaccharides fractions was capable to promote a cascade biological activities, \n\nincluding augmentation of reticuloendothelial function, modulation of immune \n\nresponses, promotion of antiviral activity, and stimulation of hematopoiesis (Jia, 2008). \n\nAcemannan, a highly acetylated polymer of mannose, is known to induce the production \n\nof several inflammatory cytokines, some of which are thought to regulate wound \n\nhealing (Barbul, 1990). In addition, acemannan can exert the antiviral and antitumoral \n\nactivities in vivo via activation of macrophages, creation of NO and enhancement of \n\ncytotoxic T-lymphocytes (Lee et al., 2001; Choi and Chung, 2003).  \n\nTopical administration of the whole leaf juice of Aloe ferox Miller, inhibit the \n\ngrowth of bacterial strains, such as Staphylococcus aureus, Klebsiella pneumoniae and \n\nPseudomonas aeruginosa and are fungitoxic to Cryptococcus neoformans only (Jia, \n\n2008).  \n\n Although its use is widely spread, there is a lack of toxicological information \n\ndetailed in the literature on this specie. Therefore, the aim of the present study was to \n\nassess the chronic toxicity of the Aloe ferox resin in Wistar rats.  \n\n \n\n2. Material and Methods \n\n \n\n2.1. Preparation of the extract \n\nAloe ferox resin was a commercial preparation, produced and supplied by Odaly \n\nSoares Laboratory, Cear\u00e1, Brazil. In the laboratory, the resin was powdered in automatic \n\nprocessor and dissolved in glycerin a.p (Vetec\u00ae) 40% (v/v). \n\n2.2. Animals \n\nAdult male and female Wistar rats (Rattus norvegicus var. albinus), aged 4-5 \n\nmonths, weighing 300\u2013350g and 250\u2013300g, respectively, were obtained from \n\nDepartment of Physiology and Pharmacology at the Federal University of Pernambuco \n\n(UFPE). They were maintained in standard environmental conditions (22 \u00b1 2\u00baC; 12:12 h \n\ndark/light cycle) and water and chow (Labina\u00ae, Purina, Brazil) were available ad \n\nlibitum. The experimental protocol was approved to Ethical Committee in Animal \n\nExperimentation of of UFPE (Process no. 007340/2009-20), in accordance with the \n\nNational Institute of Health Guide for the Care and Use of Laboratory Animals. \n\n \n\n \n\n \n\n97 \n \n\n\n\n2.3. Chronic toxicity  \n\nThe method was performed according to the Organization for Economic Co-\n\nOperation and Development (OECD) Test Guidelines with slightly modifications \n\n(OECD, 1981). Healthy rats of either sex were randomly divided into five groups by sex \n\n(13/group). Animals received glycerin 40%-vehicle orally (control group) or Aloe ferox \n\nresin with doses of 0.1, 0.5 or 1.5 g/kg/day for 12 consecutive weeks. Body weight was \n\nrecorded weekly and food consumption and water intake were monitored daily. Animals \n\nwere observed for signs of abnormalities during the treatment period. Toxic \n\nmanifestations and mortality were monitored daily. At the end of each 4-weeks period, \n\nanimals were fasted overnight, but allowed access to water ad libitum. They were then \n\nanesthetized with Nembutal\u00ae (0.035 g/kg, i.p.), and blood samples were obtained by \n\nretro-orbital puncture (Waynforth, 1980), using capillary tubes for hematological and \n\nbiochemical studies, with and without anticoagulant ethylenediaminetetraacetic acid \n\n(EDTA), respectively.  \n\n \n2.4. Hematological and biochemical analysis \n\nHematological analysis was performed using an automatic hematological \n\nanalyzer (Coulter STKS, Beckman). Parameters included: red blood cell (RBC) count, \n\nwhite blood cell (WBC) count, hemoglobin (Hb), hematocrit (Hct), mean corpuscular \n\nvolume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin \n\nconcentration (MCHC), red cell distribution width (RDW), platelets count and mean \n\nplatelet volume (MPV). The differential leukocyte count was performed with an optical \n\nmicroscopy after staining and, in each case, 100 cells were counted. For biochemical \n\nanalysis, blood was centrifuged at 1500\u00d7g for 10 min to obtain serum, which was stored \n\nat ?20 ?C until the following parameters were determined: glucose; blood urea nitrogen \n\n(BUN); creatinine; alkaline phosphatase, aspartate aminotransferase (AST); alanine \n\naminotransferase (ALT); gamma-glutamyl transpeptidase (GGT); amylase; \n\ntriglycerides; total cholesterol; high-density lipoproteins (HDL); low-density \n\nlipoproteins (LDL); total, direct and indirect bilirubin and albumine. Dosages were \n\nmade using Architect (Abott\u00ae) automation with Boehringer Ingelheim\u00ae biochemical \n\nkits. \n\n98 \n \n\n\n\n 2.5. Morphological study \nAfter sacrificed of animals by an excess of thiopental (0.140 g.kg-1, i.p.), \n\nnecropsy was proceeded (n = 10/group) for analysis of the macroscopic external of \n\nheart, liver, spleen, lungs, kidney, adrenal gland, esophagus, stomach, smal intestine \n\n(fragment of 6\u20137 cm), hypophysis, hypothalamus, brain and reproductive organs (uterus \n\nand ovary or testicle, prostate, epididymis, seminal vesicle and vas deferens). These \n\norgans were carefully removed and weighed individually. Organ weights were \n\nexpressed in terms absolute and relative (g and g.100g-1 of body weight, respectively). \n\n2.6. Statistical analysis \n\nVariance in data for body weights, food and water consumption, hematology, \n\nserum biochemistry and organ weights (both absolute and relative weights) was checked \n\nusing one-way ANOVA followed by Tukey Comparison Test. P<0.05 was considered \n\nsignificant.  Statistical analyses were performed with the aid of the software GraphPad \n\nPrism 5\u00ae. \n\n \n\n3. Results \n\n \n\n 3.1. Chronic toxicity \n\nDuring 12 consecutives weeks of treatment by oral route with Aloe ferox at \n\ndoses of 0.1, 0.5 and 1.5 g.kg-1, there were deaths among the females treated with the \n\ndose of 1.5 g.kg-1, among which 2 happened in the first month of treatment, 1 death in \n\nthe 2nd month and 2 deaths in the 3rd month. Among the males treated by the same \n\nperiod of time, only one animal treaty with Aloe ferox 0.5 g.kg-1 and one treaty with \n\nAloe ferox 1.5 g.kg-1 died during the second month of treatment. Days before the death \n\nof these encourages, toxicity signs were observed such an as abrupt weight loss and \n\nbending. \n\nNo significant differences were found between the initial and final body weight \n\nof Aloe ferox treated rats and controls (Figures 1 and 2), however was observed an \n\nincrease in the consumption of water among the treated rats (Figures 3 and 4) and no \n\ntoxic effect was observed with the consumption of food throughout the period of \n\ninvestigation (Figure 5 and 6).  \n\n99 \n \n\n\n\n 3.2. Hematological and biochemical parameters \n\nThe hematological profile of the treated and control groups are presented in \n\nTables 1 to 6. For the females, Aloe ferox (1.5 g.kg-1group) induced a reduction in the \n\nvalues of erythrocytes (22.3%), hemoglobin (23.6%) and hematocrit (22.5%) and an \n\nincrease in the value of RDW (39%) in relation to the group control in the first month of \n\ntreatment. In the second month of treatment was observed an increase in the value of \n\nRDW (39.5%) with Aloe ferox (1.5 g.kg-1). Already in the third month of treatment with \n\nwith the largest dose of Aloe ferox (1.5 g.kg-1group), the females presented an increase \n\nin the values of erythrocytes (10.3%), hemoglobin (13.9%), hematocrit (8.7%) and \n\nRDW (42.9%) in relation of the control group. For the males, Aloe ferox (1.5 g.kg-\n\n1group) induced a reduction in the value of erythrocytes (15%) in relation to the group \n\ncontrol in the first month of treatment. In the second month of treatment there were no \n\nstatistically significant differences for the hematological parameters; and in the third \n\nmonth of treatment (1.5 g.kg-1group) the males presented a decrease in the value of \n\nplatelets (12.6%) and an increase in the values of erythrocytes (10.3%), hemoglobin \n\n(13.9%) and hematocrit (8.7%) in relation of the control group.  \n\nThe biochemical profile of the treated and control groups are presented in Tables \n\n7 to 12. For the females, Aloe ferox (1.5 g.kg-1group) were observed a reduction in the \n\nvalues of creatinine (29%), triglyceride (40.7%) and high-density lipoprotein (HDL) \n\n(24.6%), while Aloe ferox 0.5 g.kg-1group presented a decrease in the values of total \n\ntriglyceride (40.8%) and high-density lipoprotein (HDL) (20.6%) in relation to the \n\ncontrol group in the first month of treatment. In the second month were observed an \n\nincrease in the values of total bilirubin (49.6%), direct bilirubin (49.2%) and indirect \n\nbilirubin (57.1%) in the females treated with Aloe ferox 1.5 g.kg-1group; and in the third \n\nmonth of treatment there were no statistically significant differences for the biochemical \n\nparameters. For the males, Aloe ferox (1.5 g.kg-1group) induced a reduction of the value \n\nof creatinine (27.6%). Already in the second month was observed an increase of the \n\nvalues of alkaline phosphatase (58.0%) (0.5 g.kg-1group), total bilirubin (8.8%)(1.5 \n\ng.kg-1group) and indirect bilirubin (74.3%)(1.5 g.kg-1group) in relation to the control \n\ngroup. In the third month of treatment, the males rats present an increase of alkaline \n\nphosphatase (46.5% and 88.5%)(0.5 and 1.5 g.kg-1groups respectively) and a decrease \n\nin the values of alanine aminotransferase (32.2%) (1.5 g.kg-1group). \n\n100 \n \n\n\n\n 3.3. Morphological parameters \n\nThe absolute tissue weights and external morphology macroscopic were altered \n\nby treatment with Aloe ferox Miller (Table 13 and Table 14). For the females treated \n\nwith Aloe ferox (1.5 g.kg-1group) the absolute tissue weight was observed a decreased \n\nfor spleen (45.8%). The relative tissue weights of the females was decreased for spleen \n\n(31.2%) and increased for brain (30.5%) and heart (11.4%). For the males treated with \n\nAloe ferox (1.5 g.kg-1group) the absolute tissue weight were decreased for the small \n\nintestine (62.3%), brain (22.2%), prostate (38.8%) and lungs (29.9%). In relation to the \n\nrelative weight, the male rats treated with Aloe ferox 1.5 g.kg-1g the relative weight were \n\na decrease in the small intestine (56.6%). \n\n \n\n4. Discussion \n\n The signs of systemic toxicity are defined from the reduction in body mass of \n\nanimals experimental. Besides the reduction of development weight, the systemic \n\ntoxicity is manifested through the reduction in consumption of water and food, changes \n\nbehavior, apathy and poor condition of hair, as the presence of hair horrified (Mello, \n\n2001). Other signs of toxicity can be expressed by the change on the mass of bodies, \n\nhematological changes and biochemical blood (Gonz\u00e1lez and Silva, 2003). \n\n In the chronic toxicity assay the Aloe ferox Miller extract resin was not well \n\ntolerated by oral route. The results indicate that administration of Aloe ferox produced \n\nclinical signs of toxicity and deaths for the 0.5 and 1.5 g.kg-1 treated groups. \n\nThe rats treated with Aloe ferox presented a loss of corporal mass in the first \n\nmonth; this result is in agreement with previous reports of cathartic effects of ALOE \n\n(Ishii et al., 1994; Akao et al., 1996); however there were no statistical differences \n\nsignificant when compared to the group controls. Besides, that loss of corporal mass did \n\nnot stay the following months of treatment. In what refers to the consumption of water, \n\nthere was an increase of this consumption when compared the animals treated with the \n\ngroup control; this increase in the consumption of water is natural, due to the high \n\ndefecation as a consequence of the laxative action of Aloe ferox. As for the ration \n\nconsumption, there was not variation when compared the animals treated with the group \n\ncontrol. The doses used in the present study represent one, five and fifteen teams the \n\neffective doses to exert laxative activity, found in previous studies in our laboratory.  \n\nAnalysis of blood parameters is relevant to risk evaluation as the changes in the \n\nhematological system have a higher predictive value for human toxicity, when the data \n\n101 \n \n\n\n\nare translated from animal studies (Olson et al., 2000). The hematological examination \n\nshowed that the animals treated with Aloe ferox reduced the quantify of erythrocytes for \n\nmale and females, and hemoglobin and hematocrit for the males in the first month of \n\ntreatment and elevation in the follow months, so that in the third month was observed an \n\nincrease of that parameters in relation of the control group in both sexes (MATSUDA et \n\nal., 2008). Since there has been no report about relation between anemia and ALOE, \n\ndose-related decrease of hemoglobin, erythrocytes and hematocrit in females groups and \n\ndecrease of erythrocytes for males was not explained. It is possible that the elevation of \n\nthe hemoglobin, erythrocytes and hematocrit levels in the following months it is due to \n\na hyperactivation of the hematopoietic system as defense of erythrocytes decrease in the \n\nfirst month of treatment. However, they are necessary studies more deepened for \n\nconfirmation. \n\nIn the biochemical analyses was observed that the animals treated with Aloe \n\nferox Miller presented a reduction in the creatinine levels in the first month of treatment. \n\nCreatinine is found in the heart, skeletal muscle, brains and testes, but not in the liver. \n\nElevated levels are found in muscular disorders, myocardial infarction and pulmonary \n\ndisorders (Kaneko, 1989), however, reduced levels of creatinine do not present clinical \n\nmeaning (Newhouse et al., 2008). The female rats also presented a reduction in the \n\nlevels of HDL and triglycerides among the female groups treated with Aloe ferox; the \n\ndecrease in triglyceride levels might represent a reduced lipid metabolism.   \n\n It is known that many toxic plants compounds accumulate in the liver where \n\nthey are detoxified (Clarke and Clarke, 1977). A study of liver function tests may \n\ntherefore prove useful in assessing especially the toxic effects of medicinal plants on the \n\nliver. These tests involve mainly determination of AST and ALT (Tilkian, 1979) and \n\nany marked necrosis of the liver cells lead to a significant rise of these enzymes in the \n\nblood serum. A small elevation in plasma bilirubin is an important indicator of liver \n\ndamage in laboratory animals or could be a sign of biliary duct obstruction (Rasekh et \n\nal., 2008). In the second month of treatment with Aloe ferox were observed an increase \n\nin the values of total bilirubin, direct bilirubin and indirect bilirubin in the females \n\ntreated with Aloe ferox, and an increase in the values of total bilirubin and indirect \n\nbilirubin for the males. This elevation remained following month of treatment, but this \n\nincrease was not statistically significant compared to control. This way it is possible \n\nthat Aloe ferox exercise hepatotoxic effect. \n\n102 \n \n\n\n\n Alkaline phosphatase (ALP) is an important enzyme mainly derived from the \n\nliver, bones and in lesser amounts from intestines, placenta, kidneys and leukocytes. An \n\nincrease in ALP levels in the serum is frequently associated with a variety of diseases. \n\nThe three major underlying etiologies founded were obstructive biliary diseases, \n\ninfiltrative liver diseases and sepsis (Friedman et al., 1996). Aloe ferox promoted an \n\nincrease in alkaline phosphatase levels in males treated with doses of 0.5 and 1.5 g.kg-1, \n\nwhich from the previous data may be associated with liver disease. \n\n The aminotransferases (AST and ALT) are well known enzymes used as \n\nbiomarkers predicting possible toxicity (Rahman et al., 2001). Generally, damage to the \n\nparenchymal liver cells will result in elevations of both these aminotransferases (Wolf et \n\nal., 1972). However, Aloe ferox promoted a decrease in ALT levels in male rats in the \n\nthird month of treatment, which is not clinically significant. \n\n The macroscopic examination of the viscera, encephalon and reproductive \n\norgans, as well as the absolute and relative weight of these organs presented changes in \n\nthe animals survived the treatment. With respect to females treated with aloe ferox, \n\nthere was a reduction in absolute and relative mass of spleen; this shows a possible \n\nimmunotoxic effect of Aloe ferox since the spleen plays a major role in immunological \n\nmechanisms (Laure  et al.; 2007). Moreover, it was observed an increase in the relative \n\nmass of hearth and brain. The increase in the hearth relative mass may indicate that \n\nAloe ferox induces heart diseases, a hypothesis due to the increased RDW level found \n\nin females treated with Aloe ferox, which is also indicative of heart diseases. For the \n\nmales treated with Aloe ferox was observed a decrease in the absolute tissue weight of \n\nbrain, prostate, lungs and small intestine and a decrease in a relative weight of small \n\nintestine. This reduction in the relative and absolute of intestine can have the \n\ndevelopment of tumor in intestine, once that the continue use of anthraquinoids (present \n\nin Aloe species) can induce pseudomelanosis coli,a risck factor for colorectal neoplasma \n\n(Hara, 2008). \n\nIn conclusion, the chronic oral administration of Aloe ferox resin extract induce \n\nsignificant alterations in several biochemical, hematological and morphological \n\nparameters in rats of both sexes, indicating that Aloe ferox exercises toxic effects on the \n\norganism of Wistar rats. \n\n \n\n \n\n103 \n \n\n\n\nAcknowledgements \n\n \n\nThe authors thank Rejane de Souza Silva for excellent technical assistance and \n\nCAPES for financial support. \n\n \n\n \n\n \n\nReferences \n\n \n\nAkao, T., Che, Q.M., Kobashi, K., Hattori, M., Namba, T., 1996. A purgative action of \n\nbarbaloin is induced by Eubacterium sp. strain BAR, a human intestinal anaerobe, \n\ncapable oftransforming barbaloin to aloe-emodin anthrone. Biological and \n\nPharmaceutical Buletin. 19, 136\u2013138. \n\n \n\nBarbul, A., 1990. Immune Aspects of Wound Repair. Clinics in Plastic Surgery 17, 433-\n\n442. \n\n \n\nChoi, S., Chung, M.-H., 2003. A review on the relationship between Aloe Vera \n\ncomponents and their biologic effects. Seminars in Integrative Medicine 1, 53\u201362. \n\n \n\nClarke, E.G.C., Clarke, M.L., 1977. Veterinary Toxicology. Cassel and Collier \n\nMacmillan Publishers, London, pp. 268\u2013277. \n\n \n\nCrouch, N.R., Symmonds, R., Spring, A., Diederichs, N., 2006. Fact sheets for growing \n\npopular medicinal plant species. Commercialising Medicinal Plants: A Southern African \n\nGuide. Sun Press, 100\u2013102. \n\n \n\nEscop, 2003. Monographs on the Medicinal Uses of Plant Drugs, European Scientific \n\nCooperative on Phytotherapy.2nd edition. \n\n \n\nForbes V.S., 1986. Carl Peter Thunberg Travels at the Cape of Good Hope. 1, 1772\u2013\n\n1775. \n\n \n\n104 \n \n\n\n\nFriedman LS, Martin P, Munoz SJ: Liver Function tests and the objective evaluation of \n\nthe patient with liver disease. In: Hepatology: a Textbook of Liver Disease (Edited by \n\nZakim D, TD Boyer TD). Philadelphia, WB Saunders, 1996, 791-833.  \n\n \n\nGonz\u00e1lez, F. H. D. Silva, S. C., 2003. Introdu\u00e7\u00e3o \u00e0 Bioqu\u00edmica Cl\u00ednica Veterin\u00e1ria. \n\nPorto Alegre, UFRGS, 179-198 p. \n\n \n\nGrace O.M., Simmondsa M.S.J., Smith G.F., vanWikg A.E. 2008. Therapeutic uses of \n\nAloe  L. (Asphodelaceae) in southern Africa. Journal of Ethnopharmacology 119:604-\n\n614. \n\n \n\nHara H. ,Ise Y., Morimoto N., Shimazawa M., Ichihashi K., Ohyama M., Iinuma . \n\nlaxative effect of agarwood leaves and its mechanism. bioscience, biotechnology and \n\nbiochemistry, v.72, p. 335-345, 2008. \n\n \n\nIshii, Y., Tanizawa, H., Takino, Y., 1994. Studies of aloe. V. Mechanism of cathartic \n\neffect. Biological and Pharmaceutical Buletin. (4), 17, 651\u2013653. \n\n \n\nJia Y., Zhaoa G., Jia J. 2008. Preliminary evaluation: The effects of Aloe ferox Miller \n\nand Aloe arborescens Miller on wound healing. Journal of Ethnopharmacology \n\n120,181\u2013189. \n\n \n\nJones K., Hughes J., Hong M., Jia Q., Orndorf S., 2002. Modulation of melanogenesis \n\nby aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Residual. 15, 335-340. \n\n \n\nKaneko J.J. In: Clinical biochemistry of domestic animals, 4th ed. San Diego: Academic \n\nPress; 1989. \n\n \n\nKruger, D.W., Beyers, G.J., 1977. Dictionary of South African Biography. Tafelberg \n\nPublishers .3, 231\u2013232. \n\n \n\nLaure B. Mabekua,K., Benga, V.P; Kouamb, J.; Essame O.; Etoa, F.X., 2007. \n\nToxicological evaluation of ethyl acetate extract of Cylicodiscus gabunensis stem bark \n\n(Mimosaceae) Journal of Ethnopharmacology 111, 598\u2013606. \n\n105 \n \n\nhttp://www.biomedcentral.com/sfx_links.asp?ui=1471-2296-2-2&amp;bibl=B2\n\n\n \n\nLee, J.K., Lee, M.K., Yun, Y.-P., Kim, Y., Kim, J.S., Kim, Y.S., Kim, K., Han, S.S. and \n\nLee, C.-K., 2001. Acemannan Purified From Aloe Vera Induces Phenotypic and \n\nFunctional Maturation of Immature Dendritic Cells. International \n\nImmunopharmacology 1, 1275-1284. \n\n \n\nMagalh\u00e3es, P. M. Plantas Medicinais: Eu posso ser um produtor?  Confiram 10 itens  \n\nimportantes para este prop\u00f3sito . Bolet\u00edn  Latinoamericano y Del Caribe  de Plantas \n\nMedicinales y Aromaticas , v. 4, n.  5 , p. 87 \u2013 91, 2005. \n\n \n\nMagwa, M.L., Gundidza, M., Coopoosamy, R.M. and Mayelyso, B., 2006. Chemical \n\ncomposition of volatile constituents from the leaves of Aloe ferox. African Journal of \n\nBiotechnology. 5, 1652-1654. \n\n \n\nMarloth, R., 1915. The Flora of South Africa, Darter. \n\n \n\nMatsuda Y. , Yokohira,M.; Suzuki, S.; Hosokawa, K. ; Yamakawa, K.; Zeng, Y.; \n\nNinomiya, F.; Saoo, K.; Kuno, T.; Imaida, K.,2008.One-year chronic toxicity study of \n\nAloe arborescens Miller var.natalensis Berger in Wistar Hannover rats. A pilot study. \n\nFood and Chemical Toxicology.46, 733\u2013739. \n\n \n\nMello, F. B., 2001. Estudo dos efeitos de Lantana c\u00e2mara (Verbenaceae) sobre \n\nfertilidade e reprodu\u00e7\u00e3o de ratos. Disserta\u00e7\u00e3o (Mestrado em Ci\u00eancias Veterin\u00e1rias)-\n\nPrograma de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias Veterin\u00e1rias, Universidade Federal do Rio \n\nGrande do Sul. Porto Alegre, RS. p.120. \n\n \n\nNewhouse, J.F. , Kho, D., Rao, Q.A.; Starren, J., 2008. Frequency of Serum Creatinine \n\nChanges in the Absence of Iodinated Contrast Material: Implications for Studies of \n\nContrast Nephrotoxicity. AJR: 191.  \n\n \n\nOlson, H.; Betton, G.; Robinson, D.; Thomas, K.; Monro, A.; Kolaja, G.; Lilly, P.; \n\nSanders, J.; Sipes, G.; Bracken, W.; Dorato, M.; Deun, K.V.; Smith, P.; Berger, B.; \n\nHeller, A.; 2000. Concordance of toxicity of pharmaceuticals in humans and in animals. \n\n \n\n106 \n \n\n\n\nPalgrave, K.C., 1984. Trees of Southern Africa. Struik Publisheres. 2, 72-86. \n\n \n\nPlants in Use Among the Natives. Lovedale, 2nd ediction. \n\n \n\nRahman, M.F., Siddiqui, M.K., Jamil, K., 2001. Effects ofVepacide (Azadirachta \n\nindica) on aspartate and alanine aminotransferase profiles in a sub chronic study with \n\nrats. Journal of Human and Experimental Toxicology 20, 243\u2013249.  \n\n \n\nRasekh, H.R., Nazari,P.; Kamli-Nejad,M.; Hosseinzadeh, L. ,2008. Acute and \n\nsubchronic oral toxicity of Galega officinalis in rats. Journal of Ethnopharmacology 116  \n\n21\u201326. \n\n \n\nReynolds, G.W., 1950. The Aloes of South Africa. The Trustees of the Aloes of South \n\nAfrica Book Fund. \n\n \n\nRobertson, H.M., 1979. The aloe boers of the Gouritz River District. Quarterly Bulletin \n\nof the South African Library 34, 59\u201369. \n\n \n\nSmith, A., 1888. A Contribution to the South African Materia Medica, Chiefly from \n\nSteenkamp, V., Stewart, M.J., 2007.Medicinal applications and toxicological activities \n\nof Aloe products. Pharmaceutical Biology 45, 411\u2013420. \n\n \n\nTilkian, S.M., 1979. Clinical Implications of Laboratory Tests. The C.V. Mosby \n\nCompany, Missouri, pp. 11\u201317. \n\n \n\nVan Wyk, B.-E., Van Oudtshoorn, M.C.B.V., Smith, G.F., 1995. Geographical variation \n\nin the major compounds of Aloe ferox leaf exudate. Planta Medica.61, 250\u2013253. \n\n \n\nVan Wyk, B.E., 2008. A broad review of commercially important southern African \n\nmedicinal plants. Journal of Ethnopharmacology. 119, 342\u2013355. \n\n \n\nWatt, J.M., Breyer-Brandwijk,M.G., 1962.Medicinal and Poisonous Plants of Southern \n\nand Eastern Africa. E. &amp; S. Livingstone. \n\n \n\n107 \n \n\n\n\nWolf, P.L.,Williams, D., Tsudaka, T., Acosta, L., 1972. Methods and Techniques in \n\nClinical Chemistry. John Wiley &amp; Sons, USA. \n\n108 \n \n\n\n\n \n\n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n10\n\n20\n\n30\n\n40\n\n50\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\nWeeks\n\nB\nod\n\ny \nm\n\nas\ns \n\nga\nin\n\n (\ng)\n\n \n \n\nFigure 1: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on body weigth gain of female Wistar rats for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 8-13/group). \n\n \n\n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n10\n\n20\n\n30\n\n40\n\n50\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\nWeeks\n\nB\nod\n\ny \nm\n\nas\ns \n\nga\nin\n\n (\ng)\n\n \n \n\nFigure 2: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on body weigth gain of male Wistar rats for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 12-13/group). \n\n109 \n \n\n\n\n \n \n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n20\n\n40\n\n60\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\nWeeks\n\nW\nat\n\ner\n In\n\nta\nke\n\n (\nm\n\nL/\nra\n\nt/\nda\n\ny)\n\n \n \n\nFigure 3: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on water consumption of female Wistar rats for for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 8-13/group). \n\n \n\n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n20\n\n40\n\n60\n\n80\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\nWeeks\n\nW\nat\n\ner\n In\n\nta\nke\n\n  (\nm\n\nL/\nra\n\nt/\nda\n\ny)\n\n \n \n\n \n\nFigure 4: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on water consumption of male Wistar rats for for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 12-13/group). \n\n110 \n \n\n\n\nFigure 6: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on food consumption of male Wistar rats for for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 12-13/group). \n\n111 \n \n\n \n \n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n5\n\n10\n\n15\n\n20\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\nWeeks\n\nFo\nod\n\n In\nta\n\nke\n (\n\ng/\nra\n\nt/\nw\n\nee\nk)\n\n \n \n\n \nFigure 5: Effect of the administration of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-\n\n1) by oral route on food consumption of female Wistar rats for for 13 weeks. The data \n\nrepresent the mean \u00b1 SEM (n = 8-13/group). \n\n \n\n \n\n \n\n1 2 3 4 5 6 7 8 9 10 11 12 13\n0\n\n10\n\n20\n\n30\n\nWeeks\n\nFo\nod\n\n In\nta\n\nke\n(g\n\n/r\nat\n\n/d\nay\n\n)\n\n \n\nControl\nAf 0.1 g/kg\nAf 0.5 g/kg\nAf 1.5 g/kg\n\n \n\n\n\nTable 1: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in female Wistar rats treated for 4 \n\nweeks. \n\n \n\nPARAMETERS CONTROL \n(n = 13) \n\nAf 0.1 g.kg-1 \n(n = 13) \n\nAf 0.5g.kg-1 \n(n = 13) \n\nAf 1.5 g.kg-1 \n(n = 11) \n\nErythrocytes (106/\u00b5L) 7.89\u00b1 0.09 7.94\u00b10.11  7.98\u00b1 0.11 6.13\u00b1 0.11*\n\nHemoglobin (g/dL) 15.65\u00b1 0.10 15.73\u00b1 0.17 15.44\u00b1 0.18 11.96\u00b1 0.11*\n\nHematocrit (%) 46.70\u00b1 0.47 47.08\u00b1 1.03 45.12\u00b1 0.95 36.17\u00b1 0.64*\n\nMCV (fL) 59.20\u00b1 0.91 59.19\u00b1 1.07 56.85\u00b1 0.95 58.94\u00b1 0.53 \nMCH (pg) 19.86\u00b1 0.17 19.78\u00b1 0.11 19.45\u00b10.08  19.60\u00b1 0.16 \n\nMCHC(g/dL) 33.54\u00b10.36  33.49\u00b10.60  34.30\u00b1 0.44 33.08\u00b1 0.21 \nRDW (%) 12.69\u00b1 0.21 13.09\u00b1 0.20 13.46\u00b1 0.19 17.64\u00b10.65*  \n\nPlatelets (103/\u00b5L) 765.8\u00b1 20.83 814.8\u00b1 21.08 851.2\u00b1 21.80 862.4\u00b152.94 \nWBC (103/\u00b5L) 13.43\u00b1 1.09 13.91\u00b1 0.96 14.25\u00b1 1.67 18.39\u00b1 1.52 \n\nMPV (fL) 5.82\u00b1 0.09 5.91\u00b1 0.06 5.80\u00b1 0.03 5.59\u00b10.11  \nNeutrophils (%) 4.60\u00b1 1.97 10.86\u00b1 3.53 23.08\u00b1 5.75 16.37\u00b14.59  \nLimphocytes (%) 93.58\u00b1 2.03 84.02\u00b1 3.94 74.45\u00b1 5.64 77.17\u00b13.28  \nMonocytes (%) 0.45\u00b1 0.06 3.81\u00b11.90  1.77\u00b1 0.69 4.24\u00b1 0.94 \n\nEosinophyls (%) 1.35\u00b1 0.16 1.32\u00b1 0.30 0.68\u00b1 0.17 0.81\u00b1 0.12 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. * Statistically different from control group (ANOVA followed by \nTukey, p &lt;0.05). \n\n112 \n \n\n\n\nTable 2: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in female Wistar rats \ntreated for 8 weeks. \n \n\nPARAMETERS CONTROL \n(n = 13) \n\nAf 0.1 g.kg-1 \n(n = 13) \n\nAf 0.5g.kg-1 \n(n = 13) \n\nAf 1.5 g.kg-1    \n(n = 10) \n\nErythrocytes (106/\u00b5L) 7.37\u00b1 0.16 7.75\u00b1 0.17 7.57\u00b1 0.19 7.76\u00b1 0.18 \n\nHemoglobin (g/dL) 14.70\u00b10.25  15.30\u00b1 0.23 14.73\u00b1 0.16 14.81\u00b1 0.29 \nHematocrit (%) 41.33\u00b1 0.81 43.29\u00b1075 40.53\u00b1 0.89 43.28\u00b1 0.86 \nMCV (fL) 54.46\u00b1 1.52 55.76\u00b1 0.43 53.50\u00b10.35  55.82\u00b1 1.16 \nMCH (pg) 23.02\u00b13.10  19.78\u00b10.20  19.51\u00b1 0.41 19.13\u00b1 0.42 \nMCHC(g/dL) 35.60\u00b1 0.14 35.42\u00b1 0.16 36.46\u00b1 0.58 34.28\u00b10.39  \nRDW (%) 14.47\u00b1 0.25 14.90\u00b1 0.32 16.08\u00b1 0.32 20.19\u00b1 1.98* \nPlatelets (103/\u00b5L) 870.30\u00b1 21.85 915.00\u00b1 16.40 950.30\u00b1 40.58 902.00\u00b1 53.20 \nWBC (103/\u00b5L) 10.02\u00b1 0.85 11.48\u00b10.73  13.58\u00b1 1.11 13.33\u00b10.66 \nMPV (fL) 5.64\u00b1 0.08 5.93\u00b1 0.10 5.68\u00b1 0.09 5.63 \u00b1 0.10 \nNeutrophils (%) 21.18\u00b1 3.69 22.98\u00b13.65  22.19\u00b1 5.21 35.44\u00b1 7.26 \nLimphocytes (%) 75.45\u00b1 3.97 73.31\u00b13.79  72.52\u00b16.27  62.39\u00b17.04  \nMonocytes (%) 1.12\u00b1 0.97 1.92\u00b11.50  4.26\u00b1 3.02 1.34\u00b10.60 \nEosinophyls (%) 2.25\u00b1 0.38 1.79\u00b1 0.22 1.28\u00b1 0.09 1.72\u00b1 0.32 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. * Statistically different from control group (ANOVA followed by \nTukey, p &lt;0.05). \n\n \n\n113 \n \n\n\n\nTable 3: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in female Wistar rats treated for \n13 weeks. \n\n \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5g.kg-1 \n\n(n = 13) \nAf 1.5 g.kg-1    \n\n(n = 8) \n\nErythrocytes (106/\u00b5L) 7.56\u00b1 0.13 7.74\u00b1 0.11 7.79\u00b1 0.12 8.34\u00b1 0.28* \n\nHemoglobin (g/dL) 13.92\u00b1 0.24 14.10\u00b1 0.15 13.71\u00b1 0.16 15.86\u00b1 0.52* \nHematocrit (%) 41.78\u00b1 0.65 42.46\u00b1 0.47 41.23\u00b1 0.67 45.41\u00b1 1.60* \nMCV (fL) 55.20\u00b1 0.44 54.83\u00b1 0.28 52.85\u00b1 0.46* 54.40\u00b1 0.87 \nMCH (pg) 18.39\u00b1 0.19 18.23\u00b1 0.10 17.93\u00b10.11  19.03\u00b1 0.35 \nMCHC(g/dL) 33.28\u00b1 0.15 33.20\u00b1 0.12 33.28\u00b1 0.36 34.24\u00b1 0.21 \nRDW (%) 13.71\u00b1 0.35 14.49\u00b1 0.31 17.58\u00b1 1.65 19.59\u00b1 1.87* \nPlatelets (103/\u00b5L) 894.40\u00b1 19.47 872.40\u00b1 21.76 862.90\u00b1 53.01 781.40\u00b1 36.75 \nWBC (103/\u00b5L) 12.20\u00b1 2.58 11.07\u00b1 0.70 11.38\u00b1 0.87 15.80\u00b1 1.43 \nMPV (fL) 5.63\u00b1 0.13 5.84\u00b1 0.09 5.67\u00b1 0.09 5.96\u00b1 0.17 \nNeutrophils (%) 19.33\u00b1 3.67 22.42\u00b1 3.92 26.92\u00b1 3.54 20.36\u00b1 7.76 \nLimphocytes (%) 76.66\u00b1 4.02 71.75\u00b1 4.61 68.41\u00b1 3.80 77.56\u00b1 6.58 \nMonocytes (%) 1.95\u00b1 0.92 2.16\u00b1 0.82 3.62\u00b1 1.21 1.31\u00b1 0.44 \nEosinophyls (%) 1.98\u00b1 0.36 2.87\u00b1 0.81 1.07\u00b1 0.22 1.31\u00b1 0.25 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. * Statistically different from control group (ANOVA followed by \nTukey, p &lt;0.05). \n\n \n\n114 \n \n\n\n\nTable 4: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in male Wistar rats \ntreated for 4 weeks. \n \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5g.kg-1 \n\n(n = 13) \nAf 1.5 g.kg-1 \n\n(n = 13) \n\nErythrocytes (106/\u00b5L) 8.02\u00b1 0.07 7.16\u00b10.15* 7.79\u00b1 0.09 6.82\u00b10.19* \n\nHemoglobin (g/dL) 14.28\u00b1 0.13 13.29\u00b1 0.29 14.10\u00b1 0.17 12.74\u00b10.19 \nHematocrit (%) 40.93\u00b1 0.74 38.45\u00b11.30 39.99\u00b1 0.75 38.14\u00b10.57 \nMCV (fL) 51.01\u00b1 0.91 53.57\u00b1 1.40 51.28\u00b1 0.90 56.10\u00b11.02 \nMCH (pg) 17.83\u00b1 0.14 18.58\u00b1 0.28 18.08\u00b1 0.19 18.76\u00b10.33 \nMCHC(g/dL) 35.03\u00b1 0.72 34.78\u00b1 0.62 35.28\u00b1 0.38 33.43\u00b10.14 \nRDW (%) 15.33\u00b10.40 16.61\u00b1 0.53 16.45\u00b10.35 20.54\u00b11.45 \nPlatelets (103/\u00b5L) 839.70\u00b1 43.39 683.00\u00b1 56.87 887.70\u00b1 33.58 995.60\u00b141.22 \nWBC (103/\u00b5L) 15.25\u00b1 1.14 15.56\u00b1 0.95 17.33\u00b1 1.54 19.93\u00b11.64 \nMPV (fL) 5.880\u00b1 0.07 5.81\u00b1 0.14 5.16\u00b1 0.11 5.30\u00b10.093 \nNeutrophils (%) 7.71\u00b12.71 9.62\u00b12.94 22.10\u00b15.94 13.48\u00b14.46 \nLimphocytes (%) 87.08\u00b13.19 86.08\u00b12.87 74.08\u00b15.67 74.75\u00b1418 \nMonocytes (%) 0.36\u00b10.10 1.45\u00b10.79 2.04\u00b11.04 13.48\u00b14.55 \nEosinophyls (%) 2.7\u00b10.28 2.84\u00b10.50 1.77\u00b10.24 0.75\u00b10.13 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. * Statistically different from control group (ANOVA followed by \nTukey, p &lt;0.05). \n\n \n\n115 \n \n\n\n\nTable 5: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in male Wistar rats \ntreated for 8 weeks. \n \n\nPARAMETERS CONTROL \n(n = 13) \n\nAf 0.1 g.kg-1 \n(n = 13) \n\nAf 0.5g.kg-1 \n(n = 12) \n\nAf 1.5 g.kg-1    \n(n = 12) \n\nErythrocytes (106/\u00b5L) 7.56\u00b1 0.42 7.93\u00b1 0.13 7.53\u00b10.37  7.75\u00b1 0.15 \n\nHemoglobin (g/dL) 13.61\u00b1 0.39 14.06\u00b1 0.21 14.10\u00b1 0.16 14.61\u00b1 0.20 \nHematocrit (%) 40.31\u00b1 1.03 42.46\u00b1 0.41 41.89\u00b1 0.50 41.15\u00b1 0.58 \nMCV (fL) 54.99\u00b1 3.29 53.61\u00b1 0.94 57.32\u00b1 4.63 53.21\u00b1 0.94 \nMCH (pg) 18.53\u00b10.99  17.72\u00b1 0.20 19.30\u00b1 1.54 18.80\u00b1 0.33 \nMCHC(g/dL) 33.74\u00b1 0.17 33.13\u00b10.40  33.66\u00b10.17  34.71\u00b1 0.30 \n\nRDW (%) 25.73\u00b1 3.34 21.55\u00b1 2.27 21.78\u00b1 2.89 24.83\u00b1 2.86 \nPlatelets (103/\u00b5L) 857.70\u00b1 87.46 879.20\u00b1 37.48 875.60\u00b188.54  925.60\u00b1 19.86 \nWBC (103/\u00b5L) 17.13\u00b1 1.18 16.64\u00b1 1.12 16.40\u00b1 1.64 15.56\u00b1 1.07 \nMPV (fL) 6.36\u00b1 0.16 6.04\u00b1 0.09 6.55\u00b1 0.44 6.37\u00b1 1.02 \nNeutrophils (%) 22.22\u00b1 7.31 25.94\u00b1 7.15 22.09\u00b16.89  26.57\u00b1 4.95 \nLimphocytes (%) 72.21\u00b1 7.41 68.82\u00b1 7.01 67.88\u00b1 7.30 65.40\u00b1 5.13 \nMonocytes (%) 3.53 \u00b1 1.06 2.62\u00b1 1.17 9.56\u00b13.90  0.43\u00b10.22  \nEosinophyls (%) 2.04\u00b10.30 2.63\u00b1 0.24 2.09\u00b1 0.29 1.83 0.18 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. No statistically different from control group (ANOVA, p > 0.05). \n\n \n \n\n116 \n \n\n\n\nTable 6: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route on hematological parameters in male Wistar rats \ntreated for 13 weeks. \n \n\nPARAMETERS CONTROL \n(n = 13) \n\nAf 0.1 g.kg-1 \n(n = 13) \n\nAf 0.5g.kg-1 \n(n = 12) \n\nAf 1.5 g.kg-1    \n(n = 12) \n\nErythrocytes (106/\u00b5L) 7.74\u00b1 0.12 7.87\u00b1 0.15 7.97\u00b10.09  8.67\u00b1 0.11* \n\nHemoglobin (g/dL) 14.04\u00b1 0.18 14.42\u00b1 0.17 14.47\u00b1 0.18 16.13\u00b1 0.35* \nHematocrit (%) 39.91\u00b1 0.69 40.52\u00b10.55  40.69\u00b1 0.49 46.10\u00b1 0.72* \nMCV (fL) 51.50\u00b1 0.40 51.49\u00b1 0.58 50.99\u00b1 0.40 53.16\u00b1 0.96 \nMCH (pg) 18.17\u00b1 0.13 18.37\u00b1 0.17 18.18\u00b1 0.16 18.58\u00b1 0.25 \nMCHC(g/dL) 35.22\u00b1 0.21 35.65\u00b1 0.22 33.64\u00b1 1.97 34.98\u00b1 0.63 \nRDW (%) 20.53\u00b1 2.59 23.66\u00b1 3.05 23.06\u00b1 3.06 30.45\u00b1 2.71 \nPlatelets (103/\u00b5L) 1039.00\u00b1 38.68 918.30\u00b1 27.07 919.80\u00b1 18.06 829.40\u00b1 17.54* \nWBC (103/\u00b5L) 17.13\u00b1 1.18 16.64\u00b1 1.12 16.40\u00b1 1.64 18.15\u00b1 0.85 \nMPV (fL) 5.90\u00b10.06  5.97\u00b10.10 5.87\u00b1 0.08 6.09\u00b10.11  \nNeutrophils (%) 26.02\u00b1 2.26 13.42\u00b1 2.85 15.60\u00b1 3.21 24.20\u00b15.62  \nLimphocytes (%) 70.20\u00b1 2.28 79.69\u00b1 3.87 81.17\u00b1 2.98 68.90\u00b1 4.48 \nMonocytes (%) 1.40\u00b1 0.58 4.17\u00b1 3.34 0.42\u00b1 0.12 5.73\u00b1 3.37 \nEosinophyls (%) 2.38\u00b1 0.45 2.72\u00b1 0.19 2.81\u00b1 0.29 1.17\u00b1 0.15 \n\nValues represent the mean \u00b1 SEM. MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin \nconcentration; RDW,  \nred cell distribution width; WBC, white blood cell; MPV, mean platelet volume. * Statistically different from control group (ANOVA followed by \nTukey, p &lt;0.05). \n\n \n\n117 \n \n\n\n\nTable 7: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in female Wistar rats \ntreated for 4 weeks. \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n = 13) \nAf 1.5 g.kg-1 \n\n(n = 11) \n\nGlucose (mg/dL) 104.90\u00b15.70 93.05\u00b12.21 92.81\u00b1 1.64 92.99\u00b12.62  \nAlkaline Phosphatase (U/L) 154.80\u00b122.86 175.30\u00b1 25.24 195.60\u00b121.17  191.60\u00b121.76  \nCreatinine (mg/dL) 0.62\u00b10.03 0.61\u00b10.02 0.63\u00b10.02 0.44\u00b10.02*\n\nAST (U/L) 87.17\u00b13.48 98.58\u00b1 3.24 96.23\u00b15.07 143.10\u00b19.71  \nALT (U/L) 57.33\u00b12.93  68.08\u00b13.37 65.77\u00b13.86 71.78\u00b112.47 \nTotal cholesterol (mg/dL) 96.09\u00b1 4.65 91.70\u00b14.65 79.19\u00b14.12 87.90\u00b15.25 \nTriglycerides (mg/dL) 81.03\u00b1 7.75 61.40\u00b1 5.14 48.01\u00b1 5.92* 48.05\u00b13.91*\n\nHDL (mg/dL) 78.48\u00b11.30 75.03\u00b1 3.62 62.35\u00b12.98 * 59.16\u00b13.69*\n\nAmylase (U/L) 664.60\u00b134.26  551.30\u00b1 28.31 539.30\u00b136.26 604.00\u00b146.46 \nGGT (U/L) 4.00\u00b1 0.04 3.97\u00b1 0.04 3.99\u00b1 0.03 3.95\u00b1 0.03 \nTotal bilirrubin (mg/dL) 0.29\u00b10.04 0.47\u00b10.01 0.38\u00b1 0.02 0.122\u00b10.008 \nDirect bilirrubin (mg/dL) 0.076\u00b1 0.005 0.083\u00b10.004 0.087\u00b10.004 0.079\u00b1 0.005 \nIndirect bilirrubin (mg/dL) 0.24\u00b1 0.04 0.382\u00b1 0.009 0.29\u00b1 0.03 0.043\u00b10.006 \nLDL (mg/dL) 3.64\u00b11.30 4.68\u00b11.05 4.66\u00b11.21 7.43\u00b11.71 \nBUN (mg/dL) 39.65\u00b10.94 39.02\u00b11.46 41.82\u00b12.04 40.60\u00b16.42 \n\nAlbumin (g/dL) 4.31\u00b10.09 4.37 \u00b10.10 4.06\u00b10.08 4.50\u00b10.06 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL , low-\ndensity lipoproteins; GGT, gamma-glutamyl transpeptidase. * Statistically different from control group (ANOVA followed by Tukey, p &lt;0.05). \n* Statistically different from control group (ANOVA followed by Tukey, p &lt;0.05). \n\n118 \n \n\n\n\nTable 8: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in female Wistar rats \ntreated for 8 weeks. \n \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n =13) \nAf 1.5 g.kg-1 \n\n(n = 10) \nGlucose (mg/dL) 91.33\u00b12.15 88.28\u00b12.77 83.75\u00b11.24 100.80\u00b13.52 \nAlkaline Phosphatase (U/L) 180.60\u00b17.24 192.20\u00b125.28 285.40\u00b129.00* 227.10\u00b119.83 \nCreatinine (mg/dL) 0.50\u00b10.00 0.49\u00b10.02 0.46\u00b10.02 0.54\u00b10.03 \nAST (U/L) 127.90\u00b15.27 134.40\u00b15.08 123.10\u00b15.66 114.30\u00b12.34 \nALT (U/L) 63.67\u00b13.16 76.00\u00b14.23 68.42\u00b13.64 63.33\u00b14.71 \nTotal cholesterol (mg/dL) 79.53\u00b12.99 73.11\u00b12.91 76.37\u00b13.55 82.97\u00b13.41 \nTriglycerides (mg/dL) 77.38\u00b16.19 69.65\u00b110.47 75.19\u00b16.35 65.81\u00b16.11 \nHDL (mg/dL) 50.70\u00b11.90 20.46\u00b11.38 47.27\u00b12.61 57.64\u00b12.49 \nAmylase (U/L) 827.80\u00b112.59 783.60\u00b136.18 718.40\u00b138.13 813.20\u00b146.43 \nGGT (U/L) 3.98\u00b10.03 3.98\u00b10.03 4.00\u00b10.04 4.00\u00b10.04 \nTotal bilirrubin (mg/dL) 0.136\u00b10.005 0.145\u00b10.006 0.115\u00b10.005 0.18\u00b10.01*\n\nDirect bilirrubin (mg/dL) 0.101\u00b10.003 0.114\u00b10.005 0.092\u00b10.008 0.087\u00b10.007 \nIndirect bilirrubin (mg/dL) 0.035\u00b10.005 0.031\u00b10.005 0.022\u00b10.006 0.09\u00b10.01*\nLDL (mg/dL) 13.46\u00b10.93 9.73\u00b11.87 13.50\u00b11.20 13.63\u00b11.58 \nBUN (mg/dL) 39.39\u00b11.88 37.51\u00b11.22 36.68\u00b11.72 37.46\u00b11.60 \nAlbumin (g/dL) 3.88\u00b10.05 3.75\u00b10.05 3.75\u00b10.10 3.77\u00b10.10 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL \n, low-density lipoproteins; GGT, gamma-glutamyl transpeptidase. * Statistically different from control group (ANOVA followed by Tukey, \np &lt;0.05). \n\n119 \n \n\n\n\nTable 9: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in female Wistar rats \ntreated for 13 weeks. \n\n \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n = 13) \nAf 1.5 g.kg-1 \n\n(n = 8) \nGlucose (mg/dL) 100.40\u00b14.64 81.50\u00b14.63 91.50\u00b13.31 105.87\u00b19.71 \nAlkaline Phosphatase (U/L) 120.80\u00b115.84 178.00\u00b141.49 150.10\u00b111.05 161.70\u00b120.22 \nCreatinine (mg/dL) 0.95\u00b10.01 0.88\u00b10.03 0.95\u00b10.02 0.88\u00b10.02 \nAST (U/L) 109.50\u00b110.72 101.60\u00b15.08 126.40\u00b121.10 121.30\u00b19.64 \nALT (U/L) 55.09\u00b1 3.78 57.20\u00b1 3.57 69.42\u00b1 12.36 41.00\u00b1 2.60 \nTotal cholesterol (mg/dL) 104.30\u00b1 4.09 100.40\u00b1 3.48 88.22\u00b1 5.52 100.70\u00b1 4.73 \nTriglycerides (mg/dL) 77.98\u00b1 6.02 73.51\u00b1 10.28 76.38\u00b1 7.66 74.60\u00b1 8.04 \nHDL (mg/dL) 70.31\u00b12.87 65.95\u00b12.64 59.69\u00b13.35 73.19\u00b12.64 \nAmylase (U/L) 705.20\u00b1 29.05 702.10\u00b1 31.47 635.80\u00b1 24.25 676.70\u00b1 46.79 \nGGT (U/L) 4.00\u00b10.04 3.97\u00b10.04 3.99\u00b10.03 3.95\u00b10.03 \nTotal bilirrubin (mg/dL) 0.25\u00b10.01 0.24\u00b10.01 0.22\u00b10.01 0.201\u00b10.01 \nDirect bilirrubin (mg/dL) 0.13\u00b10.01 0.12\u00b10.01 0.12\u00b10.01 0.09\u00b10.01 \nIndirect bilirrubin (mg/dL) 0.14\u00b10.01 0.12\u00b10.01 0.10\u00b10.01 0.11\u00b10.01 \nLDL (mg/dL) 8.28\u00b1 1.97 9.18\u00b1 1.94 6.11\u00b1 1.21 7.11\u00b1 0.51 \nBUN (mg/dL) 40.80\u00b11.53  40.83\u00b12.61 40.65\u00b11.43 40.95\u00b12.39 \nAlbumin (g/dL) 4.39\u00b10.16 4.42\u00b10.19 4.22\u00b10.09 4.38\u00b10.11 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL \n, low-density lipoproteins; GGT, gamma-glutamyl transpeptidase. No statistically different from control group (ANOVA, p > 0.05). \n\n120 \n \n\n\n\nTable 10: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in male Wistar rats \ntreated for 4 weeks. \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n = 13) \nAf 1.5 g.kg-1 \n\n(n = 13) \nGlucose (mg/dL) 108.39\u00b1 3.85 88.69\u00b1 5.12 98.08\u00b1 5.64 106.11\u00b15.53  \nAlkaline Phosphatase (U/L) 178.3\u00b115.23  235.10\u00b1 40.50 267.00\u00b119.50 227.20\u00b1 13.21 \nCreatinine (mg/dL) 0.58\u00b1 0.02 0.61\u00b1 0.03 0.57\u00b10.02 0.42\u00b1 0.01*\n\nAST (U/L) 157.90\u00b1 9.77 153.40\u00b1 12.21 123.30\u00b1 6.67 139.60\u00b19.07  \nALT (U/L) 70.58\u00b1 4.46 98.33\u00b1 14.68 70.08\u00b1 3.67 65.25\u00b1 3.49 \nTotal cholesterol (mg/dL) 72.65\u00b1 4.20 60.84\u00b1 1.88 64.82\u00b1 3.62 84.92\u00b1 5.07 \nTriglycerides (mg/dL) 68.50\u00b1 8.45 44.28\u00b1 8.29 43.06\u00b13.12 66.80\u00b1 6.99 \nHDL (mg/dL) 50.72\u00b1 3.26 42.50\u00b1 1.60 46.58\u00b12.54 54.78\u00b1 3.60 \nAmylase (U/L) 808.10\u00b142.71  729.70\u00b114.70 695.30\u00b1 32.39 744.10\u00b1 43.37 \nGGT (U/L) 3.97\u00b1 0.03 3.97\u00b1 0.04 4.00\u00b1 0.03 3.97\u00b1 0.03 \nTotal bilirrubin (mg/dL) 0.145\u00b1 0.005 0.138\u00b1 0.003 0.119\u00b1 0.004 0.118\u00b1 0.005 \nDirect bilirrubin (mg/dL) 0.093\u00b1 0.006 0.084\u00b1 0.008 0.091\u00b1 0.003 0.083\u00b1 0.003 \nIndirect bilirrubin (mg/dL) 0.044\u00b1 0.006 0.036\u00b1 0.005 0.029\u00b1 0.003 0.035\u00b1 0.005 \nLDL (mg/dL) 8.26\u00b12.37 33.52\u00b14.21* 10.85\u00b11.78 16.29\u00b12.20 \nBUN (mg/dL) 39.45\u00b11.79 39.77\u00b11.56 38.75\u00b11.75 37.43\u00b11.66 \nAlbumin (g/dL) 3.92\u00b10.06 3.73\u00b10.05 3.78\u00b10.06 3.72\u00b10.07 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL \n, low-density lipoproteins; GGT, gamma-glutamyl transpeptidase. * Statistically different from control group (ANOVA followed by Tukey, \np &lt;0.05). \n \n\n121 \n \n\n\n\nTable 11: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in male Wistar rats treated \nfor 8 weeks. \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n = 12) \nAf 1.5 g.kg-1 \n\n(n = 12) \n\nGlucose (mg/dL) 91.33\u00b12.15 88.28\u00b12.77 83.75\u00b11.24 100.80\u00b13.52 \n\nAlkaline Phosphatase (U/L) 180.60\u00b17.24 192.20\u00b125.28 285.40\u00b129.00* 227.10\u00b119.83 \nCreatinine (mg/dL) 0.50\u00b10.00 0.49\u00b10.02 0.46\u00b10.02 0.54\u00b10.03 \nAST (U/L) 127.90\u00b15.27 134.40\u00b15.08 123.10\u00b15.66 114.30\u00b12.34 \nALT (U/L) 63.67\u00b13.16 76.00\u00b14.23 68.42\u00b13.64 63.33\u00b14.71 \nTotal cholesterol (mg/dL) 79.53\u00b12.99 73.11\u00b12.91 76.37\u00b13.55 82.97\u00b13.41 \nTriglycerides (mg/dL) 77.38\u00b16.19 69.65\u00b110.47 75.19\u00b16.35 65.81\u00b16.11 \nHDL (mg/dL) 50.70\u00b11.90 20.46\u00b11.38 47.27\u00b12.61 57.64\u00b12.49 \nAmylase (U/L) 827.80\u00b112.59 783.60\u00b136.18 718.40\u00b138.13 813.20\u00b146.43 \nGGT (U/L) 3.98\u00b10.03 3.98\u00b10.03 4.00\u00b10.04 4.00\u00b10.04 \nTotal bilirrubin (mg/dL) 0.136\u00b10.005 0.145\u00b10.006 0.125\u00b10.005 0.148\u00b10.011*\n\nDirect bilirrubin (mg/dL) 0.101\u00b10.003 0.114\u00b10.005 0.092\u00b10.008 0.087\u00b10.007 \nIndirect bilirrubin (mg/dL) 0.035\u00b10.005 0.031\u00b10.005 0.022\u00b10.006 0.061\u00b10.003*\nLDL (mg/dL) 13.46\u00b10.93 9.73\u00b11.87 13.50\u00b11.20 13.63\u00b11.58 \nBUN (mg/dL) 39.39\u00b11.88 37.51\u00b11.22 36.68\u00b11.72 37.46\u00b11.60 \nAlbumin (g/dL) 3.88\u00b10.05 3.75\u00b10.05 3.75\u00b10.10 3.77\u00b10.10 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL \n, low-density lipoproteins; GGT, gamma-glutamyl transpeptidase. * Statistically different from control group (ANOVA followed by Tukey, \np &lt;0.05). \n\n122 \n \n\n\n\n123 \n \n\n           Table 12: Effect of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by oral route biochemical parameters in male Wistar rats \ntreated for 13 weeks. \n \n\nPARAMETERS CONTROL (n = 13) \nAf 0.1 g.kg-1 \n\n(n = 13) \nAf 0.5 g.kg-1 \n\n(n = 12) \nAf 1.5 g.kg-1 \n\n(n = 12) \n\nGlucose (mg/dL) 101.60\u00b13.42 87.09\u00b15.69 100.50\u00b15.57 102.70\u00b14.49 \n\nAlkaline Phosphatase (U/L) 140.20\u00b111.13 171.10\u00b117.80 264.30\u00b120.25* 205.4\u00b114.40* \nCreatinine (mg/dL) 0.92\u00b10.03 0.88\u00b10.03 0.91\u00b10.04 0.79\u00b10.04 \nAST (U/L) 150.60\u00b13.90 129.40\u00b15.31 111.10\u00b16.93 118.70\u00b14.84 \nALT (U/L) 66.60\u00b13.75 65.89\u00b15.96 54.67\u00b13.10 45.17\u00b13.65* \nTotal cholesterol (mg/dL) 99.58\u00b12.49 86.24\u00b12.47 85.32\u00b11.49 87.57\u00b15.20 \nTriglycerides (mg/dL) 91.17\u00b112.54 73.34\u00b18.26 68.22\u00b18.07 73.72\u00b19.80 \nHDL (mg/dL) 67.14\u00b11.89 62.26\u00b12.55 58.47\u00b11.91 61.16\u00b12.88 \nAmylase (U/L) 776.10\u00b142.48 650.60\u00b162.29 695.30\u00b163.00 904.50\u00b156.15 \nGGT (U/L) 3.97\u00b10.04 3.97\u00b10.04 3.98\u00b10.04 3.98\u00b10.03 \nTotal bilirrubin (mg/dL) 0.203\u00b10.008 0.20\u00b10.01 0.19\u00b10.01 0.20\u00b10.01 \nDirect bilirrubin (mg/dL) 0.11\u00b10.01 0.139\u00b10.008 0.109\u00b10.008 0.119\u00b10.009 \nIndirect bilirrubin (mg/dL) 0.09\u00b10.01 0.07\u00b10.01 0.079\u00b10.007 0.08\u00b10.01 \nLDL (mg/dL) 12.74\u00b11.45 10.48\u00b11.72 11.18\u00b10.88 10.04\u00b11.17 \nBUN (mg/dL) 39.92\u00b10.06 39.14\u00b11.39 37.21\u00b11.73 37.94\u00b11.62 \nAlbumine (mg/dL) 3.90\u00b10.06 3.74\u00b10.05 3.79\u00b10.08 3.74\u00b10.08 \n\nValues represent the mean \u00b1 SEM. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoproteins; LDL , low-\ndensity lipoproteins; GGT, gamma-glutamyl transpeptidase. * Statistically different from control group (ANOVA followed by Tukey, p &lt;0.05). \n\n\n\nTable 13: Effect of dry extract of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by \n\noral route on absolute live (g) and relative body weight ratio (g/100g of animal) in \n\nfemale Wistar rats treated for 13 weeks. \n\n \n\nTISSUES CONTROL Af 0.1 g.kg-1 Af 0.5 g.kg-1 Af 1.5 g.kg-1\n\nSpleen (g) \n(g/100g) \n\n0.493\u00b1 0.039 \n0.199\u00b1 0.015 \n\n0.487\u00b10.035 \n0.183\u00b1 0.011 \n\n0.421\u00b1 0.024 \n0.174\u00b1 0.010 \n\n0.267\u00b1 0.013* \n\n0.137\u00b1 0.005* \nBrain (g) \n(g/100g) \n\n1.165\u00b1 0.048 \n0.456\u00b1 0.035 \n\n1.233\u00b1 0.036 \n0.469\u00b1 0.013 \n\n1.194\u00b1 0.016 \n0.504\u00b1 0.007 \n\n1.145\u00b1 0.108 \n0.595\u00b1 0.068* \n\nHeart (g) \n(g/100g) \n\n0.802\u00b1 0.046 \n0.317 \u00b1 0.010 \n\n0.839\u00b10.019 \n0.322\u00b1 0.004 \n\n0.785\u00b1 0.017 \n0.333\u00b1 0.006 \n\n0.683\u00b10.010 \n0.353\u00b1 0.005* \n\nEsophagus (g) \n(g/100g) \n\n0.071\u00b1 0.006 \n0.026\u00b1 0.002 \n\n0.085\u00b1 0.008 \n0.032\u00b1 0.002 \n\n0.094\u00b1 0.014 \n0.047\u00b1 0.008 \n\n0.135\u00b1 0.055 \n0.070\u00b1 0.029 \n\nStomach (g) \n(g/100g) \n\n1.563\u00b10.235 \n0.724\u00b1 0.036 \n\n1.681\u00b10.059 \n0.641\u00b1 0.022 \n\n1.644\u00b10.062 \n0.688\u00b1 0.025 \n\n1.790\u00b10.087 \n0.773\u00b1 0.077 \n\nLiver (g) \n(g/100g) \n\n8.984\u00b10.598 \n3.532\u00b1 0.173 \n\n8.287\u00b10.385 \n3.194\u00b1 0.125 \n\n8.289\u00b10.362 \n3.423\u00b1 0.143 \n\n6.717\u00b1 0.425 \n3.455\u00b1 0.126 \n\nAdrenal gland (g) \n(g/100g) \n\n0.0356\u00b1 0.0067 \n0.0158\u00b1 0.0038 \n\n0.0266\u00b1 0.0021 \n0.0100\u00b10.0005 \n\n0.0260\u00b1 0.0033 \n0.0108\u00b1 0.0017 \n\n0.0401\u00b1 0.0015 \n0.0202\u00b1 0.0008 \n\nHypophysis (g) \n(g/100g) \n\n0.0074\u00b1 0.0004 \n0.0033\u00b1 0.0002 \n\n0.0071\u00b1 0.0009 \n0.0028\u00b1 0.0003 \n\n0.0062\u00b1 0.0006 \n0.0022\u00b1 0.0003 \n\n0.0082\u00b1 0.0010 \n0.0041\u00b1 0.00071 \n\nHypothalamus (g) \n(g/100g) \n\n0.0276\u00b1 0.0037 \n0.0321\u00b1 0.0248 \n\n0.0314\u00b1 0.0028 \n0.0126\u00b1 0.0009 \n\n0.0222\u00b1 0.0023 \n0.0071\u00b1 0.0011 \n\n0.0295\u00b1 0.0032 \n0.0219\u00b1 0.0074 \n\nSmall intestine (g) \n(g/100g) \n\n1.733\u00b1 0.279 \n0.688\u00b1 0.160 \n\n1.282\u00b1 0.116 \n0.500\u00b1 0.052 \n\n1.605\u00b1 0.276 \n0.648\u00b1 0.128 \n\n2.108\u00b1 0.438 \n1.245\u00b1 0.442 \n\nOvary (g) \n(g/100g) \n\n0.023\u00b10.005 \n0.010\u00b1 0.002 \n\n0.033\u00b10.002 \n0.015\u00b1 0.003 \n\n0.032\u00b1 0.002 \n0.014\u00b1 0.001 \n\n0.057\u00b1 0.024 \n0.021\u00b1 0.003 \n\nLungs (g) \n(g/100g) \n\n1.266\u00b10.053 \n0.493\u00b1 0.029 \n\n1.213\u00b1 0.045 \n0.477\u00b1 0.025 \n\n2.071\u00b1 0.789 \n0.528\u00b1 0.013 \n\n0.991\u00b10.045 \n0.517\u00b1 0.023 \n\nKidney (g) \n(g/100g) \n\n0.980\u00b1 0.049 \n0.4937\u00b1 0.109 \n\n1.016\u00b1 0.128 \n0.375\u00b1 0.030 \n\n0.866\u00b1 0.033 \n0.368\u00b1 0.015 \n\n0.776\u00b1 0.044 \n0.399\u00b10.016 \n\nUterus (g) \n(g/100g) \n\n0.652\u00b1 0.036 \n0.210\u00b1 0.014 \n\n0.448\u00b1 0.048 \n0.174\u00b1 0.018 \n\n0.389\u00b1 0.055 \n0.171\u00b1 0.028 \n\n0.359\u00b1 0.042 \n0.185\u00b1 0.023 \n\nValues represent the mean \u00b1 SEM (n=5/group). \n* Statistically different from control group (ANOVA followed by Tukey, p &lt;0.05). \n\n \n \n \n \n \n \n \n \n \n \n \n\n124 \n \n\n\n\nTable 14: Effect of dry extract of Aloe ferox resin extract (0.1, 0.5 and 1.5 g.kg-1) by \n\noral route on absolute live (g) and relative body weight ratio (g/100g of animal) in \n\nmale Wistar rats treated for 13 weeks. \n\n \n\nTISSUES CONTROL Af 0.1 g.kg-1 Af 0.5 g.kg-1 Af 1.5 g.kg-1\n\nSpleen (g) \n(g/100g) \n\n0.538\u00b1 0.033 \n0.126\u00b1 0.009 \n\n0.646\u00b1 0.045 \n0.151\u00b10.013  \n\n0.518\u00b1 0.045 \n0.125\u00b1 0.009 \n\n0.816\u00b1 0.144 \n0.163\u00b1 0.010 \n\nBrain (g) \n(g/100g) \n\n1.376\u00b1 0.069 \n0.311\u00b1 0.017 \n\n1.261\u00b1 0.045 \n0.310\u00b10.009 \n\n1.246\u00b1 0.021 \n0.307\u00b1 0.014 \n\n1.07\u00b1 0.067*\n\n0.317\u00b10.0261  \nHeart (g) \n(g/100g) \n\n1.310 \u00b1 0.051 \n0.295\u00b1 0.010 \n\n1.222 \u00b1 0.028 \n0.302\u00b1 0.010 \n\n1.186 \u00b1 0.122 \n0.293\u00b1 0.036 \n\n1.158\u00b1 0.109 \n0.341\u00b1 0.037 \n\nVas deferens (g) \n(g/100g) \n\n0.362 \u00b1 0.025 \n0.080 \u00b1 0.003 \n\n0.342 \u00b1 0.029 \n0.083 \u00b1 0.005 \n\n0.293 \u00b10.029  \n0.072 \u00b1 0.006 \n\n0.254 \u00b1 0.012 \n0.068 \u00b1 0.005 \n\nEpididymis (g) \n(g/100g) \n\n0.639 \u00b1 0.047 \n0.143 \u00b1 0.009 \n\n0.601 \u00b1 0.031 \n0.153\u00b1 0.008 \n\n0.653 \u00b1 0.036 \n0.160 \u00b1 0.011 \n\n0.563\u00b1 0.022 \n0.165 \u00b1 0.008 \n\nEsophagus (g) \n(g/100g) \n\n0.123\u00b10.014  \n0.027 \u00b1 0.003 \n\n0.107 \u00b1 0.009 \n0.026\u00b1 0.002 \n\n0.093 \u00b1 0.007 \n0.022 \u00b1 0.002 \n\n0.087 \u00b1 0.003 \n0.020\u00b1 0.002 \n\nStomach (g) \n(g/100g) \n\n2.268 \u00b10.114  \n0.513\u00b1 0.028 \n\n2.182 \u00b1 0.094 \n0.537\u00b1 0.019 \n\n1.965 \u00b1 0.079 \n0.481 \u00b1 0.020 \n\n1.961 \u00b1 0.103 \n0.545 \u00b1 0.030 \n\nLiver (g) \n(g/100g) \n\n13.80 \u00b1 0.62 \n3.730\u00b1 0.193 \n\n12.26\u00b1 0.44 \n3.439 \u00b1 0.202 \n\n12.06\u00b1 0.24 \n3.372 \u00b1 0.219 \n\n12.99 \u00b1 0.55 \n3.550 \u00b1 0.199 \n\nAdrenal gland (g) \n(g/100g) \n\n0.0257 \u00b1 0.0019 \n0.0056\u00b10.0003 \n\n0.0264\u00b1 0.0033 \n0.0063 \u00b1 0.0009 \n\n0.0269\u00b10.0018  \n0.0067\u00b1 0.0006 \n\n0.0259 \u00b1 0.0069 \n0.0060 \u00b1 0.0010 \n\nHypophysis (g) \n(g/100g) \n\n0.0038\u00b1 0.0007 \n0.0008\u00b10.0001 \n\n0.0050\u00b1 0.0006 \n0.0012 \u00b10.0001 \n\n0.0069 \u00b1 0.0008 \n0.0017 \u00b10.0002 \n\n0.0034\u00b1 0.0013 \n0.0010 \u00b10.0004 \n\nHypothalamus (g) \n(g/100g) \n\n0.0247\u00b1 0.0023 \n0.0056 \u00b10.0007 \n\n0.0305 \u00b1 0.0040 \n0.0075 \u00b1 0.0010 \n\n0.0307\u00b10.0030  \n0.0074\u00b1 0.0007 \n\n0.0134\u00b1 0.0012 \n0.0035\u00b10.0006 \n\nSmall intestine (g) \n(g/100g) \n\n3.967 \u00b1 0.263 \n1.144 \u00b1 0.147 \n\n3.109 \u00b1 0.035 \n0.864 \u00b1 0.140 \n\n2.832 \u00b1 0.256 \n0.728 \u00b1 0.097 \n\n2.491 \u00b1 0.237*\n\n0.609 \u00b1 0.097*\n\nProstate (g) \n(g/100g) \n\n1.181\u00b1 0.066 \n0.268 \u00b1 0.018 \n\n1.052 \u00b1 0.107 \n0.256\u00b1 0.020 \n\n1.026 \u00b1 0.094 \n0.241\u00b1 0.021 \n\n0.723 \u00b1 0.052*\n\n0.211\u00b1 0.017 \nLungs (g) \n(g/100g) \n\n1.775\u00b1 0.099 \n0.432\u00b1 0.019 \n\n1.596\u00b1 0.083 \n0.442\u00b1 0.016 \n\n1.520\u00b1 0.087 \n0.380\u00b1 0.026 \n\n1.338\u00b1 0.081*\n\n0.387\u00b1 0.016 \nKidney (g) \n(g/100g) \n\n1.514\u00b1 0.109 \n0.404 \u00b10.011  \n\n1.498\u00b1 0.058 \n0.368 \u00b1 0.011 \n\n1.425 \u00b1 0.053 \n0.350 \u00b10.018  \n\n1.403\u00b1 0.075 \n0.406 \u00b1 0.011 \n\nTesticle (g) \n(g/100g) \n\n1.680\u00b1 0.031 \n0.344 \u00b1 0.045 \n\n1.526 \u00b1 0.061 \n0.378\u00b1 0.014 \n\n1.588\u00b1 0.054 \n0.390 \u00b10.019  \n\n1.541\u00b1 0.048 \n0.421\u00b1 0.024 \n\nSeminal vesicle (g) \n(g/100g) \n\n1.307 \u00b1 0.196 \n0.294 \u00b1 0.041 \n\n1.095\u00b1 0.071 \n0.271\u00b1 0.018 \n\n1.027 \u00b1 0.060 \n0.251 \u00b10.016  \n\n0.906 \u00b1 0.107 \n0.258 \u00b1 0.024 \n\nValues represent the mean \u00b1 SEM (n=5/group). \n* Statistically different from control group (ANOVA followed by Tukey, p &lt;0.05). \n\n \n \n \n \n\n125 \n \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n6.CONCLUS\u00c3O \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n126 \n \n\n\n\n \n\n6. CONCLUS\u00c3O \n\n \n\nCom base nos resultados obtidos, pode-se concluir que o extrato da resina de \n\nAloe ferox Miller quando administrado por via oral em ratos: \n\n \n\n Exerceu atividade laxante em camundongos quando administrado nas doses \n\nde 0.05,0.1 and 0.2 g/kg; \n\n \n Demonstrou ap\u00f3s administra\u00e7\u00e3o cr\u00f4nica (13 semanas) em ratos Wistar de \n\nambos os sexos, efeitos t\u00f3xicos sobre os par\u00e2metros bioqu\u00edmicos, \n\nhematol\u00f3gicos e morfol\u00f3gicos. \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n127 \n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n7.REFER\u00caNCIAS \n \n\n128 \n \n\n\n\n7. REFER\u00caNCIAS  \n\n \n\nALBUQUERQUE, U.P. Plantas medicinais e m\u00e1gicas comercializadas nos mercados \n\np\u00fablicos do Recife \u2013 PE. Ci\u00eancia e Tr\u00f3pico, v. 25, n. 1, p. 7 \u2013 15, 1997. \n\nBACH, D.B.; LOPES, M.A. Estudo da viabilidade econ\u00f4mica do cultivo da babosa \n\n(Aloe vera L). Ci\u00eancia e Agrotecnologia, v. 31, n.4,p. 1136 \u2013 1144, 2007. \n\nBARBUL, A. Immune aspects of wound repair. Clinics in Plastic Surgery, n.17, p. \n\n433 \u2013 442, 1990. \n\nBAUTISTA, R.; SEGURA, D.; VASQUEZ, B. In vitro antibradykinin activity of Aloe \n\nbarbadensis gel. Journal of Ethnopharmacology, In Press, 2004. \n\nBENDAZOLLI, W.S. Fitomedicamentos; perspectivas de resgate de uma terapia \n\nhist\u00f3rica. Mundoo Sa\u00fade, v. 24, n. 2, p. 123 \u2013 126, 2000. \n\nBLAND, J.  Effect of orally consumed Aloe vera juice on gastrointestinal function in \n\nnormal humans. Preventive Medicine, v. 14, p. 152 \u2013 154, 1985. \n\nBLUMENTHAL, M.; BUSSEIN, W.R.; GOLDBERG, A.; HALL, T. et al. Austin: \n\nAmerican botanical  council and integrative medicine communications. German \n\nComission and Monographs, 1998. \n\nBOELSTERLI, U.A. Animal models of human disease in drug safety assessment. \n\nJournal of Toxicological Sciences, v. 28, n. 3, p. 109 -121, 2003. \n\nBRAND\u00c3O, M.B.C.; ZANETTI, N.N.S.; OLIVEIRA, G.R.R.; GOULART, L.O.; \n\nMONTE-MOR, R.L.M. Other medicinal plants and botanical products from the first \n\nedition of the Brazilian Official Pharmacopeia. Brazilian Journal of Pharmacognosy, \n\nv. 18, n. 1, p. 127 \u2013 134, 2008. \n\nBRASIL. Minist\u00e9rio da sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. \u00c1reas de \n\nAtua\u00e7\u00e3o. Medicamentos. Legisla\u00e7\u00e3o. Portarias. Portaria n. 116 de 8 de Agosto de 1996. \n\nDispon\u00edvel em: http://www.anvisa.gov.br/medicamentos/legis/portaria.htm. Acesso \n\nem: 05 de novembro de 2009. \n\nBRASIL. Minist\u00e9rio da sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria.Consultas \n\nP\u00fablicas. \u00c1reas de Atua\u00e7\u00e3o. Medicamentos. Legisla\u00e7\u00e3o.Resolu\u00e7\u00f5es. Resolu\u00e7\u00e3o \u2013 RDC \n\nn. 17 de 24 de fevereiro de 2000. Dispon\u00edvel em: \n\nhttp://www.anvisa.gov.br/medicamentos/legis/resol.htm. Acesso em 05 de novembro \n\nde 2009. \n\n129 \n \n\nhttp://www.anvisa.gov.br/medicamentos/legis/portaria.htm\nhttp://www.anvisa.gov.br/medicamentos/legis/resol.htm\n\n\nBRASIL. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia Sanit\u00e1ria. Portaria n. 6/95. \n\nNormatiza\u00e7\u00e3o do registro de fitoter\u00e1picos. Di\u00e1rio Oficial da Uni\u00e3o, Bras\u00edlia, \n\n06/02/1995. \n\nCALIXTO, J.B. Efficacy, safety, quality control, marketing and regulatory guildelines \n\nfor herbal medicines (phytotherapeutic agents). Brazilian Journal of Biological \n\nResearch, v.33, p. 179 \u2013 189, 2000. \n\nCAN, A.; AKEV,N.;OZSOV, N.; BOLKENT,S.; ARDA, B.P.; et al. Effect of Aloe \n\nvera  leaf gel and pulp extract on the liver in type II diabetic rat models.  Biological &amp; \n\nPharmaceutical Bulletin, v. 27, n. 5, p. 694 \u2013 698, 2004. \n\nCASTRO, J.L.Medicina vegetal: teoria e pr\u00e1tica conforme a natiroterapia.Europa-\n\nAm\u00e9rica, 2\u00aa Ed., 304p., 1981. \n\nCHITHRA, P. NDRAKASAN, G. Influence of Aloe vera  on collagen characteristics in \n\nhealing dermal wounds in rats. Molecular and Cellular Biochemistry, v. 181, p. 71 \u2013 \n\n76, 1998. \n\nCHOI, S.; CHUNG, M.H. A review of the relationship between Aloe vera components \n\nand their biologic effects. Seminars in Integrative Medicine, v. 1, p. 53 \u2013 62, 2003. \n\nCLAYTON, L.T. Taber\u2019s cyclopedic medical dictionary. Philadelphia: F.A. Davis \n\nCompany, 1993. \n\nCUNHA, A.P.; SILVA, A.P.R.; ROQUE, O.R. Plantas e produtos vegetais em \n\nfitoterapia. Lisboa: Calouste Gulbenkian, 701p., 2003. \n\nDAVIS, R.D.; STEWART, G.J.; BREGMAN, P.J. Aloe vera inflamed synovial pouch \n\nmodel. Journal of American Pediatric Medical Assistence, v.84, n. 2, p. 77 \u2013 81, \n\n1992. \n\nDIXIT, V.P. &amp; JOSHI, S. Effect of Aloe barbadensis and clofibrate on serum lipids in \n\ntriton induced hyperlipidaemia in Presbytis monkeys. Indian Journal of Medical \n\nResearch, v. 78, p. 417 \u2013 421, 1983. \n\nEAST, L.; ISACKE, C.M. Aloe vera: a valuable ingredient for the food, pharmaceutical \n\nand cosmetic industries \u2013 a review. Critical Reviews in Food Science and Nutrition, \n\nv. 44, p. 91 \u2013 96, 2002. \n\nELDIN, S.; DUNFORD, A. Fitoterapia na aten\u00e7\u00e3o prim\u00e1ria \u00e0 sa\u00fade. S\u00e3o Paulo: \n\nMacule, 163 p., 2001. \n\nGLEN, H.F. &amp; HARDY, D.S. Aloaceae (First part): Aloe. Flora of Southern Africa. \n\nNational Botanical Institute, v. 5, n. 1, 2000. \n\n130 \n \n\n\n\nGRINDLAY, D.; REYNOLDS, T. The Aloe vera phenomena: a review of the \n\nproperties and modern uses of the leaf parenchyma gel. Journal of \n\nEthnopharmacology, v. 16, p. 117 \u2013 151, 1986. \n\nHOUCK, K.A., KAVLOCK, R.J. Understanding mechanisms of toxicity: Insights from \n\ndrug discovery research. Toxicology and Applied Pharmacology, v. 277, p. 163 \u2013 178, \n\n2008. \n\nJIA,Y.; ZHAO, G.; JIA, J. Preliminary evalution: the effects of Aloe ferox Miller and \n\nAloe arborescencis Miller on wound haling. Journal of Ethnopharmcology, v.120, p. \n\n181 \u2013 189, 2008. \n\n KAMBISI, L.; AFOLAYAN, A.J. Extracts from Aloe ferox and Withania somnifera \n\ninhibit Candida albicans and Neisseria gonorrhea. African Journal of Biotechology, \n\nv. 7, n. 1, p. 12 \u2013 15, 2008. \n\nKAMBISI, L.; FOLAYAN, A.J. Extracts from Aloe ferox and Withania somnifera  \n\ninhibit Candida albicans and Neisseria gonorrhoae. African Journal of \n\nBiotechnology, v. 7, n. 1, p. 12 \u2013 15, 2008. \n\nKAMBISI, L.; GOOSEN B.M.; TAYLOR, M.B.; AFOLAYAN, A.J. Anti-viral effects \n\nof Aloe ferox and Withania somnifera  on herpes simplex virus type 1 in cell culture. \n\nSouth African Journal of Science, 2007. \n\nKAMBISI, L.; GOOSEN, B.M.; TAYLOR M.B.; AFOLAYAN, A.J. Anti-viral effects \n\nof Aloe ferox and Withania somnifera on herpes simplex virus type 1 in cell culture. \n\nSouth African Journal of Sciences, 2007. \n\nKAMBISI, L.; SULTANA, N.; AFOLAYAN, A.J. Bioactive compounds isolated from \n\nAloe ferox: a plant traditionally used for the treatment of sexually transmitted infections \n\nin the Eastern Cape, South Africa. Journal of Pharmaceutical Biology, v. 42, n. 8, p. \n\n636 \u2013 639, 2004. \n\nKAMBISI, L.; SULTAWA, N.; AFOLAYAN, A.J. Bioactive compounds isolated from \n\nAloe ferox: A plant traditionally used for the treatment of sexually transmitted infections \n\nin the Eastern Cape, South Africa. Journal of Pharmaceutical Biology, v.42, n. 8, p. \n\n636 \u2013 639, 2004. \n\nKELLER, K. Herbal medicinal products in Germany and Europe: experiences with \n\nnational and European assessment. Drug Information Journal,v.30,p. 933 \u2013 948, \n\n1996. \n\n131 \n \n\n\n\nKODYM, A.; BUJAK, T. Physiochemical  and microbiological properties as well as \n\nstability of ointments containing Aloe extract ( Aloe arborescences Mill) or Aloe extract \n\nassociated to neomycin sulphate. Pharmazie, v. 57, p. 834 \u2013 837, 2002. \n\nKUO, P.L. LIN, T.C.; LIM, C.C. The anntiproliferative activity of aloe-emodin is \n\nthrough p53-dependent and p21-dependent apoptotic pathways  in human hepatome cell \n\nlines. Life Sciences, v. 71, p. 1879 \u2013 18922, 2002. \n\nKUO, P.L.; LIN, T.C.; LIN, C.C. The antiproliferative activity of aloe-emodin is \n\nthrough p53-dependent and p21-dependent apoptotic pathways in human hepatome cell \n\nlines. Life Sciences, v.71, p. 1879 \u2013 1892, 2002. \n\nLAPA, A.J. et al. Farmacologia e toxicologia de produtos naturais. In: Sim\u00f5es, C.M.O. \n\net al. Farmacognosia \u2013 da planta ao medicamento. Porto Alegre/Florian\u00f3polis: Ed. \n\nUFRS/UFSC, cap. 11, p. 247 \u2013 261, 2003.  \n\nLAPA, A.J.; SOUCCAR, C.; LIMA-LANDMAN, M.T.; GODINHS, R.O.; LIMA, \n\nT.C.M. Farmacologia e toxicologia de produtos naturais. In:SIM\u00d5ES, C.M.O. (org.). \n\nFarmacognosia da planta ao medicamento. 2\u00aa ed. Porto Alegre/Florian\u00f3polis: Editora \n\nda UFRS/ Editora da UFSC, p. 181 \u2013 196, 2000. \n\nLEE, J.K.; LEE, M.K.; YUN, Y.P.; KIM, J.S.; KIM, Y.S.; KIM, K.; HAN, S.S.; LEE, \n\nF.K. Acemannan purified from Aloe vera  induces phenotypic and functional maturation \n\nof immature dendritic cells. International Immunopharmacology, v. 1, p. 1275 \u2013 \n\n1284, 2001. \n\nLEITE, E.; AMORIM,M.L. Toxicologia geral. Belo Horizonte, Universidade Federal \n\nde Minas Gerais, p. 1 \u2013 62, 2006. \n\nLEUNG, M.Y.K.; LIU, C.; ZHU, L.F.; HUI, Y.Z.; YU, B.; FUNG, K.P. Chemical and \n\nbiological characterization of a polysaccharide biological response modifier from Aloe \n\nvera L. var. chinenses. Berg. Glycobiology, v. 14, p. 501 \u2013 510, 2004. \n\nLOOTS, D.T.; VAN DER WESTHUIZEN, F.H.; BOTES, L. Aloe ferox leaf gel \n\nphytochemical content, antioxidant capacity, an possible health benefits. Journal of \n\nAgricultural and Food Chemistry, v.55, p. 6891 \u2013 6896, 2007., L.; CH \n\nLOPES, R.K.; RITTER, M.R.; RATES, S.M.K. Revis\u00e3o das atividades biol\u00f3gicas e \n\ntoxicidade das plantas ornamentais mais utilizadas no Rio Grande do Sul, Brasil. \n\nRevista Brasileira de Bioci\u00eancias, v. 7, n. 3, p. 305 \u2013 315, 2009. \n\nMAGWA, M.L.; GUNDIDZA, M.; COOPOOSAMY, R.M.; MAYEKISO, B. Chemical \n\ncomposition of volatile constituents from the leaves of Aloe ferox. African Journal  of \n\nBiotechnology, v. 5, n. 18, p. 1652 \u2013 1654, 206. \n\n132 \n \n\n\n\nMCDANIELS, S.H.; COMBS, H.R.M.; CARPENTER, R.; KEMP, M.; NALLY, B. An \n\nincrease in circulating monocyte/macrophage (M/M) is induced by oral acemannan in \n\nHIV-1 patients. American Journal of Clinical Pathology, v. 94, p. 516 \u2013 517, 1990. \n\nMCNEES, P. Skin and wound assessment and care in oncology. Seminars in Oncology \n\nNursing, v. 22, p. 130 \u2013 143, 2006. \n\nMELO, J.R.B.; MELO, F.B.; LANGELOH, A. Toxicidade pr\u00e9-cl\u00ednica de fitoter\u00e1pico \n\ncontendo Aloe ferox, Quassia amara, Cynara scolymus, Gentiana l\u00fatea, Peumus boldus, \n\nRhamnus purshiana, Solanum paniculatum e Valeriana officinalis.Latin American \n\nJournal of Pharmacy, v.28, n. 1, p. 183 \u2013 191, 2009. \n\nNUSKO, G.; SCHNEIDER, B.; SCHNEIDER, I; WITTWKIND, C.; HAHN,E.G. \n\nAnthranoid laxative use is not a risk factor for colorectal neoplasia: results of a \n\nprospective case control study. Gut, v. 46, n. 5, p. 651 \u2013 655, 2000. \n\nPECERE, T.; GAZZALO, V.; MUCIGNAT, C.; PAROLIN, C.; et al. Aloe-emodin is a \n\ntype of anticancer agent with selective activity against neuroectodermal tumours. \n\nCancer Research, v. 60, p. 2800 \u2013 2804, 2000. \n\nPUPO, M.T.; GALLO, M.B.C.; VIEIRA, P.C. Biologia Qu\u00edmica: Uma estrat\u00e9gia \n\nmoderna para a pesquisa em produtos naturais. Qu\u00edmica Nova, v. 30, n. 6, p. 1446 \u2013 \n\n1455, 2007. \n\nREYNOLDS, T.; DWECK, A.C. Aloe vera leaf gel: a review update. Journal of \n\nEthnopharmacology, v. 68, p. 3 \u2013 37, 1999. \n\nRYAN, F.D.; PAUL, A.M.; CORONA, M.C.; STUART ELBORN, J.; TUNNEY, M.M. \n\nDelivery of photosensitivers and light trhough mucus: investigations into the potential \n\nuse of photodynamic therapy for the treatment of Pseudomonas aureuginosa cystic \n\nfibrosis pulmonary infection. Journal of Controlled Release, v. 117, p. 217 \u2013 226, \n\n2007. \n\nSCHMELZER, G.H.; GURIB-FAKIM, A. Medicinal plants. Plant Resources of \n\nTropical Africa, v.11, 775 p. 2008. \n\nSHACKLETON, C.M.; GAMBIZA, J. Grouth of Aloe ferox Mill. At selected sites in \n\nthe Makan region of the Eastern Cape. South African Journal of Botany, v.73, p. 266 \n\n\u2013 269, 2007. \n\nSHELTON, R.M. Aloe vera: its chemical and therapeutic properties. International \n\nJournal of Dermatology, v. 30, p. 679 \u2013 683, 1991. \n\n133 \n \n\n\n\nSOEDA, M. FUKIWARA, M.; OTOMO, M. Studies onf the effect of Cape aloe for \n\nirradiation leucopenia. Nippon Igaku Hoshasen Gakkai Zasshi, v. 24, p. 1109 \u2013 1112, \n\n1964. \n\nSOEDA, M. Studies on the anti \u2013 tumor activity in cape aloe . Journal of The Medical \n\nsociety of Toho University, v. 16, p. 365 \u2013 369, 1969. \n\nSOEDA, M.; OTOMO, M.; OME, M.; KAWASHIMA, K. Studies on anti-bacterial and \n\nanti-fungal activities of cape aloe. Japan Journal of Bacteriology, v. 21, n. 10, p. 609 \n\n\u2013 614, 1966. \n\nSOUZA, F.C.F.; MELO, C.T.V.; CIT\u00d3, M.C.O.; F\u00c9LIX, F.H.C.; VASCONCELOS, \n\nS.M.M.; BARBOSA-FILHO, J.M.; VIANA, G.S.B.; Plantas medicinais e seus \n\nconstituintes bioativos: Uma revis\u00e3o  da bioatividade e potenciais ben\u00e9ficos nos \n\ndist\u00farbios da ansiedade em modelos animais. Revista Brasileira de Farmacognosia, v. \n\n18, n. 4, p. 642 \u2013 654, 2008. \n\nSTICKLAND, F.M. Immune regulation by polysaccharides: implications for skin \n\ncancer. Journal of Photochemistry and Photobiology, v. 63, p. 132 \u2013 140, 2001. \n\nTALMADGE, J.; CHAVEZ, J.; JACOBS, L.; MUNGER, C.; CHINNAH, T.; CHOW, \n\nJ.T.; WILLIAMSOSN, D.; YATES, K. Fractionation of Aloe vera L., inner gel, \n\npurification and molecular profiling of activity. International Imunnopharmacology, \n\nv.4, p. 1757 \u2013 1773, 2004. \n\nTIZARD, I.; CARPENTER, R.H.; MCNALLY, B.H.; KEMP, M. The biological \n\nactivity of mannans andrelated complex carbohydrates. Molecular Biotherapy, v. 1, p. \n\n290 \u2013 296, 1989. \n\nVAN WYK, B.E.; VAN RHEEDE, VAN OUDTSHOORN, M.C.B.; SMITH, G.F. \n\nGeographical variation in the major compounds of Aloe ferox leaf exsudates. Planta \n\nMedica, v. 61, p. 250 \u2013 253, 1995. \n\nVASCONCELOS, N.M.S.; ALMEIDA, M.M.D.; LOPES, M.F.G.; NOGUEIRA, \n\nC.M.D.; MORAIS, NN.M.T. Plantas medicinais: um estudo anal\u00edtico.Anais da \n\nAssocia\u00e7\u00e3o Brasileira de Qu\u00edmica, v. 49, n. 3, p. 115 \u2013 118, 2000. \n\nVASQUEZ, B. AVILA, G. SEGURA, D. ESCALANTE, B. Anti-inflammatory activity \n\nof extracts from Aloe vera gel. Journal of Ethnopharmacology, v. 55, p. 69 \u2013 75, \n\n1996. \n\nVEIGA-J\u00daNIOR,VV,F,; PINTO, A.C.; MARCIEL, M.A.M. Plantas medicinais:; cura \n\nsegura? Qu\u00edmica Nova, v. 28, n. 3, p. 519 \u2013 528, 2005. \n\n134 \n \n\n\n\nVENANCIO, A.M.; Toxicidade aguda e atividade antinociceptiva do \u00f3leo essencial do \n\nOcimum basilicum L.(Manjeric\u00e3o), em Mus musculus (camundongos). Disserta\u00e7\u00e3o \n\nMestrado. Universidade Federal de Sergipe. N\u00facleo de P\u00f3s-gradua\u00e7\u00e3o em \n\nMedicina, p. 108, 2006. \n\nVIEGAS-J\u00daNIOR, C.; REZENDE, A.; SILVA, D.H.S.; CASTRO-GAMB\u00d4A, I.; \n\nBOLZANI, V.S. Aspectos qu\u00edmicos, biol\u00f3gicos e etnofarmacol\u00f3gicos do g\u00eanero \n\nCassia. Qu\u00edmica Nova, v.29, n. 6, p. 1279 \u2013 1286, 2006. \n\nVILJOEN, A. A chemotaxonomic study of phenolic leaf compounds in the genus \n\nAloe.PhD dissertation, Rand Afrikaan University, 1999. \n\nWANG, H.; CHUNG, J.; HO, C.; WU, L.; CHANG, S. Aloe-emodin effects arylamin-\n\nN-acetyltrasferase activity in the bacterium Heliobacter pylori. Planta Medica, v.64, p. \n\n176 \u2013 178, 1998. \n\nWORLD HEALTH ORGANIZATION. Guidelines for the assessment of herbal \n\nmedicines, Geneva, 1991. \n\nWYK, A.; WYK, G. Medicinal plants of South \u00c1frica, 2000,reipresso 2002. \n\nYAGI, A. HARADA, N. YAMADA, S.; NISHIOKA, I. Antibradykin active material in \n\nAloe saponaria. Journal of Pharmaceutical Sciences, v. 71, n. 10, p. 1172 \u2013 1174, \n\n1982. \n\nYAMAMOTO, I. Aloe ulcin, a new principle of Cape Aloe and gastrointestinal \n\nfunction, especially experimental ulcer in rats. Journal of the Medical Society, v. 17, \n\np. 243 \u2013 347, 1973. \n\nYEN, G.C.; DUH, P.D.; CHUANG, D.Y. Antioxidant activity of anthraquinones and \n\nanthrone. Food Chemistry, v.70, p.437 \u2013 441, 2000. \n\nYUSUF, S.; AGUNU, A.; DIANA, M. The effect of Aloe vera Berger (Liliaceae) on \n\ngastric acid secretion and acute gastric mucosal injury in rats. Journal of \n\nEthnopharmacology, 2004. \n\nCARVALHO, A.C.B.; BALBINO, E.E.; MACIEL, A.; PERFEITO, J.P.S. Situa\u00e7\u00e3o do \n\nregistro de medicamentos fitoter\u00e1picos no Brasil. Revista Brasileira de \n\nFarmacognosia, v. 18, p. 314 \u2013 319, 2008. \n\nCUNHA, P.; SILVA, A.P.; ROQUE, O. P. Plantas e produtos vegetais em fitoterapia. \n\nLisboa: Calouste Gulbenkian, 2003. \n\nGOTLIEB, O.R.; BORIN, M.R.M.B.; PAGOTTO, C.L.A.C.; ZOCHER, D.H.T. \n\nBiodiversidade: enfoque interdisciplinar brasileiro. Ci\u00eancia &amp; Sa\u00fade Coletiva, v.3, p. \n\n97 \u2013 102, 1998. \n\n135 \n \n\n\n\nGARCIA, E.S. Biodiversity, biotechnology and health. Caderno de Sa\u00fade P\u00fablica, v. \n\n11, n. 3, p. 495 \u2013 500, 1995. \n\nKLAASSEN, C.P.; WATKINS, J.B. Toxicologia: a ci\u00eancia b\u00e1sica dos t\u00f3xicos de \n\nCsarett e Doull. 5. Ed. Lisboa:McGraw- Hill de Portugal, 280 p. ,2001. \n\nKUSTER, R.; ROCHA, M. Cumarinas, cromonas e xantonas. In: SIM\u00d5ES, C.M.O. et \n\nal. Farmacognosia: da planta ao medicamento. 2.ed. Porto Alegre/ \n\nFlorian\u00f3polis:UFRGS/UFSC, cap. 21, p. 458 \u2013 462, 2000. \n\nLARINI, L. Toxicologia. 3 ed. S\u00e3o Paulo: Manole, 280 p, 1997. \n\nLEAL, L.K.A.M.; FERREIRA, A.A.; BEZERRA, G.A.; MATOS, F.J.; VIANA, G.S. \n\nAntinociceptive, anti-inflamatory and bronchodilatador activities of brazilian medicinal \n\nplants containing coumarin: a comparative study. Journal of Ethnopharmacology, v. \n\n70, p. 151 \u2013 159, 2000. \n\nLOPES-GONZ\u00c1LES, J.S.; SULLIVAN L\u00d3PES-GONZ\u00c1LEZ, J.; PRADO GARCIA, \n\nH.; AGUILAR, C.D.; MOLINA, G.J.A.; MANDOOKI, J.J.; MEDINA, M.F. Efecto em \n\nciclo celular de l\u00edneas de adenocarcinoma pulmonar por cumarina y 7-hidroxicumarina. \n\nRevista del Instituto Nacional de Enfermedades Respiratorias, v.13, n.4, p. 192 \u2013 197, \n\n2000. \n\nPODOLLSKY, J. Atividade antioxidante de los flavon\u00f3ides. Antioxidante Cali Vida, \n\nv.1, n.2, p. 10 \u2013 12, 1994. \n\nROBBERS, S.J.E. et al.Farmacognosia Biotecnologia, S\u00e3o Paulo: Premier, 372 p., \n\n1997. \n\nSANTOS, A.C.; MART\u00cdNEZ, E.; MADRIGAL , E.; RUIZ, L.E.; CHAMORRO , G.A.  \n\nEffect  of naturally  ocurring flavonoids on lipid   peroxidation  and membrane \n\npermeability transition in mitochondria. Free Radical Biology and Medicine, v.24, n.  \n\n9, p.  1455 - 1461, 1998. \n\nMATOS, F.J.A. Plantas medicinais: guia de sele\u00e7\u00e3o e emprego de plantas usadas \n\nem fitoterapia no nordeste do Brasil. 3.ed. Fortaleza: Ed. UFC, 203 p, 2000. \n\nAMBROGINI J\u00daNIOR, O. Obstipa\u00e7\u00e3o intestinal cr\u00f4nica. RBM revista brasileira de \n\nmedicina, v. 60, p. 133 \u2013 138, 2003. \n\nBOHMER, C.J. et al. The prevalence of constipation in institutionalized people with \n\nintellectual disability, Journal of Intellectual Disability Research, v.45, n. 3, p. 212 \u2013 \n\n218, 2001. \n\nCHONG,S.K. Gastrointestinal problems in the handicapped child, Current Opinion of \n\nPediatry, v.13, n. 5, p. 441- 446, 2001. \n\n136 \n \n\n\n\nEMLY, M.; ROCHESTER, P. A new look at constipation management in the \n\ncommunity, Brazilian Journal of Nursing, v.11, n.8, p. 326 \u2013 332, 2006. \n\nESCOTT-STUMP, S. Nutri\u00e7\u00e3o relacionada ao diagn\u00f3stico e tratamento. 5.ed. S\u00e3o \n\nPaulo:Manole, 847 p., 2007. \n\nGALAL, N. et al. Constipation in childhood: a mutidisciplinary approach to \n\nmanagement in the community. Paediatric Nursing, v.19, n.7, p. 20 \u2013 22, 2007. \n\nKRIGGER, K.W. Cerebral palsy: an overview. American Family Physician Journal, \n\nv. 73, n.1, p. 91 \u2013 100, 2006. \n\nMELO, M.C.B. et al. Constipa\u00e7\u00e3o intestinal. Revista M\u00e9dica de Minas gerais, v.13, \n\nn.4, supl. 2, p. 35 \u2013 53, 2003. \n\nPREECE, J. Introducing abdominal massage in palliative care for the relief of \n\nconstipation. Complement ther nurs midwifery, v. 8, n. 2, p. 101 \u2013 105, 2002. \n\nSANTOS, J.C.M.J. Laxantes e purgatives: o paciente e a constipa\u00e7\u00e3o intestinal. Revista \n\nBrasileira de coloproctologia, v. 23, n.2, p. 130 \u2013 134, 2003. \n\nTOBIAS, N. et al. Management principles of organic causes of childhood constipation. \n\nJournal Pediatric Health Care, v. 22, n.1, p. 12 \u2013 23, 2008.  \n\nLENNARD-JONES, J.E. Sleisenger &amp; Fordtran\u2019s Gastrointestinal and Liver \n\nDisease, Ed. Saunders Philadelphia. pp. 181 \u2013 210, 2002. \n\nFUCHS, F.D.L.; WANNMACHER, M.B. FERREIRA. Farmacologia Cl\u00ednica: \n\nFundamentos da Terap\u00eautica racional, Guanabara Koogan. , p. 815 \u2013 823, 2004. \n\nNORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, \n\nHEPATOLOGY AND NUTRITION (NASPGHAN). Evaluation and treatment of \n\nconstipation in child: summary of update recommendations of north american society \n\nfor pediatric gastroenterology nutrition, v. 43, n.3, p. 405 \u2013 407, 2006. \n\nSCHENKEL, E.P.; ZANNIN M.; MENTZ, L.A.; BORRDIGNON, S.A.L.; IRGANG, \n\nB. Plantas t\u00f3xicas. IN: Sim\u00f5es C.M.O., Schenkel, E.P., Gosmann, G.; Mello, J.C.P.; \n\nMentz, L.A.; Petrovick, P.R. Farmacognosia: da planta ao medicamento. Porto \n\nAlegre: Ed. UFRS e Florian\u00f3polis: Ed. UFSC, p. 755 \u2013 788, 2000. \n\nBOTHAM, P.A. Acute systemic toxicity -  prospects for tiered testing strategies. \n\nToxicology in vitro, v.18, n.2, p. 227 \u2013 230, 2004. \n\nORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT \n\n(OECD). Guidelines for the testing of chemicals, OECD420. Acute Oral Toxicity-\n\nfixed Dose Procedure. Organization for economic cooperation and development, Paris, \n\n2001. \n\n137 \n \n\n\n\nORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT \n\n(OECD). Guidelines for the testing of chemicals, OECD423. Acute Oral Toxicity-\n\nacute Toxic Class Method. Organization for economic cooperation and development, \n\nParis, 2001. \n\nORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT \n\n(OECD). Guidelines for the testing of chemicals, OECD425. Acute Oral Toxicity-\n\nmodified Up and Down Procedure. Organization for economic cooperation and \n\ndevelopment, Paris, 2001. \n\nTREVAN, J.W. The error on determination of toxicity. Proceedings  of the Royal \n\nSociety, v.101B, p. 483 \u2013 514, 1927. \n\nUKELIS, U.; PETER-J\u00dc\u00dcRGEN, K.; OLEJNICZAK, K.; MUELLER, S.O. \n\nReplecement of in vivo acute oral toxicity studies by in vitro citotoxicity methods: \n\nOpportunities, limits and regulatory status. Regulatory Toxicology and \n\nPharmacology, v.52, p. 108 \u2013 118, 2008. \n\nVALADARES, M.C. Avalia\u00e7\u00e3o da toxicidade aguda: estrat\u00e9gias ap\u00f3s a \u201cera do teste \n\nDL50\u201d. Revista Eletr\u00f4nica de Farm\u00e1cia, v. 3, n.2, p. 93 \u2013 98, 2006. \n\nSCHLEDE, E. et al. Oral acute toxicity class method: a successful alternative to the oral \n\nLD50 test. Regulatory Toxicology and Pharmacology, v. 42, p. 15 \u2013 23, 2005. \n\nVAN-WYK, B.E. &amp; SMITH, G. Guide to the Aloes of South Africa, 2. Ed., Pretoria: \n\nBriza, 2003. \n\nJALDIN, R.G. et al. O processo ateroscler\u00f3tico em art\u00e9rias de coelhos submentidos a \n\ndieta suplementada com gema de ovo: modelo experimental a baixo custo. Jornal \n\nVascular Brasileiro, v.5, n.4, p. 247 \u2013 256, 2006. \n\n \n\n \n\n \n \n\n \n \n \n \n \n \n \n \n \n\n138 \n \n\n\n\n \n\n139 \n \n\n\n\tAcknowledgements\n\tAcknowledgements\n\tErythrocytes (106/\u00b5L)\n\tErythrocytes (106/\u00b5L)\n\tErythrocytes (106/\u00b5L)\n\tErythrocytes (106/\u00b5L)\n\tErythrocytes (106/\u00b5L)\n\tErythrocytes (106/\u00b5L)\n\tGlucose (mg/dL)\n\tGlucose (mg/dL)\n\tGlucose (mg/dL)\n\tGlucose (mg/dL)\n\tGlucose (mg/dL)\n\tGlucose (mg/dL)\n\tAlbumine (mg/dL)"}]}}}